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C   degree Celsius 
µF   micro Farad 
µl   micro liter (10-9l) 
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Ab   antibody 
AKP   alkaline phosphatase 
APC   antigten presenting cell 
Aqua dest.  destilled water 
ATP   adenosine tri-phosphate 
 
BAC   bacterial artificial chromosome 
BAL   brochoalveolar lavage 
bp   base pairs 
BCR   B cell receptor 
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DNA   desoxribonucleic acid 
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dNTP   2´-Desoxyribonukleosid-5´-triphosphat  
DTT   dithiothreitrol 
 
EAE   experimental autoimmune encephalomyelitis 
EDTA   ethylene diamine tetra acetic acid 
e.g.   example given 
ELISA   enzyme-linked immunosorbent assay 
ES cell   embryonic stem cell 
E.coli   Escherichia coli 
Et al.   Et alii 
 
FACS   fluorescence-activated cell sorting 
FCS   fetal calf serum 
FITC   fluorescin isothiocyanate 
 
g   gramm 
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h   hour 
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HRP   horseraddish peroxidase 
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IFN   interferon gamma 
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RT   room temperature 
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SDS   sodium dedecyl sulfate 
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STAT   signal transducer and activator of transcription 
 
TAE   Tris-Acetate-EDTA-buffer 
T-bet   T-box transcription factor, T-box21 
TCR   T cell receptor 
 TCR  gamma delta T cell receptor 
TGF-β   tumor growth factor beta 
TH   T helper 
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SUMMARY 
 
The transcription factor interferon regulatory factor (IRF) 1 is essential for T helper cell 1 
differentiation. Hereby, the respective Irf1 knockout mouse displays a severe immune defect 
and has an Th2 directed immune status per se. This effect is measurable by increased 
production of interleukin-4, a Th2 associated cytokine, and increased levels of 
immunoglobulin E. By this, the mouse is incapable to cope with intracellular pathogens and 
eventually dies from infection (e.g. Leishmania major infection). Allergies are also mediated 
by a Th2 driven immune response, therefore the question raised, whether this knockout mouse 
would react stronger in case of an induced allergy. To address this topic, the murine OVA 
model for acute asthma was used. Interestingly and despite wide-ranging analyses, it could be 
shown in this thesis work that the IRF1 deficiency did not result in a more severe asthma 
pathology. The herein presented data urgently suggest to reconsider the long-standing 
paradigm of asthma as only being a Th2-diven disease. Newly dicovered Th cell subsets 
support this opinion. 
The Irf1 knockout mouse not only has a defect in Th cell differentiation, but also clearly 
shows the requirement of IRF1 in CD8 development. The numbers of CD8+ cells in the 
periphery is extremely reduced, mainly due to a thymic misregulation of MHC class I. In 
order to reveal cell-specific functions of IRF1, a conditionally targeted mouse for Irf1 was 
successfully generated in the framework of this thesis. This mouse will help to address a 
variety of questions regarding IRF1 function in a given setting. 
Beside IRF1, another factor of the IRF family, namely IRF4 is important for Th 
differentiation. IRF4 has functions in Th2, Th9 and Th17 cell development, and the IRF4 
deficient mouse is completely resistant to murine experimental autoimmune 
encephalomyelitis, a model for the human disease multiple sclerosis, due to the total 
incapacity to generate Th17 cells producing IL-17. Surprising data are shown in this thesis, in 
which γδ T cells from Irf4 knockout mice are nevertheless totally capable of producing IL-17. 
The underlying mechanism was closer investigated, and although it was not possible to reveal 
the actual pathway (which is apparently different from the one triggering IL-17 production in 
Th17 cells), the possibilities were narrowed down by excluding many other apparently 
obvious pathways. 
 
SUMMARY VIII
ZUSAMMENFASSUNG 
 
Der Transkriptionsfaktor inteferon regulatory factor (IRF) 1 ist essentiell für die T Helfer 
(Th)-Zell-Differenzierung in Richtung Th1. Die entsprechende Knockout-Maus hat 
diesbezüglich einen so schwerwiegenden Defekt, daß sie per se eine Th2 gerichtete 
Immunantwort zeigt. Diese zeigt sich in einem erhöhten Level am Th2-Zytokin Interleukin 
(IL)-4 und einem erhöhten Immunglobulin E-Spiegel. Damit einhergehend ist diese Maus 
auch anfällig für intrazelluläre Pathogene, denen sie gegebenenfalls erliegt (z.B. eine 
Leishmania major-Infektion). Allergien zeigen ebenfalls eine Th2-gerichtete Immunantwort, 
daher lag die Vermutung nahe, daß die IRF1-defiziente Maus einen schweren Allergieverlauf 
aufweisen könnte. Im akuten murinen Asthmamodell, bei dem eine allergische Reaktion 
mittels Ovalbumin (OVA) provoziert wird, sollte diese Frage untersucht werden. Trotz 
breitgefächerter Analysen konnte in dieser Arbeit gezeigt werden, daß die IRF1 Maus 
erstaunlicherweise keine stärkere Pathologie entwickelt. Dieses Ergebnis macht besonders 
deutlich, daß die seit langem vorherrschende Meinung, daß Allergien, insbesondere Asthma, 
eine Th2-vermittelte Erkrankung sind, neu überdacht werden muß. Zur Zeit werden immer 
neue T helfer Subtypen beschrieben, die die hier gezeigten Ergebnisse weiter untermauern.  
 
Die IRF1 defiziente Maus weist auch einen Entwicklungsdefekt von CD8+ T Zellen auf, der 
deutlich macht, daß IRF1 auch andere Funktionen hat, die sich unabhängig von der T Helfer 
Zell-Differenzierung abspielen. In der Peripherie sind erheblich weniger CD8 positive Zellen 
zu finden, hauptsächlich weil im Thymus die MHCI-Präsentation fehlgeleitet ist. Um 
zellspezifische Funktionen von IRF1 aufzuklären, wurde im Rahmen dieser Arbeit eine für 
IRF1 konditionell getargetete Maus generiert, die sicherlich im Rahmen vielfältigster 
Fragestellungen hilfreich sein wird. 
Neben IRF1 hat IRF4 eine äquivalente Funktion in der Th2 Zelldifferenzierung, zusätzlich ist 
es aber ebenso wichtig für Th9 und Th17 Immunantworten. Im Fall der Th17 Zellen ist dieser 
Effekt derart drastisch, daß in der Irf4 Knockoutmaus keine Th17-Differenzierung stattfindet 
und die Maus im murinen Modell für Multiple Sklerose, der experimentellen autoimmunen 
Enzephalomylitis, für diese Krankheit vollständig resistent ist. Daher überraschte die in dieser 
Arbeit gezeigte IL-17 Produktion von IRF4 defizienten γδ T-Zellen. Obwohl der 
zugrundeliegende Mechanismus noch nicht aufgedeckt werden werden konnte, ist es dennoch 
möglich gewesen, im Rahmen dieser Arbeit verschiedene, naheliegende Signalwege 
auszuschließen und damit die Möglichkeiten stark einzugrenzen. 
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1. INTRODUCTION 
 
 
1.1 ADAPTIVE IMMUNITY 
 
The immune system is comprised of biological structures and mechanisms to protect 
and defend the organism against foreign pathogens such as bacteria, viruses or parasites 
or to prevent self-destruction of the organism. Two major parts can be distinguished: the 
innate immune system and the adaptive immune system. 
The innate immune system is able to react immediately and in an unspecific way by few 
evolutionary conserved mechanisms after encountering a foreign structure. The 
recognition is triggered by so-called pathogen pattern recognition receptors that 
recognise widespread microbial components. Examples of cells of the innate immune 
system are macrophages, natural killer cells and granulocytes. 
In contrast, the evolutionary younger adaptive immune system allows a highly specific 
and efficient response to selected pathogenic structures. This intervention needs training 
and a tight regulation to prevent unnecessary damage. In case of reinfection this training 
enables a much faster and more efficient strike. The function of the adaptive immune 
system is mainly based on T- and B-cell interactions. They are able to specifically 
recognise a variety of pathogens via highly selective receptors on their surfaces, which 
are generated by somatic hyper-mutation.  
 
 
1.1.1 T HELPER CELLS 
 
T helper (Th) cells represent a sub-group of lymphocytes and play an important role in 
establishing and maximising the capabilities of the adaptive immune system, as well as 
in activating and directing other immune cells during the course of an immune response. 
All Th cells are characterised by cluster of differentiation molecule (CD) 4 and develop 
from lymphoid progenitors and finally maturate in the thymus just like cytotoxic T 
cells, which can be identified by CD8. During their thymic development, peptide loaded 
major histocompatibility complexes (MHC) test correct engagement of the T cell 
receptors (TCRs) in a process called positive selection. To avoid autoreactivity, MHC-
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molecules of the thymic epithelium present self-antigens to the developing T cells. A 
strong avidity leads to elimination of the reactive cell. This mechanism illustrates the 
phenomenon of central tolerance. 
 
With the discovery that T cell-derived cytokines regulate immunoglobulin (Ig) E 
production by B cells, T helper cell subsets were first described in mice (MOSMANN ET AL. 
1986, MOSMANN AND COFFMAN 1989) and later in humans (DEL PRETE ET AL. 1991). Among 
these, Th1 cells produce mainly interferon-gamma (IFN-) and tumor necrosis factor-
beta (TNF-), thereby increasing the killing efficiency of macrophages and cytotoxic T 
cells in response to intracellular pathogens. Lymphotoxin (LT) and TNF enhance this 
mechanism by activating neutrophils and also B cells to produce opsonising antibodies, 
which in turn increase microbe elimination. In addition, Th1 cells have been correlated 
with autoimmune diseases such as type1 diabetes (SKURKOVICH AND SKURKORVICH 2003). 
 
Although more and more cell types and T helper cell subpopulations come into play, 
according to the current model Th2 cells seem to direct the major response in allergic 
reactions to common environmental allergens. Th2 cells trigger the recruitment and 
involvement of other cell types with their production of soluble factors that in the sum 
result in an inflammatory cascade of an unequalled complexity. Th2 cells are able to 
directly recognise allergen peptide via their T cell receptor and account for combined 
involvement of immunoglobulin (Ig) E-producing B cells by secreting interleukin (IL)-4 
and IL-13, of mast cells via IL-10 in conjuction with IL-4 (THOMPSON-SNIPES ET AL. 1991) 
and of eosinophils as well as granulocytes by recruiting them via IL-5. It is of note that 
the secretion of these cytokines is the same reaction Th2 cells give in response to 
helminth infection! In the industrialised world, a Th2 setting is correlated with the 
development of allergic diseases such as asthma. Observations in a murine model 
sustain a major Th2 participation in the development of allergic diseases such as 
asthma, because transferred Th2 cells induced airway hyperresponsiveness, 
eosinophilia, and mucus hypersecretion in the recipients (COHN ET AL. 1997, COHN ET AL. 
1998). Similar observations were made in transgenic mice that overexpress Th2 
cytokines in the airway epithelium (RANKIN ET AL. 1996, LEE ET AL. 1997). These results are 
backed up by experiments in mice unable to mount a Th2 response (CORRY ET AL. 1998). 
Moreover, studies in humans also clearly demonstrated a Th2 response after allergen 
exposure in atopic patients and revealed accumulation of Th2 cells in target organs 
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(WIERENGA ET AL. 1999). In addition, successful immunotherapy redirected allergen-specific 
response from Th2 to Th1 (SECRIST ET AL. 1993, MCHUGH ET AL. 1995).  
With respect to the different T cell subsets possibly involved in diseases like asthma, it 
is of note that the long lasting Th1/Th2 paradigm has to be reviewed in terms of new T 
helper cell subgroups (Figure (Fig.) 1.1) that have recently been described (BRUESTLE ET 
AL. 2007, STAUDT ET AL. 2010) and which scientists all over the world are now eagerly 
working on to identify.  
 
Any new subset is defined by a very specific function (as for Th9 cells) and/or by a 
subset-specific transcription factor which is usually induced by subset-specific 
cytokines. Cells of a given subset differentiate from naive T cells which are defined by 
expression of CD62L on their surface and the absence of activation markers such as 
CD25 or CD69 (CARTER ET AL. 1998, CHEN ET AL. 1995, NATARAJAN ET AL. 2000). After first 
engagement of the TCR with its antigen bound to MHCII molecule the naive T cell 
differentiates to an effector cell of a particular subtype depending on the presence of 
lineage-inducing cytokine(s). Macrophages, monocytes and dendritic cells are the main 
producers of IL-12, which induces the differentiation into Th1 cells by a feedback loop 
to IFN-γ production, whereas IL-4 (initially produced by mast cells) drives the 
differentiation into Th2 direction. Both of these cytokines also block the differentiation 
of respective the other one, thereby enhancing the own signaling additionally (ABBAS ET 
AL. 1996, MOSMAN AND SAD 1996, MURPHY AND REINER 2002). IL-12 activates the transcription 
factors T box expressed in T cells (Tbet) and interferon regulatory factor (IRF1) 1 in a 
signal transducer and activator of transcription (STAT) 1-dependent manner, thereby 
promoting the transcription of cytokines (e.g. IFN-γ) that support the differentiation into 
Th1 cells. IL-4 blocks this mechanism and promote the differentiation towards Th2 by 
activation of the transcription factor GATA binding protein (GATA) 3 via STAT6 and 
IRF4 (LOHOFF ET AL. 2000, LOHOFF AND MAK 2005, LIEW 2002, MURPHY AND REINER 2002, 
Mosmann AND COFFMAN 1989 AND 1989 A). Similar pathways are found in all T helper 
subsets discovered so far. An overview of inducing cytokines and activated 
transcription factors are depicted in Fig. 1.1.  
Th2 cells differentiate from naive CD4+ T cells in a lineage-specific cytokine 
environment and are characterised by the expression of IL-4, IL-5 and IL-13, thereby 
attracting other cells such as mast cells and eosinophils to the site of inflammation and 
inducing IgE class switch in B cells.  
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Figure 1.1:  Differentiation of T helper cell subsets with differentiating cytokines (above arrows), 
involved transcription factors (within the cells) and subset function including produced cytokines (right 
part). Fully developed thymocytes are released from the thymus as naïve Th cells. Upon antigen 
recognition in a given cytokine milieu which induces the involvement of a lineage-specific transcription 
factor, a naïve Th cell differentiates into a specialised T helper cell subset that is related to an also 
specialised immunological function. The differentiation of follicular T helper (Tfh) cells takes place in the 
B cell follicle, but the circumstances and the specific cytokine milieu that lead to their differentiation are 
still controversally discussed. 
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1.1.2 γδ T CELLS 
 
The TCR is a heterodimer and consists of two protein chains. The majority of T cells 
carry the alpha-beta (αβ) TCR, whereas low percentages express a TCR with gamma-
delta (γδ) chains. Together with αβ T cells and B cells, γδ T cells are found in all 
vertebrates so far examined. This unconventional T cell subtype shares many cell-
surface and effector functions with αβ T cells, such as cytokine production or 
cytotoxicity. Just like αβ TCRs, the γδ-chains undergo rearrangements for clonal 
specificity, but the number of variable (V), diversity (D) and joining (J) gene segments 
which are available for generating different TCRs, are low for γδ TCRs. However, 
additional mechanisms secure a large repertoire also in this T cell subset. An immense 
junctional diversity in particular is achieved by N-nucleotide insertion or removal at up 
to three V/D/J joining sites. Within the γδ-chains, these form the complementary 
determining region 3 (CDR3) as a major binding site of the γδ TCR for antigens (ROCK 
ET AL. 1994, SCHILD ET AL. 1994). 
γδ T cells represent only a small proportion, less than 10 % of T cells in the periphery. 
In mice, γδ T cells have a strong tropism for epithelial surfaces, such as those of liver 
and skin, and mucosae of respiratory, digestive and reproductive organs. Here, they are 
a major T cell population (SIM 1995). It is not surprising that mucosal epithelia need an 
unique immune system, since they serve as an important barrier between inside and 
outside to protect the organism from pathogenic invasion. At the same time they 
promote the entry of solid, liquid or gaseous nutrients. γδ T cells are enriched in 
mucosal tissues compared to peripheral blood or lymphoid organs due to their non-
redundant role, which relies on a specific combination of peculiar antigen specificities, 
tissue distribution and functional properties rather than any of these features 
individually. Although theoretically 1016 varying T cell receptors can be produced for γδ 
T cells, only a limited set of receptors has been detected so far. The tissue distribution 
correlates with a predominant combination of particular γ and δ receptor chains 
(REVIEWED IN BONNEVILLE ET AL. 2010). At the population level, γδ T cells are capable of 
mediating many different functions, but for a particular cell, function is determined by a 
given tissue. For example after injury, intraepidermal Vγ5Vδ1+ T cells and intestinal 
epidermal Vγ7+ T cells display cytoprotective and immunomodulatory functions by 
secreting epithelial cell trophic factors such as insulin-like growth factor-1 (IGF1), 
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inflammatory cytokines such as IFN-γ and IL-2 and have a stronger cytotoxic activity 
(JAMESON ET AL. 2007). On the contrary, Vγ6Vδ1+ T cells mainly produce IL-17 during 
lung inflammation (SIMONIAN ET AL. 2009), Vγ1Vδ6.3+ T cells in the liver secrete IL-4 and 
IFN-γ, whereas Vγ4+ T cells were shown to produce IFN-γ and IL-17 depending on the 
system they have been investigated in (HUBER ET AL. 2002, LAHN ET AL. 2002, ROARK ET AL. 
2007). The same is true in the human system: Vδ1+ γδ T cells produce a quite broad set 
of cytokines including IL-4 and IL-17, whereas the Vδ2+ subset displays high cytotoxic 
activity and these cells produce IFN-γ and TNF (MORITA ET AL 1991, FENOGLIO ET AL. 2009). 
With their spectacular capability to produce very rapidly IL-17 and IFN-γ, γδ T cells are 
considered to be an essential component of the innate immune system (ROARK ET AL. 2007 
AND 2008). This early cytokine production by γδ T cells has drawn more and more 
attention to this special T cell subset. Further, these cells have been shown to play a 
crucial role for anti-bacterial immune responses in several infectious diseases (LOCKHART 
ET AL. 2006, SHIBATA ET AL. 2007). At steady state, γδ T cells express high levels of IL-23 
receptor (IL-23R) and also contribute to autoimmunity by hampering regulatory T cell 
responses (PETERMANN ET AL. 2010). 
The differentiation of Th17 cells requires several days and the involvement of IL-6 and 
transforming growth factor (TGF)-β (VELDHOEN ET AL. 2006 AND OTHERS). In contrast, γδ T 
cells are capable of IL-17 production already in the thymus (JENSEN ET AL. 2008, SHIBATA ET 
AL. 2008)! Apparently, this IL-17 production occurs independently of any co-stimulation 
with other cytokines such as IL-6 and also of TCR involvement (LOCHNER ET AL. 2008). 
The mechanism of this pre-setting is still enigmatic. However, a recent study introduced 
(v-rel reticuloendotheliosis viral oncogene homolog A (avian)) RelA and RelB as 
crucial factors that control IL-17 production of γδ T cells (POWOLNY-BUDNICKA ET AL. 2011). 
 
 
 
1.1.3 INTERFERON REGULATORY FACTORS  
 
It has been more than 50 years since the antiviral interferon (IFN) protein family, now 
termed type I interferon family, was first recognised (ISAACS ET AL. 1957, REVIEWED BY 
PESTKA 2007). The expression of type I interferon genes is strongly regulated, and 
interferon synthesis, which is induced by viral infections is generally transient.  
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The mammalian IRFs are a family of transcription factors which comprises 9 members 
termed IRF1-IRF9. They were first and best described as well as characterised as 
transcriptional regulators of type I interferons and interferon-inducible genes (MIYAMOTO 
ET AL. 1989, HARADA ET AL. 1989 AND1990). In addition, IRF10 has been identified in chickens, 
but is absent in humans and mice (NEHYBA ET AL. 2002). 
 
All IRFs show characteristic structural homologies, although the functions of the 
individual members of this family differ. IRFs possess an amino (N)-terminal DNA 
binding domain (DBD) that is characterised by a series of five well-conserved 
tryptophan-rich repeats. This DBD forms a helix-turn-helix structure and recognises 
DNA similar in sequence to the IFN-stimulated response element (ISRE) which is 
present in genes regulated by interferon signaling. In particular, the core sequence 
GAAA of this element is part of every IRF binding sequence. The less conserved C-
terminus of IRFs contains an IRF association domain (IAD) which mediates 
heterodimerisation. It also bears a regulatory element which divides the IRFs into two 
groups: IRF3, IRF5, IRF6, IRF7, and IRF9 which have activating functions whereas 
IRF1, IRF2, IRF4, and IRF8 can either activate or repress gene transcription. Their 
functions depend on the target gene and also on the partner they interact with. IRFs 
interact with each other and with other families of transcription factors modifying both 
their sequence-specific binding capacity and the formation of transcription initiation 
complexes (TANIGUCHI ET AL. 2001; TAMURA ET AL. 2008). In addition, posttranslational 
modifications, such as phosphorylation are known. For example, STAT3 mediates 
sumoylation of IRF1 via protein of inactivated STAT3 (PIAS3) and thereby represses 
its activity (NAKAGAWA AND YOKOSAWA 2002). The capacity to interact with multiple 
partners and posttranslational modifications account for the remarkable variety in IRF 
functions. 
IRFs participate in early host responses to pathogens, tumor suppression, and in 
hematopoietic cell differentiation. Here, IRF1, IRF2 and IRF8 are involved in myeloid 
cell differentiation. The expression of IRF1 in immature myeloid bone marrow cells is 
strongly upregulated during granulocyte differentiation of both human and murine 
myeloid progenitors in response to granulocytes colony-stimulating factor (G-CSF) 
(ABDOLLAHI ET AL. 1991, TESTA ET AL. 2004). The important role for IRF1 in allowing 
precursor cells to complete their differentiation is confirmed by the observation that 
inhibition of IRF1 by a functional antagonist such as IRF2 completely inhibits terminal 
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differentiation. At the molecular level, IRF2 prevents the effects of IRF1 on the late 
differentiation marker lactoferrin (COCCIA ET AL. 2001). 
Whereas IRF1 is widely expressed in almost all cell types, expression of IRF8 is 
restricted to cells of the immune sytem. Knockout studies revealed key functions for 
IRF8 in myeloid cell lineage selection, macrophage maturation and in control of genes 
involved in cell growth and apoptosis (TAMURA ET AL. 2005). Other knockout studies 
reported central roles for IRF4 and IRF8 in B cell development (LU ET AL. 2008).  
Several IRFs are recruited in Myeloid differentiation primary response gene 88 
(MyD88)- and Toll/Interleukin-1 receptor (TIR)-domain-containing adapter-inducing 
interferon-β (TRIF)-dependent signaling of Toll-like receptors (TLRs) and are therefore 
essential for the recognition of a variety of pathogen-associated molecular patterns 
(PAMPs) (HONDA 2006, AKIRA 2006). 
Altogether, this whole family of transcription factors is now recognised as playing a 
pivotal role in the regulation of innate and adaptive immune responses. 
 
 
1.1.3.1 INTERFERON REGULATORY FACTOR 1 
 
The main focus of this thesis lies on interferon regulatory factor 1 (IRF1). 
IRF1 was originally described as the transcriptional activator of interferon- (IFN-) 
transcription in virus-infected fibroblasts (MIYAMOTO ET AL 1988). However, the research 
focus has meanwhile been redirected to mediating IFN- responses, since gene-targeting 
studies have revealed an IRF1-independent mechanism of IFN- induction. IRF1 is 
expressed in a variety of cell types such as T cells, natural killer cells, macrophages, 
alveolar epithelial cells, endothelial cells or hematopoietic stem cells (TANIGUCHI ET AL 
2001, LOHOFF AND MAK 2005). Its transcription is induced by STAT1 (COCCIA ET AL. 2000; PINE 
ET AL. 1994, REMOLI ET AL. 2002). IRF1 possesses a C-terminal transactivation domain with 
several tyrosine residues. The phosphorylation of theses residues by casein kinase II 
increases its activity (MERANO ET AL 1999). Via IAD 2 IRF1 can interact with other IRFs 
such as IRF8 (MERARO ET AL. 1999). IRF1 regulates the induction of nitric-oxidase and 
induction of the interleukin-12p35 subunit (IL-12p35) in macrophages, binds to the IL-
4-promoter in T cells and thereby blocks Th2 development and promotes Th1 
differentiation (COCCIA ET AL. 2000, ELSER 2002). Not surprisingly, Irf1-/- mice exhibit a 
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strongly reduced IFN- production during Leishmania major infection in a gene dose-
dependent manner. Instead, higher amounts of Th2 cytokines such as IL-4 and IL-10 are 
produced, meaning that the T cell response shifts towards Th2 (LOHOFF ET AL. 1997). This 
Th2 type immune response also results in higher amounts of IgE isotype in serum. 
Furthermore, IRF1 is associated with autoimmune diseases (GORDON 2003; LIU ET AL. 2004), 
tumor suppression and apoptosis (HARADA ET AL. 1998; ROMEO ET AL. 2002; TANAKA ET AL. 1994; 
BOUKER ET AL. 2005): cells from IRF1-deficient mice are resistant to UV-light and drug-
induced apoptosis (REIS ET AL. 1994). IRF1 and IRF2 share a binding domain in the IFN--
gene that is also recognised by Blimp-1, which in turn has an important role in the late 
stages of B cell development (KUO AND CALAME 2004). It would be of interest to know 
whether and to what extent IRF1 participates in B cell differentiation. However, IRF1-
deficient mice do not show any altered B cell populations in spleen, peripheral blood, 
lymph nodes, bone marrow, and peritoneal exudate cells (MATSUYAMA 1993). Instead, the 
number of TCRCD4-CD8+ T cells is dramatically reduced, resulting in a higher 
susceptibility of these animals to intracellular pathogens. Several years before 
generation of the IRF1 deficient mouse, it was reported that the development of 
TCRCD4-CD8+ T cells is dependent on MHC I expression (ZIJLSTRA ET AL. 1990; KOLLER 
ET AL. 1990; VAN KAER ET AL. 1992 AND OTHERS) and that its promoter responds to IRF1 
(KORBER ET AL. 1988; MIYAMOTO ET AL. 1988 AND OTHERS). Admittedly, there was no other 
obvious defect detectable in the Irf1-/- mice. Later, it was convincingly demonstrated 
that IRF1 controls MHC class I expression in the thymus and hence, is responsible for 
the misregulated CD8+ T cell selection. IRF1 binds also to the promoters of the peptide 
transporters TAP1 (transporter associated with antigen processing-1) and LMP2 (latent 
infection membrane protein-2) (WHITE ET AL. 1996) which are required for peptide 
presentation by MHC class I molecules. Expression of these molecules in thymic 
stromal cells and mature thymocytes was impaired in IRF1-deficient mice (PENNINGER ET 
AL. 1997).  
 
 
 
 
 
 
INTRODUCTION 9
IRF1 IN ASTHMA 
 
Since allergic diseases are considered to be driven by a Th2-mediated immune response, 
the role of IRF1 has come more into focus, since it drives the T cell differentiation 
towards Th1 by acting in many cell types, not only T cells.  
Type I and type II interferons are induced by environmental factors, such as microbial 
exposure and may suppress atopic reactions. In this context, IRF1 is of special interest, 
since it mediates the effects of interferons intracellularly and is induced by viruses, 
lipopolysaccharide (LPS) and IL-1. 
The development of asthma is influenced by poorly understood environmental and 
genetic factors (COOKSON 2004, OBER AND HOFFJAN 2006). Genome wide screening analyses 
of single nucleotide polymorphisms (SNPs) of several genes revealed their implication 
in childhood asthma (MOFFATT ET AL. 2007). The Irf1 gene is located in a cytokine cluster 
on chromosome 5q 31 that has been shown to be associated with the development of 
asthma (XU ET AL. 2000, and MANSUR ET AL. 1998). Sequence studies have revealed that Irf1 
SNPs influence IgE regulation and atopy (SCHEDEL ET AL 2008). In humans, polymorphisms 
of Irf1 have been associated with a predisposition to develop asthma in the pediatric 
population (WANG ET AL. 2006) .  
A dominant feature of asthma pathology is a high level of IgE. The Irf1-/- mouse is 
prone to develop an up-regulated Th2 response, which correlates with secretion of 
higher amounts of IgE and IgG1, while a Th1 response would lead to production of 
IgG2a (IgG2c in C57BL/6 mice) (SNAPPER AND PAUL 1987). Taken together, the lack of 
IRF1 or abnormalities in its expression, including gene variations like SNPs, may 
contribute to the development and/or severity of allergic asthma. 
 
 
1.1.3.2 INTERFERON REGULATORY FACTOR 4 
 
The expression of IRF4 is restricted to the immune system. IRF4 as well as IRF8 are 
unique members of the IRF-family in that they are highly homologous to each other 
rather than to other IRFs. Both factors have evolved to be critical in mediating the 
development of lymphoid, myeloid and dendritic cells (OZATO ET AL. 2007, PERNIS 2002; LU 
2008, KANNO ET AL. 2005, TAMURA ET AL. 2008). 
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Unlike IRF1, IRF4 expression is not induced by interferon, but rather by diverse 
mitogenic stimuli, such as antigen receptor engagement, LPS or CD40 signaling 
(MITTRÜCKER ET AL. 1997, GUPTA ET AL. 1999, GRUMONT & GERONDAKIS 2000). All of these stimuli 
activate the transcription factor nuclear factor 'kappa-light-chain-enhancer' of activated 
B-cells (NFκB) pathway, which in turn leads to Irf4  promoter activation by NFκB 
heterodimers (GUPTA ET AL. 1999, GRUMONT & GERONDAKIS 2000, SHAFFER ET AL. 2006, SAITO ET AL. 
2007). Additionally, IL-4 can activate Irf4 transcription via STAT6 signaling (GUPTA ET AL. 
1999, GRUMONT & GERONDAKIS 2000). IRF4 can act as a counterregulator of other IRFs 
especially of IRF1 and 2. For example, IRF4 is able to repress the expression of some 
interferon-inducible genes by binding to the ISREs in their promoters, displacing IRF1 
and IRF2 (BRASS ET AL. 1996, YAMAGATA ET AL. 1996). The mechanism how IRF4 represses 
other genes, such as B cell lymphoma 6 protein (BCL6) is yet undefined. By using its 
C-terminal transactivation domain, IRF4 can function as a positive transcriptional 
regulator, but DNA binding of IRF4 alone is weak (BRASS ET AL. 1996). However, in 
conjunction with the ETS-family member PU.1 IRF4 can bind to the 3’ enhancers of 
both κ and λ immunoglobulin light chains (PONGUBALA ET AL. 1992, EISENBEIS ET AL. 1995, SU 
ET AL. 1996) with high avidity. Due to its structural high similarity IRF8 interacts as nice 
with PU.1, while other IRF family members cannot (ESCALANTE ET AL. 2002, MARECKI ET AL. 
1999). The composite DNA binding element of the IRF4 and PU.1 binding motifs on this 
enhancer is termed the ETS/ISRE-consensus element (EICE). Similar domains mediate 
cooperative binding on other genes including TLRs (REHLI ET AL. 2000; VAN DER STOEP ET AL. 
2004), leading to decreased IL-12 production. 
The most striking discovery of IRF4 function was its involvement in B cell 
development. The finding that IRF4 and IRF8 bind to an EICE motif in the 
immunoglobulin enhancer region provided early evidence for an overlapping role of 
both factors in pre-B-cell development (SZABO ET AL. 2000, OUYANG ET AL. 1998). Studies in 
IRF4 and IRF8 compound mutant mice (Irf4/8-/-) revealed both to be individually 
sufficient to rescue pre-B-cell development. Interestingly, Irf4,8-/- pre-B-cells are 
hyperproliferative, suggesting a negative regulation by IRF4 (and IRF8) of pre-B cell 
development (MA ET AL. 2006). More recent studies demonstrated a role of IRF4 and 8 for 
the transition from large pre-B-cells to small pre-B-cells by induction of the 
transcription factors Ikaros and Aioles (LAUERENCE ET AL. 2007).  
Moreover, IRF4 has a critical role in the adaptive immune response of mature B cells. 
In ageing Irf4 knockout mice, mature B cells accumulate in spleen and lymph nodes and 
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a quantitative defect in the percentages of IgMhi, IgDlo and CD23lo populations has been 
described (MITTRÜCKER ET AL. 1997). In addition, serum immunoglobulins of all isotypes 
are exceedingly low, because these mice completely lack Ig-secreting plasma cells 
(KLEIN ET AL. 2006). 
Apart from its effects in B cells, IRF4 has crucial impact on Th2 and Th17 cell 
differentiation by controlling cytokine expression and apoptosis (RENGARAJAN ET AL. 2002, 
LOHOFF ET AL. 2004, HONMA ET AL. 2008, HU ET AL. 2002, BRÜSTLE ET AL. 2007). As a consequence 
IRF4 deficient mice have a decreased capability to raise Th2 and Th17 immune 
responses. In wildtype cells, IRF4 cooperates with nuclear factor of activated T cells 
(NFAT)1 and/or 2 (TOMINAGA ET AL. 2003, RENGARAJAN ET AL. 2002) to directly bind to the IL-
4 promoter and activate the IL-4 transcription with implications for Th2 differentiation. 
Additionally, Irf4 knockout mice also show a decrease expression of the Th17 lineage-
specific transcription factor RORγt, suggesting the involvement of IRF4 in its 
regulation. This is in line with the incapacity of these mice to develop experimental 
autoimmune encephalomyolitis (EAE, mouse model for multiple sclerosis) due to the 
lack of Th17 cells. Transfer of wildtype congenic CD4+ T cells from Ly5.1 mice 
completely rescued disease development (BRÜSTLE ET AL. 2007) and confirmed that exactly 
the transferred cells were the producers of IL-17. Additional data support the 
importance of IRF4 in the context of Th17 immune regulation, by elucidating the role of 
IRF4 in orchestrating the transcription factors RAR-related orphan receptor (ROR) α, 
RORγt and also forkhead box (Fox) p3 (HUBER ET AL. 2008), a lineage-specific 
transcription factor for regulatory T cells (Treg). The expansion of Tregs and Th17 cells 
seems to be reciprocally regulated (BETTELLI ET AL. 2006, MANGAN ET AL. 2006, VELDHOEN ET AL. 
2006, LAURENCE ET AL. 2007) and any misregulation (e.g. by lack of IRF4) therefore may 
have severe implications in autoimmune disease. TGF-β plays a central role in inducing 
and maintaining Tregs (REVIEWED BY GORELIK AND FLAVELL 2002A, CHEN ET AL. 2003, ZHOU ET AL. 
2008, KULKARNI ET AL. 1995, POWRIE ET AL. 1996, LI ET AL. 2007), and the TGF-β produced by 
Tregs is suggested to be the main source of this cytokine in Th17 differentiation (LI ET AL 
2007); vice versa IL-21 and IL-23 produced by Th17 cells suppress Treg generation 
(FANTINI ET AL, 2007, IZCUE ET AL, 2008)   
Altogether therefore, IRF4 plays an important role in differentiation of several Th 
subsets and thereby has a central position in immune regulation. 
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1.2 ASTHMA BRONCHIALE  
 
 
Asthma (Greek for “shortness of breath”) is a serious, chronic inflammatory disease. If 
left untreated it is potentially life threatening and affects about 7 % of the population in 
the United States of America, 3-5 % of adults and approximately 10 % of children in 
Germany and a total of 300 million people worldwide. Reported incidence is increasing 
globally, causing an increasing burden on health services in both industrialised and 
developing countries. 
(FROM AMERICAN LUNG ASSOCIATION, WWW.LUNG.USA.ORG AND GERMAN SOCIETY OF PNEUMOLOGY 
AND RESPIRATION MEDICINE, WWW.PNEUMOLOGIE.DE) 
 
 
1.2.1 THE IMMUNOLOGY OF ASTHMA 
 
Like food allergies, asthma is initiated at mucosal surfaces where environmental 
allergens contact epithelia. These allergens may possess a variety of properties such as 
protease activity, stability, or molecular mimicry which gives them the capacity to 
penetrate mucosal surfaces and induce immune responses. One of the earliest steps in 
allergic sensitisation is the generation of antigen-specific T cell responses, which is 
initiated by antigen-presenting dendritic cells (DC) (MELLMANN 2001). Dendritic cells 
survey the lungs for invading pathogens and inhaled antigens in a network located under 
the airway epithelium. The epithelia may provide adjuvant signals in response to 
antigens that direct the migration and maturation state of DCs and T cells (HUH ET AL. 
2003, HOLT ET AL.1990). The DCs then migrate to the draining lymph node to present 
antigen and costimulatory signals to the T cells, which then in turn migrate to the 
airways to secrete cytokines and other mediators. These mediators direct the asthmatic 
response in the lung, for example IL-5 promotes airway eosinophilia, whereas IL-9 
recruits mast cells to the lung. The magnitude of both acute and chronic asthma attacks 
correleates with the number of eosinophils present in the lung (BRADLEY ET AL. 1991) and 
with an increase in bronchial hyperresponsiveness (CARTIER ET AL. 1982; COCKROFT ET AL. 
1987). From biopsy studies, it is known that infiltrating eosinophils degranulate at 
subepithelial sites, but also deeper in the interstitium (AALBERS ET AL. 1993 ). Presumably, 
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toxic eosinophil-derived products such as eosinophilic cationic protein and major basic 
protein are able to induce shedding of epithelials cells, as seen in human adults with 
asthma, where sloughing of the epithelium has occurred. (BOUSQUET ET AL. 1990). Mast 
cells are well established effectors in the context of allergic diseases and asthma: 
inhaled antigen crosslinks FcRI (which is the high affinity receptor for the Fc region of 
IgE)-bound immunoglobulin IgE, thereby triggering rapid degranulation and release of 
preformed mediators, such as histamine and certain proteases. IL-13 seems to be 
involved in goblet cell metaplasia and mucus production. (REVIEWED IN HOLGATE AND 
POLOSA 2008, BARRETT AND AUSTEN 2009). In addition, long-lived memory T cells are also 
generated, which take over the monitoring role. 
 
 
1.2.1.1 PATHOLOGY 
 
Atopy (from the Greek ‘atopos’ meaning “out of place”) describes a tendency to be 
“hyperallergic”. This encompasses the classical allergic diseases such as atopic 
dermatitis (“neurodermatitis”), allergic rhinitis (“hay fever”) and asthma, which often 
occurs as a result of untreated or mistreated allergic rhinitis. Although atopy has various 
definitions, most consistently it is defined by the presence of highly elevated serum 
levels of IgE antibodies, leading to a positive skin-prick test to common and otherwise 
harmless allergens (e.g. food, dander, pollen and insect venoms) (KAY 2001). Instead, 
non-atopic individuals react with equally high-affinity IgG1 levels. Asthma and atopy 
have been noted to cluster in family and twin studies, all of which suggest a significant 
genetic component for predisposition (BLUMENTHAL AND BLUMENTHAL 2001). 
 
Asthma is a chronic obstructive condition of the lung that is usually not considered to be 
part of chronic obstructive pulmonary disease (COPD) (REVIEWED IN BARNES 2008) as this 
term refers to a combination of bronchiectasia, chronic bronchitis, and emphysema. 
Instead, asthma is characterised by occasional reversible airway obstruction, bronchial 
inflammation, bronchial smooth muscle cell hyperreactivity to bronchoconstrictors, and 
is often associated with excessive mucus production, as illustrated in Fig. 1.2. However, 
if left untreated asthma can result in permanent inflammation and irreversible airway 
obstruction. Acute attacks may be triggered by exposure to environmental stimulants 
(allergens), cold air, exercise or emotional stress. In children, viral illnesses are the most 
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common triggers (ZHAO ET AL. 2002). Moreover, genetic predisposition has been 
demonstrated to play a role in the pathogenesis of asthma. Certain SNPs have been 
associated with the development of asthma in childhood (BOUZIGON ET AL. 2008). Genome-
wide searches have highlighted several distinct loci that are linked to asthma, for 
example the cytokine gene cluster on chromosome 5q, whereas others do not have 
obvious links to asthma (MOFFATT ET AL. 2007, COOKSON 2004, ALLEN ET AL. 2003, MANSUR ET AL. 
1998). 
 
 
 
 
 
Figure 1.2: Left: healthy bronchus with clear airway; Right: inflamed, mucus-filled brochus.  
 (Modified from http://cjcotton.files.wordpress.com/2009/03/asthma.jpg) 
 
 
 
 
It is agreed that atopy is a risk factor for asthma, but it remains controversial to what 
extent atopy accounts for asthma. The International Study of Asthma and Allergies in 
Childhood (ISAAC) revealed great variations of the prevalence of asthma and atopic 
diseases such as allergic rhinoconjunctivitis and atopic dermatitis and raised the 
question whether the same factors are responsible for disease development in different 
areas of the world (BEASELY 2003, ISAAC STUDY 1998). Still, asthma and atopy show complex 
correlation. Depending on both the type and amount of sensitisation, preexisting atopy 
can increase the risk of developing asthma by 10-20 fold (HOLGATE 1999).  
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1.2.1.2 ATOPIC AND NON-ATOPIC ASTHMA 
 
By early 20th century, the disease of asthma has been classified in “intrinsic” (non-
atopic) asthma and “extrinsic” (atopic asthma) (RACKEMANN 1921). Atopic asthma is the 
most common form in patients. This is indicated by a positive skin-prick test and the 
presence of IgE to common allergens such as house dust mite. These patients have 
allergic inflammation of airways, higher epithelial damage and an increase in basal 
membrane thickness (AMIN ET AL. 2000). 
Patients suffering from intrinsic asthma show a negative skin-prick test result. This form 
of the disease occurs rarely, but tends to be more severe. Although the airway 
inflammation shows similarities to atopic asthma inflammation and to some extent 
incorporates the same effector cells, it is mediated by local rather than by systemic IgE 
production (WENZEL 2006). In contrast to atopic asthma, the non-atopic asthma implies the 
absence of sensitisation (AMIN ET AL. 2000). 
Approximately 5 % of patients have severe atopic or non-atopic asthma, which is more 
difficult to control, even with maximal inhaler therapy. For these people in particular, 
new therapeutic approaches are desperately needed. 
 
 
1.2.1.3 EOSINOPHILIC AND NON-EOSINOPHILIC ASTHMA 
 
In eosinophilic asthma, bronchial biopsies, bronchoalveolar lavage fluid and sputum 
reveal infiltration by eosinophils. The magnitude of both acute and chronic asthmatic 
reactions correlates with the number of eosinophils present in the lung (BRADLEY ET AL. 
1991). Activated eosinophils in particular play a major effector role in the asthma 
pathogenesis by releasing proinflammatory lipid mediators, cytokines, cytotoxic 
cationic proteins such as eosinophil peroxidase (EPO) and fibrogenic growth factors 
such as TGF1 (LEASK AND ABRAHAM 2004). These mediators promote airway 
inflammation, tissue injury and lead to mucus overproduction. Eosinophil chemotactic 
factors, such as CC-chemokine ligand 11 (CCL11, also known as eotaxin-1) and related 
chemokines are mainly secreted by airway epithelial cells (KRANEVELD ET AL. 1997). On the 
whole, several studies report a strong correlation between clinical severity and the 
degree of airway eosinophilia (WARDLAW ET AL. 1988, BOUSQUET ET AL. 1990, JAYRAM ET AL. 
2006), whereas eosinophilia and airway hyperresponsiveness appear to be independent 
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components of the asthma phenotype (BRIGHTLING ET AL. 2002); but these findings are 
controversial (CARTIER ET AL. 1982; CROCKROFT ET AL. 1987).  
The development of simple methods to assess airway inflammation non-invasively 
using induced sputum which are applicable to a wide variety of patients has renewed 
interest in investigation of the pathological diversity of asthma. It was detected that, in 
contrast to eosinophilic asthma, non-eosinophilic asthma is characterised by neutrophil 
infiltration and in this shows similarity to COPD. In addition, several studies have 
clearly shown that eosinophils are not omnipresent in asthma (TURNER ET AL. 1995, FAHY ET 
AL. 1995). Instead, neutrophil infiltration has been noted in some patients with severe 
asthma (JATAKANON ET AL. 1999, WENZEL ET AL. 1999) and in those who died suddenly and 
unexpectedly of asthma (SUR ET AL. 1993). 
Non-eosinophilic asthma is of particular interest for a few reasons. Several uncontrolled 
studies suggested that there is a correlation between non-eosinophilic pathology with a 
faint short-term response to inhaled steroid therapy (PAVORD ET AL. 1997, TURNER ET AL. 1995, 
MEIJER ET AL. 2002, BACCIO ET AL. 2006). This has been confirmed in a double blind controlled 
placebo study (BERRY ET AL. 2005). Subsequently, non-eosinophilic asthma has been shown 
to be present in 25 % of adult patients and in about 50 % of patients treated with high 
dose of inhaled corticosteroids (GIBSON ET AL. 2001). These findings are also supported by 
Wenzel and coworkers (1999), who described a subgroup of patients with refractory 
asthma that had a distinct non-eosinophilic pathology with normal basal membrane 
thickness on bronchial biopsy. However, it remains unclear whether and to what extent 
(strong) corticosteroid treatment is particularly associated with more severe disease. 
Potentially pathogenic bacteria have been identified in 43 % of patients with 
neutrophilic asthma, a finding that is in keeping with Rackemann’s identification and 
classification (1921 AND 1927, PAVORD 2007). 
This pathology of non-eosinophilic asthma makes clear that the concept of a mainly 
Th2-driven disease has to be reconsidered and the involvement of the innate immune 
system must not be underestimated (DOUWES ET AL. 2002). However, there is evidence for T 
helper 2 cells in animal studies and human mediating allergic airway inflammation. 
Links may exist to other condition of neutrophilic airway inflammation such as in 
response to a wide variety of stimuli instancing viral and bacterial infection or inhaled 
irritants such as saline or cigarette smoke and other pollutants (ANEES ET AL. 2002, CLAPP ET 
AL. 1994).  
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1.2.1.4 T HELPER CELLS AND ASTHMA  
 
The long standing paradigm of asthma as a Th2-mediated disease loses more and more 
its plausibility. For instance, although mucus production is mediated via the Th2 
product IL-13 (WHITTAKER ET AL. 2002, STEENWINCKEL ET AL. 2007), both in vivo and in vitro 
studies have demonstrated that the cytokine IL-9 induces metaplasia directly in the 
absence of inflammation (READER ET AL. 2003; VERMEER ET AL. 2003). Large amounts of IL-9 
are produced by Th9 cells which have recently been distinguished from Th2 cells as a 
new T helper cell subset (VELDHOEN ET AL. 2008, DARDALHON ET AL. 2008). In IL-9 transgenic 
mice, subepithelial fibrosis was observed and seems to be involved in airway 
remodelling (VAN DEN BRÛLE ET AL. 2007, DOHERTY ET AL. 2009). However, their role in the 
human disease is still speculative and one has to keep in mind that IL-9 can be produced 
by several cell types including mast cells (VOCK ET AL. 2010) 
The identification of Th17 cells a few years ago lead to the development of a new 
immunological hot spot. The participation of Th17 cells in asthma has been first 
introduced in 2001 in reports that present high amounts of their product IL-17 in plasma 
samples (WONG ET AL. 2001) and increased IL-17 mRNA levels in tissue samples of 
asthmatic patients (MOLET ET AL. 2001). But not until 2008, this new T helper cell subset 
was identified as disease-mediating cells. The study by Pène et al. demonstrated highly 
activated Th17 cells in biopsies from patients with severe asthma. In fact, these cells 
represented 20 % of all infiltrating lymphocytes (PÈNE ET AL. 2008). These findings suggest 
that Th17 cells play a crucial role in the development of a severe asthma phenotype and 
are further supported by data that show glucocorticoid resistance of these cells in the 
setting of a murine asthma model (MCKINLEY ET AL. 2008). Taken together Th17 cells are 
significantly involved in cellular responses during development of airway disease and 
resistance to common treatment strategies with steroids.  
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1.2.2 EPIDEMIOLOGY 
 
In developed countries, asthma and allergic inflammation, including food allergies have 
increased over the past 50 years and are now the most prevalent chronic diseases of 
childhood. Between 1980 and mid-1990s, childhood asthma prevalence has more than 
doubled in the United States of America (LOCKSLEY 2010), following similar trends for 
other allergic disorders (BACH 2002). The increase in relatively short time periods 
implicates environmental parameters as overwhelming factors of disease risk. 
The reunification in Germany provided the unique opportunity to monitor the effects of 
different lifestyles and changing environmental factors on allergic diseases. Results of 
the Federal Health Survey in 1998 showed that 40-43 % of adults have had an allergy. 
Regarding allergic rhinitis, 17 % of adults living in Western Germany and only 11 % of 
those living in Eastern Germany claimed in interviews of the study that they were 
allergic. When comparing this study to earlier studies, the prevalence of allergic rhinitis 
increased over 70 % during less than one decade. The relative increase was higher in 
East than West Germany. In general, women suffer more frequently from an allergic 
disease than men. The increase of prevalence of allergy is supported by three studies of 
the national health survey of the German Cardiovascular Prevention Study (DHP) from 
1984-1991 (HERRMANN-KUNZ 2000, WIESNER ET AL. 1994) and the german Health Survey East 
from 1990/91 (HOFFMEISTER AND BELLACH 1995). 
Results from several pediatric studies conducted after the fall of the iron curtain showed 
a decrease in positive skin-prick tests from west to east, from Sweden to the Baltic 
states, and as far east as Uzbekiztan. This can be interpreted as confirmation that 
Western lifestyle and living conditions induce or promote the development of allergic 
sensitisation, at least in children (BJÖRKSTEN 1996, NICOLAI ET AL. 1997). 
It is of note that in Germany, children with an immigration background and children 
from a lower socio-economic status are less affected by an atopic disease as determined 
by the Children and Youngsters Health Survey (KINDER-UND JUGENDGESUNDHEITSSURVEY 
KIGGS, SCHLAUD 2007). This is in contrast to a British study, where the most deprived had 
higher incidences and lifetime prevalence of asthma and more histories of being 
prescribed an asthma-related drug (SIMPSON 2010). 
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It should be kept in mind that prevalence rates depend on the phenotypic definition 
applied at the time of a study and that some decrease or plateau-phases in industrialised 
countries during the last years are a result of redesigned questions. The National Health 
Intelligence Service (NHIS) findings in the UK are a good example of this 
phenomenon. In contrast to the previous NHIS asthma survey that produced asthma 
period estimates, the new-designed questions in 1997-2000 produced an estimate of 
asthma attack prevalence, which is a more specific definition and lowered the asthma 
prevalence statistics compared to pre-1997 (AKINBAMI ET AL. 2003). 
When evaluating literature on a multinational level over time (EDER ET AL. 2006), the 
diversity of asthma prevalence is remarkable, and reflects the complex character of the 
disease. In general, in developed countries asthma prevalence is rising, but considerable 
difficulty remains in comparing the data of different countries, not only due to the study 
design, but also because of the lack of studies for comparable types of patients in the 
same space of time. In Germany the most prevailing data for children come from the 
KiGGS in 2007, whereas the most recent data concerning adults are from the 1990s!  
The rise of asthma is paralled by a rise of atopy, as measured by a positive skin-prick 
test, but only part of the rise in asthma can be associated and explained by atopy (PEARCE 
ET AL. 1999). Triggers for both include exposure to tobacco smoke, allergens and air 
pollution, whereas living on a farm, especially during early childhood, seem to play a 
protective role (LEYNAERT ET AL. 2001, BRAUN-FAHRLANDER ET AL. 2002). Several factors such as 
breast feeding and early-childhood infections, access to day care and the number of 
siblings remain controversially discussed (WEISS 1997, NICOLAI ET AL. 1997). 
The change to a modern, Western life style comes along with high hygiene standards 
and reduced exposure to microbes. These living conditions seem to increase the risk of 
developing atopy. In the more affluent, industrialised world asthma has become the 
most common chronic disease in children. One possible explanation is what has been 
summarised as and is now known as the hygiene hypothesis.  
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1.2.2.1 HYGIENE HYPOTHESIS 
 
The hygiene hypothesis was originally postulated by David Strachan in 1989. He 
studied the epidemiology of a national sample of 17.414 British children born during 
one week in March 1958 and followed them up to the age of 23. The most striking 
observation was that at the age of 11 (when it was assumed most families were 
complete), the incidence of hay fever was inversely related to the number of children in 
the household, excema in the first year of life was related independently of hay fever to 
the number of older children in the household. He reckoned that allergic diseases could 
be “prevented by infection in early childhood transmitted by unhygienic contact with 
older siblings, or acquired prenatally from a mother infected by contact with her other 
children.” (STRACHAN 1989). The idea of the beneficial impact of infection for atopic 
illnesses had been proposed much earlier. Strachan based his hypothesis on 
epidemiological association, namely by statistical relation of two variables, while the 
interrelation of infection and atopy had been noted in several studies suggesting the 
beneficial effects of parasite infection (GODFREY 1975, PRESTON 1970) and microbe-rich 
environment (GERRARD 1976). 
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1.3 GENERATION OF A CONDITIONAL GENE KNOCKOUT MOUSE 
 
1.3.1 IN THE BEGINNING, THERE WAS THE MOUSE (APOLOGIES TO THE BIBLE) 
 
For almost an entire century, the mouse has been used in genetic analyses to reveal the 
mechanism of cancer biology and immunological processes. The mouse is the most 
widely used model in medical research, for very simple reasons. It is relatively small, it 
occupies only a small amount of space in animal facilities and is very reproductive. 
Also, the costs are reasonably low for mice compared with larger animals such as rats.  
The progress, scientists have made over the past decades in molecular biological 
techniques have also resulted in genetically modified animals, especially mice. Since it 
has become possible to genetically modify and even target single genes in mice, a vast 
surge of interest in almost all facets of mammalian biology using mouse models, has 
spread over the scientific community. 
 
 
1.3.1.1 GENE TARGETING 
 
Until it was possible to create planned gene alterations at a specific locus in the genome, 
a long way around had to be taken. The first gene targeting studies were performed with 
yeast (HINNEN ET AL. 1978) and homologous recombination was introduced by Orr-Weaver 
and colleagues (1981). Orr-Weaver claimed that free ends of DNA appeared to be 
“recombinogenic” and insertion was much more frequent when a double strand break 
was present in both the host DNA and the incoming DNA in the region of homology. In 
the early 1980s, several laboratories began model experiments to investigate 
homologous recombination following the introduction of exogenous DNA into 
mammalian cells (REVIEWED IN BOLLAG ET AL. 1989). The most striking study was reported 
by Smithies and colleagues in 1985 in which they demonstrated homologous 
recombination in the human β-globin locus in a planned manner (1985). Several 
principles for directed gene targeting could be derived from their experiments, such as, 
and probably most importantly that native gene targeting is possible. Using a joined 
marker such as a G418 resistance allows selection and enrichment of positive events 
and the targeting of a gene can be achieved without introduction of foreign or additional 
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sequences into other sites within the genome. Parameters that affect the targeting 
frequency, including length of homology between locus and incoming DNA (THOMAS 
AND CAPECCHI 1989), the size of the DNA fragment to be inserted (MANSOUR ET AL. 1990 AND 
MOMBAERTS ET AL. 1991), and the transcriptional state of the selected gene (NICKOLOFF AND 
REYNOLDS 1990) have all been widely examined. 
The “progenitors” of present day stem cells were pluripotent embryonal carcinoma cells 
derived from transplantable teratomas. More than 40 years ago, Stevens and Little 
observed the spontaneous occurrence of these kind of teratomas in mouse strain 129 
(STEVEN AND LITTLE 1954). The pluripotency of these cells was illustrated by generation of 
a variety of different tissues all derived from a single cell (KLEINSMITH AND PIERCE 1964). 
However, the majority of these teratomas were karyotypically abnormal in vivo and 
were not applicable in germline transmission experiments.  
The embryonal stem cells (ES cells) that are now used and referred to as EK cells, were 
isolated by Evans and Kaufman in 1981 from the inner cell mass of a 129 SvE mouse 
blastocyst (1981); independently, similar cells were isolated by Martin from Imprinting 
Control Region mice (1981). The Sv129-derived ES cells proved to permit germline 
transmission allowing the routine construction of chimeric mice, which are capable of 
transmitting the targeted gene to their offspring (BRADLEY ET AL. 1984). The first germline-
competent chimeras were obtained in 1986 by two different groups using different 
methods. Robertson and colleages infected ES cells retrovirally with a neomycin 
resistance gene (ROBERTSON ET AL. 1986), whereas Gossler used calcium phosphate DNA 
precipitation to introduce the DNA into the stem cells (1986). The germline-competent 
animals were obtained after returning G418 resistant cells into a blastocyst. 
In culture, usually on primary embryonic fibroblasts (GOSSLER ET AL. 1986) or embryonic 
fibroblast cell lines (BRADLEY ET AL. 1984), it is important that ES cells are kept in an 
undifferentiated status. Leukemia inhibiting factor (LIF) is capable of inhibiting ES cell 
differentiation (SMITH ET AL. 1988, WILLIAMS ET AL. 1988 ). However, different ES cell lines 
vary in their capability of germline transmission. Frequencies can range from 0 to 70 % 
(MCMAHON AND BRADLEY 1990). Cultured ES cells may accumulate mutations or epigenetic 
changes such as methylations, which may affect their pluripotency in a given culture. It 
is possible that culture conditions and handling impact on the quality of the ES cells. It 
is also of note that germline transmission is affected by the choice of the blastocyst 
donor mouse strain. C57BL/6 mice have been shown to be the fittest blastocyst donors 
in their capability of germline transmission (KOLLER ET AL. 1989, SCHWARTZBERG ET AL. 1989). 
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With this background, several groups have isolated cell lines derived from C57BL/6 
mice (SCHMITT ET AL. 1991) and Birgit Ledermann and colleagues have found that 
C57BL/6-derived stem cells are germline-competent when injected into BALB/c 
blastocysts (personal communication with Dr. Birgit Ledermann). 
Several studies have been carried out to develop methods for the differentiation of ES 
cells into cells of selected tissues (REVIEWED IN DONOVAN AND GEARHART 2001). In 1998, 
human ES cells were established, raising great hope for human ES cell donors in tissue 
transplantation therapies (THOMSON ET AL. 1998). However, allograft rejection and ethical 
concerns regarding early sacrifice of human embryos are the major problems for this 
application. Therefore, a lot of effort has been dedicated to the generation of inducible 
human pluripotent stem cells, which are induced from somatic cells (TAKAHASHI ET AL. 
2007; YU ET AL. 2007). To date, the generation of knockout animals by gene-targeting, 
which involves the use of stem cells, is limited to mice. Attemps in other animals 
including rats have been unsuccessful so far. However, cloned animals can be produced 
in many species by nuclear transfer technologies (DENNING AND PRIDDLE 2003). Recently, a 
new method using spermatogonial stem cells has been introduced, which offers 
potential application in species other than the mouse (TAKEHASHI ET AL. 2010). 
 
 
1.3.1.2 INDUCIBLE GENE TARGETING - THE CRE-LOX SYSTEM 
 
Although modern molecular techniques allow very precise gene alterations in vivo, 
these approaches may result in major complications. First and most important, the 
complete loss of a given gene product can cause embryonal lethality, which makes it 
impossible to analyse its function at later developmental stages. Second, an organism 
may be capable of compensating for certain functions that do not appear in the wildtype 
state. Another possibility is that the organism reacts to the mutation with a complex, 
secondary phenotype. 
Solutions to these problems could be provided by new strategies of inducible gene 
targeting (KÜHN ET AL. 1995). Several site-specific recombinases have been described in 
yeast and bacteria. These enzymes efficiently catalyse DNA recombination at 
recognition sequences 25-150 bp in size, which is large enough to not be expected to be 
found in the mammalian genome. In 1987/88 Brian Sauer introduced the Cre-loxP site 
specific recombination in yeast and mammalian cells (1987, 1988). The Cre-recombinase 
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(cyclisation recombination) of the phage P1 appeared to be exceptionally useful, 
because of its simplicity and efficiency. In the phage, Cre has two major roles: after 
infection, it circularises the plasmid DNA, but also stabilises the plasmid by 
recombination (integration) into the host genome during the lysogenic cycle (SEGEV AND 
COHEN 1981, HOCHMAN ET AL. 1983). By that it promotes survival of the phage during 
bacterial division. In addition, dimeric plasmids are separated so they can be distributed 
equally, thereby preventing the disappearance of the vector by dilution (AUSTIN ET AL. 
1981). This happens, if the 2 daughter plasmids perform crossover and stick together. If 
this bond is not resolved at the time the cell divides, one of the daughter cells will not 
recieve a copy of the plasmid. 
P1 derived Cre is a 38-kDa protein and recognises an inverted repeat 34 bp in size, a site 
called loxP (from: locus of X-over of P1) (STERNBERG 1978, STERNBERG ET AL. 1986, HOESS AND 
ABREMSKI 1990). 
The loxP site consists of two 13 bp inverted repeats that flank an 8 bp non-palindromic 
core sequence (spacer), which gives the whole loxP site a direction (Fig 1.3). The 
recombination between two loxP sites of the same direction results in excision of the 
interjacent DNA. Inverted orientation of the two loxP sites results in inversion of the 
flanked DNA rather than excision. The breaking and religation of the DNA is restricted 
to the core region and procedes one strand after the other. This is mediated by a 
transient phosphotyrosine DNA-protein bonding with the Cre. Unlike other 
recombinases, Cre does not require help from host factors or special DNA conformation 
for efficient functionality. These properties define the enormous usefulness of Cre 
(SAUER 1987). Hence, Cre-loxP-strategies have become standard for in vivo loss of 
function studies (KÜHN ET AL. 1995, MARTH 1996). 
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Figure 1.3: Sequence of a loxP site and scheme of Cre-mediated DNA modification based on the 
models concerning strand-swapping (NUNES-DÜBY ET AL. 1995) and Cre-loxP structure (GUO ET AL. 
1997). 4 molecules of Cre-recombinase bind to the target DNA (a and 1). Conserved tyrosine (y) residues 
of the recombinase cleave the backbone of the DNA (2). The released 5’ ends undergo intermolecular 
nucleophilic attack of the partner phosphotyrosine to complete the exchange of the first strand and form a 
Holliday intermediate (3,4), before second strand cleavage (5)and finally excision (6) of the sequence 
between the loxP sites. 
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Tissue-specific gene alteration using flanking loxP sites is an attractive method that was 
introduced by Gu (GU 1994). Exogenous DNA can be incorporated into a host genome by 
pronuclear injection into a fertilized zygote. This method is used to produce transgenic 
animals as „gain-of-function“ mutants, which are designed to either express a novel 
gene or to misexpress a normal gene. Without gene homologies between the gene of 
interest and the host genome, the foreign DNA will integrate at a non-predictable site. In 
contrast, for precise gene alteration exogenous DNA integrates into the host DNA by 
homologous recombination. This mechanism is used to insert the necessary loxP sites at 
the same time together with the target sequence of the gene of interest.  
Animals created with a specifically targeted locus are then mated to Cre-transgenic mice 
to use Cre-mediated gene alteration in a given tissue. For this purpose the Cre gene has 
been inserted in a way that it is expressed under a tissue-specific promoter to ensure a 
specified deletion of the floxed (flanked by loxP sites) gene in the offspring. That this 
extraordinary mechanism is functional was originally demonstrated by T cell-specific 
inactivation by 40 % of the DNA polymerase β gene (pol β) while there was none in any 
other tissue at the same time (GU ET AL. 1993). The reason for the incomplete gene 
inactivation can be traced back to the fact that Gu et al. used the wildtype Cre. Modern 
enzymes carry a Kozak-fragment, which allows more efficient translation in 
mammalian cells due to by this mediated ribosomal binding in eucaryotic cells (KOZAK 
1986, SAUER AND HENDERSON 1990). 
In order to be able to verify this specific event, the neo resistance gene is usually used as 
a marker for positive selection of the targeted locus and is introduced into the stem cells 
together with the gene-of-interest-sequence. Unfortunately, neo itself can negatively 
affect gene expression of neighboring genes (ARTELT ET AL. 1991, RIJI ET AL. 1994, FIERING ET 
AL. 1993): the bacterial neo gene comprises cryptic splice sites that may interfere with 
eucaryotic mRNA splicing (JACKS ET AL.1994, MEYERS ET AL. 1998, NAGY ET AL. 1998) and 
subsequently reduce the effective mRNA levels of the targeted gene, potentially 
resulting in a so-called hypomorphic allele. Such an attenuated allele in the germline 
may cause a knock-down effect (LIU ET AL. 1998, YAKAR ET AL. 1999, HOLZENBERGER ET AL. 2000). 
Hence, it might be important to remove the marker from the targeted locus in an 
adjacent step. This is usually accomplished by additional loxP sites that flank the neo 
resistance gene and by transient Cre-expression in the targeted stem cells. To do this, an 
expression vector that encodes for the Cre-recombinase is transduced into the positively 
targeted stem cells to address the floxed neo gene, but of course also the floxed gene of 
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interest. However, on a statistical basis, cells will be detectable in which only the neo 
gene, but not the gene of interest was removed. Of importance for this limited activity 
of Cre is the fact that the Cre-expressing plasmid does not replicate and will eventually 
vanish from the cell culture by dilution, when the cells proliferate. Finally, cell clones 
with deleted neo, but conserved floxed gene of interest have to be identified by 
Southern blotting. 
The most convenient feature of this conditional knockout strategy is that the same loxP-
tagged mouse can be used for every tissue for which a transgene for Cre is available, 
simply by mating the animals for a desired gene disruption (Fig 1.4). This gives the 
possibility of answering a variety of questions related to a given specific gene 
expression and its function. The choice of the Cre-expressing mouse is a crucial step in 
the generation of the final conditional knockout animal in order to avoid mosaic 
expression of Cre or additional deletion apart from the desired tissue. It is important to 
analyse the Cre activity and desired tissue-specific expression prior to mating the 
animals by Western blotting.  
 
 
 
 
 
Figure 1.4: Cell-specific Cre-mediated excision of the desired target gene. By mating a targeted 
animal with a partner that expresses Cre under a specific promoter, the gene of interest  is deleted in the 
offspring.  
 
All together, Cre-mediated gene alteration provides a very successful tool to study 
selected genes in vivo in the context of a many different question. 
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1.4 OBJECTIVE 
 
In the absence of IRF1, Th cells have a severe defect in the differentiation into the Th1 
lineage. Along with this phenomenon, the respective complete knockout mouse cannot 
raise an efficient immune response towards intracellular pathogens and shows signs of 
allergy without sensitisation. Hence, this mouse was to be investigated in the settings of 
allergic asthma.  
With regard to the many functions of IRF1 and in order to be able to further specify its 
functions in a given cell type, a conditional knockout mouse for IRF1 was to be 
generated as the main task of this thesis work. 
Beside IRF1, also IRF4 has strong impact on T helper cell differentiation. IRF4 is 
essential for lineage decisions towards Th2, Th17and Th9. Parts of this thesis work 
concentrated on the function of IRF4 in γδT cell cytokine expression. 
 
2. MATERIAL AND METHODS 
 
 
2.1 MATERIAL  
 
2.1.1 ANTIBODIES 
 
2.1.1.1 UNCONJUGATED  
 
-CD3 protein A purified, 145-2C11 
-CD28 protein A purified, 37.51 
-pSTAT1 (Tyr 701) #9171, Cell Signaling 
-pSTAT3 (Tyr705)  #9131, Cell Signaling 
-STAT1 #9172, Cell Signaling 
-STAT3 124H6; #9139,Cell Signaling 
-IFN-y, ELISA capture and detection  R4-6A2, BD Pharmingen
-IL-4 BVD4-1D11, BD Pharmingen
-IL-5 TRFK5, BD Pharmingen
-IL-10 JES5-2A5, BD Pharmingen
-APC micro beads Miltenyi 
Dynabeads® Mouse T-Activator CD3/CD28 Invitrogen 
-OVA IgE  BD Pharmingen
-OVA IgG1 BD Pharmingen
 
 
2.1.1.2 CONJUGATED  
 
-CD4-Phycoerythrin (PE) GK 1.5, eBioscience
-CD8-Fluorescein isothiocyanate (FITC) 53-6.7, eBioscience
-IL-4 Alexa 486, -IL-4 PE  11B11BD, Pharmingen
-IFN--FITC XMG1.2, ebioscience
-IFN- (biotinylated) XMG1.2, BD Pharmingen
-IFN--PerCP-Cy5.5 XMG1.2, Biolegend
-γδ TCR-APC ebioGL.3, eBioscience
-IL-17-PE/FITC  ebio17B7, eBioscience
-rat IgG2a-PE (isotype control)  eBioscience
-IgG1-FITC (isotype control) eBioscience
-rat-IgG1-PerCP-Cy5.5 (isotype control) RTK 2071, Biolegend
Streptavidin-AKP 554065, BD Pharmingen
-mouse IgE (biotinylated) BD Pharmingen
-mouse IgG1 (biotinylated) BD Pharmingen
-mouse IgG (peroxidase-coupled) Sigma-Aldrich
-goat IgG-HRP eBioscience
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-beta actin AC-15, Sigma-Aldrich
-OVA IgE  BD Pharmingen
-OVA IgG1 BD Pharmingen
 
 
2.1.2 CYTOKINES 
 
recombinant (r) mouse (m) IL-23 R&D Systems
rm IL-1β PeproTech
rm IFN- PeproTech
rm IL-6 PeproTech
 
 
2.1.3 CHEMICALS 
 
Aprotinin  Biomol
-Mercaptoethanol (ME) Sigma-Aldrich
2-Amino-2-hydroxymethyl-propane1,3-diol (TRIS)  Roth
3-(N-morpholino)propanesulfonic acid (MOPS) Sigma-Aldrich
4-(2-hydroxyethyl)-1 piperazineethanesulfonic acid 
(HEPES) Roth/Sigma-Aldrich
Acrylamide Mix Rotiphorese® 30 Gel Roth
Agarose SeaKem
Albumin bovine (BSA) Sigma-Aldrich
Alpha dCTP p32 radionukleotide Hartmann Analytik
Ammonium chloride Roth
Ammonium persulfate (APS) Sigma-Aldrich
Ampicillin Sigma-Aldrich
Aqua. dest Braun
BM Blue POD Substrate Roche
Brefeldin A Sigma-Aldrich
Bromephenol blue Sigma-Aldrich
BSA Albumin Fraktion V Sigma-Aldrich
Ca2Cl Sigma-Aldrich
Chymostatin Sigma-Aldrich
Clicks RPMI Biochrom
Collagenase D Roche
Dextransulfate Sigma-Aldrich
DiffQuick® Dade-Behring
Dimethyl sulfoxide (DMSO) Sigma-Aldrich
Dithiothreitol (DTT) Sigma-Aldrich
DMEM (Dulbecco’s modified Eagle medium) PAA
DNA loading dye 6x Fermentas
Epigallocatechin-3-gallate (EGCG), STAT1 inhibitor Sigma-Aldrich
Eosin G Merck
Erythrocyte lysis buffer Sigma-Aldrich
Ethanol, absolute Merck
Ethidiumbromid 1 % (1 mg/ml) Roth
Etylene diamine tetraacetic acid (EDTA), pH8 Sigma-Aldrich
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Etylene diamine tetraacetic acid, powder (EDTA) Sigma-Aldrich
Fetal Calf Serum (FCS) Greiner
Ficoll (Typ 400-DL) Sigma-Aldrich
Ficoll powder (Typ 400) Sigma-Aldrich
Folic acid Sigma-Aldrich
Formaldehyde 37 % Sigma-Aldrich
G418 Sigma-Aldrich
Ganciclovir Sigma-Aldrich
Gelatine Sigma-Aldrich
Glacial actetic acid Roth
Glucose Fluka
Glycerol 98 % pure Roth
Glycine Roth
Halt™ Protease inhibitor Single use cocktail 100x Thermo Scientific
Hämatoxilin II, (Gill) Merck
Hank’s Balanced Salt Solution (BSS) Biochrom
Herring sperm DNA Promega
Hydrochloric acid (HCl) Roth
Inject® Alum (Al(OH)3) Pierce
Ionomycin Sigma-Aldrich
KCl Roth
K actetate Sigma-Aldrich
Ketamin (10 mg/ml) Inresa
L-Arginine Sigma-Aldrich
L-Asparagine Sigma-Aldrich
LB Agar Roth
LB Medium powder Roth
Leupeptin  Biomol
L-Glutamine Solution  Biochrom
LIF /Leucemic inhibitory factor) Cell culture, AG Pfeffer
Mangan-chloride Sigma-Aldrich
MEM NON-essential amio acids Invitrogen
Methanol p.a. Roth
Milk powder Roth
Mitomycin C Sigma-Aldrich
Monensin  eBioscience
N,N,N',N'-Tetramethylethylendiamin Sigma-Aldrich
Na acetate Sigma-Aldrich
Nacitrate Sigma-Aldrich
NaCl Sigma-Aldrich
NaHCO3 Sigma-Aldrich
NaOH pellets Sigma-Aldrich
NaOH solution Roth
NaP Sigma-Aldrich
Na pyruvate Roth
NH4Cl  Sigma-Aldrich
Ovalbumin Grade V Sigma-Aldrich
Ovalbumin Grade VI SigmaAldrich
PBS without Mg2+ and Ca2+ for ES cells Biochrom
Penicillin G Biochrom
Penicillin G/Streptomycin 100x solution Gibco
Pepstatin A  Biomol
Phenylmethanesulphonylfluoride (PMSF) Sigma-Aldrich
Percoll, Biocoll Biochrom
Phenol/Chloroform Roth
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Phorbol 12-myristate 13-actetate (PMA) Sigma-Aldrich
Phosphate Buffered Saline (PBS) Biochrom
p-Nitrophenyl Phosphate (PNPP) Sigma-Aldrich
RNase A Biozym Scientific GmbH
Rompun 2% Bayer
Roti Clear (Xylol) Roth
RPMI Roswell Park Memorial Institute Medium Sigma-Aldrich
PS1145, NFκB inhibiotor Sigma-Aldrich
Rubidium cloride Roth
Saccharose Sigma-Aldrich
Saponin Sigma-Aldrich
Sarcosyl Sigma-Aldrich
Schiff’s Reagent Roth
Sodium dodecyl sulfat (SDS)  Sigma-Aldrich
Stattic V, STAT3 inhibitor Calbiochem
SYBR Gold nucleic acid gel stain Invitrogen
TRIS-HCl Roth
Tryphan blue Gibco
Trypsin/EDTA (0.05 % (w/v) /0.02 % (w/v)) Gibco
Tween20 Roth
Vitamin solution Sigma-Aldrich
 
 
2.1.4 KITS 
 
Dual-Luciferase Reporter Assay System Promega
NucleoSpin® Plasmid Mini Kit Macherey&Nagel
NucleoSpin® Plasmid Midi Kit Macherey&Nagel
PCR Core Kit  Qiagen
NucleoSpin® Extract II-Kit Macherey&Nagel
NucleoBond BAC 100 Macherey&Nagel
Megaprime DNA labeling system (for alpha-dCTP) GE healthcare
Miltenyi γδ+ T cell isolation Kit Miltenyi Biotech
IL-22 ELISA: READY-SET-GO! Mouse Interleukin-22 (IL-22) ebioscience
IL-17 ELISA: Duo Set ELISA mouse IL-17  R&D Systems
“RNeasy Micro Kit“ Qiagen
cDNA Maxima First Strand Systhesis Kit for RT-qPCR  Fermentas
qPCR Core kit for Sybr green I Eurogentec
qPCRTM Core Kit Eurogentec
BCA protein quantification Kit Pierce
Super Signal Femto maximum sensitivity substrate Thermo Scientific
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2.1.5 LABORATORY EQUIPMENT AND CONSUMABLES 
 
Cell culture dish (150x20 mm, 100x20 mm, 50x20 mm, 35x20 mm) Becton Dickinson
Cell culture plate (96-, 48-, 24-well flat bottom, 96-well round bottom) Greiner/Costar
Cuvettes, Gene Pulser, 0.4cm (Nr. 165-2088) BioRad
Electroporator Gene Pulser Biorad
ELISA plates Dynex
ELISA reader Dynex
AriaIII Cell Sorter Becton Dickinson
Casy® Cell Counter Schärfe Systems
Fluorescence activated cell sorting FACS Calibur Becton Dickinson
Films, Kodak MS and MP Sigma-Aldrich
Film exposure cassette with 2 amplifying screens Sigma-Aldrich
 
Gel gadget for agarose gel electrophoresis  
Made inWorkshops at 
Philipps University   
Marburg and Heinrich Heine 
University Düsseldorf 
Incubator Heraeus
Hamilton Pipette Hamilton
Heating block TCR 200 Roth
Hybridisation oven Heraeus
Megafuge1.0 R / Biofuge Pico (Rotors #2704/#3328), 
1700 rpm equals 470 g Heraeu
Microscope BX51 Olympus
Microwave Sharp
Membrane Hybond-N GE Healthcare
Miltenyi LD, LS, MS colums and magnets Miltenyi
Nanodrop ND-1000 Spectrophotometer PeqLab
Nylon mesh GE Healthcare
Object slide cover slip Menzel
Object slides Menzel
Pasteur pipette Brand
PCR cycler  Biometra
Power supply Consort, Scie-Plas
Reaction cups, 1.5 and 2 ml  Eppendorf
Reaction tubes, 15 and 50 ml  Greine
Shaker  IKA
Sterile filter Sarstedt
Sterile filter, 24 mm  Costar
Sephadex colums GE Healthcare
Scintillation counter  Life technologies
Syringes and needles of different sizes BD Microlance
Heating block  Roth
Waterbath Memmer
Whatman paper Schleicher+Schüll
Western Blot gadget Peqlab
Western Blotting membrane PVDF Roche
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2.1.6 MEDIA, BUFFERS AND SOLUTIONS 
 
Acrylamide gels: 
Separation gel (8 %): 2.3 ml H2O, 0.33 ml acrylamide mix (30 %), 0.25 ml 1 M Tris (pH 8.8), 
0.02 ml SDS (10 %), 0,02 ml ammonium persulfate (APS, 10 %), 0.002 ml TEMED 
Separation gel (10 %): 1,9 ml H2O, 1,7 ml acrylamide mix (30 %), 1,3 ml 1 M Tris (pH 8.8), 
0.05 ml SDS (10 %), 0,05 ml ammonium persulfate (APS, 10 %), 0.002 ml TEMED 
Stacking gel (5 %): 1.4 ml H2O, 1.3 ml acrylamide mix (30 %), 1.3 ml 1,5 M Tris (pH 6.8), 
0.05 ml SDS (10 %), 0.05 ml ammonium persulfate (APS, 10 %), 0.003 ml TEMED 
 
Aerosol solution 
1 % OVA Grade VI in PBS. 
 
Ammonium Chloride solution (NH4Cl):  
9.1 g NH4Cl dissolved in aqua dest, 20 ml 1M HEPES solution added and filtered sterile. 
 
BSS:  
BSS-powder for 10 l, 0.6 g penicillin G, 1g streptomycin sulfate, 14.25 g NaHCO3 and 23.83 g 
HEPES dissolved in 10 l aqua dest., pH-value adjusted to 7.2 and filtered sterile. 
 
Cell lysis buffer per 5x107 cells or 1 tail tip: 
500 µl TNE (see below), 7.5 µl proteinase K (10 mg/ml), 25 µl pronase E (10 mg/ml) and 50 µl 
SDS solution (10 %), freshly prepared. 
 
Clicks Roswell Park Memorial Institute Medium (Clicks RPMI): 
Instant Clicks powder dissolved in aqua dest. plus 60 mg/l penicillinG, 100 mg/l streptomycin 
sulfate, 14.25 NaHCO3 and 23.83 g HEPES added, pH-value adjusted to 7.2 and filtered sterile.  
Add before using: 1 % l-glutamine solution (volumen/volumen (v/v)), 10 % FCS (v/v), 0.5 % 
ME-Stock (see below) solution (v/v). 
 
Clone Medium: 
500 ml Dulbecco's Modified Eagle Medium (DMEM) high glucose, supplemented with L-
Glutamine (2 mM final), β-Mercapto-Ethanol (50 µM final), penicillin/streptomycin solution 
(100 U/ml final); additions from bought solutions: 5 ml non-essential amino acids, 5 ml folic 
acid, 7.5 ml sodium pyruvate, 5 ml L-arginine/L-asparagine, 5 ml vitamin solution, 50 ml fetal 
calf serum. 
 
Cracking solution: 
100 µl 2 N NaOH, 50 µl SDS solution (10 %), 0.2 g saccharose. Adjust H2O to final volume of 
1 ml (approx. 850 µl). 
 
Denaturating buffer: 
0,5 M NaOH and 1.5 M NaCl dissolved in aqua dest, freshly prepared before use. 
 
50x Denhardt’s: 
10 g Ficoll 400, 10 g polyvinylpyrrolidone and 10 g BSA dissolved in aqua dest., adjust to a 
final volume of 1 l. 
 
Dextran sulfate solution: 
50 % (weight/volume =w/v) dextran sulfate in sterile aqua dest., stirred overnight at RT, do not 
autoclave! (heat sensitive). 
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Diethanol amine buffer: 
400 mg MgCl2·6H20 dissolved in approx. 450 ml aqua. dest., 48.5 ml diethanol amine 
added and stirred for approx. 1h. pH-value adjusted to 9.8 filled up to 500 ml. Stored at 
4 °C in the dark. 
 
1 M DTT: 
Dissolve 3.085 g 1,4-dithio-DL-threitol (DTT, MW=154.25) in 20 ml 10 mM sodium acetate 
(pH 5.2). Divide in aliquots of 1 ml and sterilise by filtration. 
 
ELISA blocking solution: 
1x PBS with 1% BSA. 
 
Coating buffer: 
0.1M NaHCO3 pH 8.2 (NaHCO3 (MW = 84.01g/mol). 
 
0,5 M EDTA: 
Dissolve 186.12 g disodium ethylenediaminetetraacetate–H2O (Na2 EDTA–2H2O, MW 
=372.24g/mol) in 800 ml H2O; adjust pH value to 8.0 and adjust volume to 1 l. Sterilize by 
autoclaving. Store at room temperature. 
 
ES cell culture medium: 
DMEM, supplemented with 1 % L-glutamine solution, penicillin/streptomycin solution 
(penicillin G sodium 100x), 0.2 U/ml Leukemia Inhibitory Factor (LIF), 500 µl of ME-Stock-
solution and 15 % FCS.  
 
EM cell freeze medium: 
80 % feeder cell medium, 10 % FCS, 10 % DMSO. 
 
ES cell freeze medium: 
70 % complete culture medium, 20 % fresh FCS and 10 % DMSO, filtered sterile. 
 
ES cell lysis buffer: 
10 mM NaCl, 10 mM Tris-HCl pH 7.5, 10 mM EDTA, 0.5 % sarcosyl, 0.4 mg/ml proteinase K 
(freshly added) 
Mastermix for one plate: 5 ml lysisbuffer + 200 µl proteinase K (10 mg/ml). 
 
FCS: 
Thawed serum inactivated by heating at 56 C for 40 min, cooled to room temperature (RT) and 
filtered sterile. 
 
Feeder cell culture medium:  
DMEM supplemented with 1 % L-glutamine solution, 5 ml penicillin/streptomycin (penicillin G 
sodium solution 100x), 500 µl of ME stock solution and 5 % FCS. 
 
0,25 N HCl: 
dilute 21 ml of a 37 % HCl-solution in 1 l of aqua dest..  
 
HEPES solution (1M): 
238.3 g HEPES dissolved in 500 ml aqua dest., stirred for 2 h at 37 C and pH-value adjusted to 
7.3. 
 
Herring sperm DNA: 10 mg/ml 
Original stock solution diluted to 10 mg/ml in aqua dest., aliquoted and frozen for longtime 
storage. 
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Immunisation solution 
10 mg OVA GradeVI in 200µl PBS per animal. 
 
Lysis buffer for Luciferase Assay 
D-luciferin 470 µM, CoenzymeA 279 µM, DTT 33.3 mM, ATP 530 µM, 
(MgCO3)4Mg(OH)2x5H2O 1.07 mM, MgSO4 2.67 mM, Tricin 20 mM, EDTA 0.1 mM, pH7.8. 
 
Lysis buffer for Western Blotting: 
40 mM Tris pH 8.0, 100 μM PMSF, 1 μg/ml chymostatin, 5 μg/ml pepstatin A, 5 μg/ml 
aprotinin, 5 μg/ml leupeptin. 
 
M2 Medium for blastocyst transfer 
M2 medium, supplemented with penicillin/streptomycin (penicillinG sodium solution, 100x). 
 
MACS buffer: 
PBS with 0.5 % BSA (w/v) and 2 mM EDTA pH 8.0. 
 
ME stock solution (10 mM): 
0.7 ml 2-mercaptoethanol dissolved in 1 l PBS and filtered sterile. 
 
Narcosis-solution for anesthesia, 5x: 
10 ml Ketamin (50 mg/ml)/3.125 ml Rompun in PBS. 
 
NaP: 
1 M sodium phosphate dissolved in aqua dest., pH value adjusted to 6.4. Autoclaved for 
longtime storage. 
 
Neutralisation buffer: 
0.5 M Tris-HCl dissolved in aqua dest., pH value adjusted to 7.4 and 0.5 M NaCl added and 
autoclaved for longtime storage. 
 
PBS: 
PBS dry substance for 10 l dissolved in aqua dest., pH value adjusted to 7.2 and autoclaved. 
 
RF1 buffer for competent cells: 
Dissolve 12 g rubidium chloride (RbCl), 9.9 g mangan chloride (MnCl2x 4 H2O), 30 ml 
potassium acetate 1 M, pH 7.5 (Ka-acetate), 1.5 g calcium chloride (CaCl2x 2H2O) and 150 g 
glycerol in 1000 ml H2O and adjust pH to 5.8 with glacial acetic acid. Filtered sterile and stored 
at 4 ºC. 
 
RF2 buffer for competent cells: 
Dissolve 1.2 g RbCl, 11 g CaCl2 x2 H2O, 150 g glycerol and 20 ml 0.5 M 3-(N-morpholino) 
propanesulfonic acid, pH 6.8 (MOPS) in 1000 ml H2O. Filtered sterile and stored at 4 ºC. 
 
Roswell Park Memorial Institute Medium (RPMI) 
500 ml medium supplemented with 10 % FCS, 5 ml non-essential amino acids, with L-
glutamine (2 mM final), β-mercapto-ethanol (50 µM final), penicillin/streptomycin solution 
(100 U/ml final). 
 
Sample buffer for Western blotting: 
150 mM Tris (pH 6.8)/ 1.2 %SDS/ 3.3 % glycerin/ 1.8 % bromphenol-blue. 
 
Saponin buffer: 
0.3 % saponin (w/v) dissolved in PBS and 2 % FCS (v/v) added. For storage filtered 
sterile. 
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20x SSC: 
3 M NaCl and 300 mM Na-Citrat x 2 H2O dissolved in aqua dest., pH value adjusted to 7.0 and 
autoclaved for longtime storage. 
 
Southern blot washing buffer 1: 
20x SSC diluted to 2x SSC in sterile aqua dest., SDS added to final concentration of 0.1 %. 
 
Southern blot washing buffer 2: 
20x SSC diluted to 0.1x SSC, SDS added to final concentration of 0.1 %. 
 
50 x TAE: 
Dissolve 242 g Tris in 500 ml aqua dest., add 100 ml EDTA (pH 8) and 57.1 ml glacial actetic 
acid, adjust volume to 1 l with aqua dest.. Store at room temperature. 
 
10/1 TE buffer: 
Tris dissolved to final concentration of 10 mM and EDTA to final concentration of 1 mM in 
H2O. 
 
TNE solution: 
10 ml 1 M Tris (pH 8.0), 20 ml 5 M NaCl, 2 ml 0.5 M EDTA diluted ad 1000 ml aqua dest. and 
autoclaved. 
 
Western blot transfer buffer: 
200 mM glycin, 25 mM Tris-HCL pH = 8.8, substituted with 20 % methanol (v/v) before use. 
 
Wash buffer for ELISA: 
PBS with 0.05 % tween (g/v). 
 
Wash buffer Western blot: 
100 mM NaCl, 10 mM Tris-HCl pH 7.5 and 0.05 % tween (v/v). 
 
Western Blot electrophoresis buffer 
30 g Tris-Base/ 10% SDS/ 250 g glycin ad 1 l dH2O. 
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2.1.7 MICE AND CELLS 
 
Mice were the only laboratory animals used for asthma and infection experiments or for 
organ extraction. Mice were kept under specific pathogen free conditions (SPF) in 
individual ventilated cages (IVC) at 20 °C and artificial light-dark-cycles (12 hours 
each). Food and water were provided ad libitum. The following inbred mouse strains, 
cell lines and bacteria were used: 
 
Mice 
C57BL/6 mice, wildtype Harlan Winkelmann
BALB/c mice, wildtype Harlan Winkelmann
CD1 mice Harlan Winkelmann
Irf1-/- mice, C57BL/6 own breeding
Irf1-/- mice, BALB/c self backcrossed to the F8 generation, own breeding 
Irf4-/- mice, C57BL/6 own breeding
Stat4-/- mice, BALB/c kindly provided by Prof. Dr. Max Löhning 
 
Cell lines 
E14.1 embryonic stem (ES) cells from Sv 
J129/Ola mice 
kindly provided by Prof. Dr. Klaus Pfeffer
C57BL/6 blastocysts  kindly provided by Prof. Dr. Klaus Pfeffer
293-mTLR9-luc kindly provided by Prof. Dr. Stefan Bauer
 
Bacteria 
Escherichia. coli DH10B strain  Invitrogen 
Escherichia. coli Top10 Invitrogen 
Streptococcus pneumoniae PN36 kindly provided by Prof. Dr. Robert Bals
 
 
2.1.8 PLASMIDS 
 
pEasyFlox  Target vector for genomic manipulation for generation of a knockout 
 mouse. 3 flox sites, Ampr, Neomycinr included, kindly provided by 
 Prof.  Dr. Klaus Pfeffer, Düsseldorf NCBI ACCESSION: 
  CQ918568 VERSION: CQ918568.1 GI:56208490 
pICre  low copy plasmid, carrying the gene for Cre-recombinase. Used to 
 excise the neomycin gene cassette within the targeted stem cell, kindly 
 provided by Prof. Dr, Klaus Pfeffer, Düsseldorf 
pBluescript   Fermentas GmbH 
IRF1 BACclone  CHORI, Children’s Hospital Oakland Research Institute 
    „RP23-303F24“Oakland, USA 
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2.1.9 ENZYMES 
 
Antarctic Phosphatase New England Biolab
AvrII/XmaJI Fermentas GmbH
BamHI  Fermentas GmbH
ClaI Fermentas GmbH
DNase I Invitrogen 
EcoRI Fermentas GmbH
EcoRV  Fermentas GmbH
HindIII Fermentas GmbH
KOD Hot start DNA polymerase Novagen
NotI Fermentas GmbH
Pfu-DNA polymerase Fermentas GmbH
Pronase E Sigma-Aldrich
Proteinase K Qiagen
RNase Biozym Scientific GmbH
SalI Roche
SpeI Fermentas GmbH
T4-Ligase Fermentas GmbH
XhoI Fermentas GmbH
 
 
 
2.1.10 OLIGONUCLEOTIDES 
 
CpG-ODN 1668  TCCATGACGTTCCTGATGCT 
 
Primers for Irf1 gene targeting 
 
5’ flanking probe  
5’fp for:    5’ GAGCAGGAGCCTATCTATGTAG 3’ 
5’fp rev:    5’ CCCTGTCTCTCCTCTGCC 3’ 
Short Arm 5’  
SA5’ for: XhoI/NotI 5’CCGCTCGAGGCGGCCGCGAGACATACACTACCATCAG 3’ 
SA5’ rev: HindIII  5’ CCCAAGCTTGGCTTAGACATCCAGCAGACTG 3’ 
Short Arm3’  
SA3’ for: BamHI  5’ CGGGATCCCCTGTAGTTACACAAGTAGCC 3’ 
SA3’ rev: ClaI  5’ GTCAATCGATGCGACCTGGGCCCTGCTGGC 3’ 
Inner Arm5’  
IA5’ for: SalI  5’ ACGCGTCGACCTCTGGGCATGTGAGAAGCCCC3’ 
IA5’rev:SalI   5’ TTCCGCGGCCGCTATGGCCGACGTCGA... 
    ...CCAGCACCTGCCCAAAGCGACC 3’ 
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Primers for quantitative realtime PCR: 
 
rorc: 
RORγt forward   5’ TTTGGAACTGGCTTTCCATC 3’ 
RORγt reverse   5’ AAGATCTGCAGCTTTTCCACA 3’ 
hprt: 
HPRT forward   5’ CTGGTGAAAAGGACCTCTCG 3’ 
HPRT reverse   5’ TGAAGTACTCATTATAGTCAAGGGCA 3’ 
Tbx21: 
Tbet forward 5’ GTGGATGTGGTCTTGGTGGAC 3’ 
Tbet reverse   5’ ACATATAAGCGGTTCCCTGGC 3’ 
rora: 
ROR forward  5’ TCTCCCTGCGCTCTCCGCCGCAC 3’ 
ROR reverse  5’ TCCACAGATCTTGACTGGA 3’ 
 
Primers for genotyping of the conventional Irf1 knockout mice: 
 
Irf1: 
IRF-1 F:   5’ TTCCAGATTCCATGGAAGCACGC 3’ 
IRF-1 R   5’ ATTCGCCAATGACAAGACGCTGG 3’ 
 
 
 
2.1.11 SOFTWARE 
GraphPadPrism4 GraphPrism
Cell Quest Pro Becton Dickinson
FlowJo Tree Star
CellF-Imaging Software Olympus
Relevation™ Dynex
XPlasMap Freeware
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2.1.12 STATISTICAL ANALYSIS 
 
Statistical calculation for asthma experiments was performed with 1 way ANOVA 
analysis including the Tukey’s Multiple Comparison Test. Associated data points were 
analysed by Grubb’s test to exclude significant outliers. 
(http://www.graphpad.com/quickcalcs/Grubbs1.cfm) 
 
 
2.1.13 SERVICES 
 
All sequencing has been conducted at Seqlab Sequencing Laboratories Göttingen 
(www.seqlab.de) 
 
 
2.1.14 DATABASES AND ONLINE TOOLS 
 
BLAST:    http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Ensembl mouse:   http://www.ensembl.org 
Primer design and analysis: http://frodo.wi.mit.edu/primer3/ 
Invitrogen’s Vector NTI:  http://www.invitrogen.com 
Online Vector drawing tool: http://www.infosake.com/plasmid/plasmidFrame.php 
ApE – Plasmid editor:  http://www.biology.utah.edu/jorgensen/wayned/ape/ 
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2.2 METHODS 
 
 
2.2.1 GENERATION OF A CONDITIONAL KNOCKOUT MOUSE LINE FOR IRF1 
 
2.2.1.1 PREPARATION OF GENOMIC DNA FROM MOUSE TISSUE 
 
For genotyping Irf1-/- mice, DNA was extracted from mouse ear punches by using the 
PUREGENE® DNA Purification Kit following the manufacturer’s instruction protocol for 
mouse tails. PCR was performed according to Matsuyama et al. (1993). In analogy to 
this mouse the targeting stategy was developed as described in 2.2.1.6. 
 
 
2.2.1.2 STANDARD POLYMERASE CHAIN REACTION (PCR) 
 
PCR is used to amplify a single or a few copies of a particular DNA fragment by 
repeated cycles of denaturation, primer annealing and generation of the complementary 
strand, thereby leading to exponential amplification of a selected part of the DNA 
template. 
Here, PCR was used to amplify all DNA fragments of the murine Irf1 gene needed for 
the construction of the target vector to manipulate the Irf1 gene for the generation of the 
conditional gene knockout. For amplification of all Irf1-fragments, the Bacterial 
Artificial Chromosome BACclone RP23-303F24 IRF1 was used as template DNA. 
Specific primers were used as indicated in the primer list. The primer sequences (see 
section 2.1.10) included sequences for specific restriction sites (see section 2.1.10) to 
allow cloning into the target vector pEasyFlox.  
The primers for the short arm (SA) on the 3’ end of the targeting location were 
combined with restriction sites for ClaI and BamHI, SA5’ for HindIII and XhoI; in 
addition, the inner arm (IA) primers received the restriction site for SalI on both sides. 
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OPTIMIZING PCR CONDITIONS 
 
Each PCR needed optimised conditions as indicated in the following table (Tab. 2.1). 
For amplification, high fidelity polymerases with proofreading activity were used. All 
PCRs constisted of a 3 step PCR programm with 30 cycles and were conducted in a 
Biometra Gradient Cycler.  
 
To develop a functional PCR protocol, several considerations were made: 
 
a) First, the amount of target DNA should not exceed certain limits in order to allow 
molecule amplification, rather than to catch too many primers which would prevent 
amplification. 
 
b) For genomic DNA, 100 ng are sufficient, plasmid DNA can be used to a lesser 
extent, mainly due to its having fewer secondary structures. Although a BAC clone 
carries the whole gene but is still a plasmid, 60 ng were considered and proven to be 
sufficient. 
 
c) The CG-content of primers should be between 40-60 % for optimal annealing. 
 
d) The calculated melting temperarture Tm of both primers used in the reaction should 
not differ by more than 5 C. 
 
e) Annealing temperature is usually chosen 5 C lower than calculated Tm, but was 
tested empirically for each reation. 
 
f) Complementary sequences between both primers and secondary structures such as 
hair pins should be avoided. Using primer design programme primer3 and BLAST 
search help to avoid secondary structures and improves primer specificity. 
 
 
 
 
 
MATERIAL AND METHODS 44
Table 2.1: PCR conditions and protocols for amplification of the required gene fragments of the 
Irf1 genomic locus (SA3’, SA5’, 5’fp, and IA) to be cloned into the target vector and for the probe, as 
required for Southern blot detection. The fragment sizes refer to their genomic lengths. Below, the cycler 
conditions are listed. 
 
Gene fragments  SA3', 575 bp SA5', 541 bp 5’fp, 532 bp IA, 1662 bp 
10x PCR Buffer 
according to 
polymerase 
5 µ buffer without 
MgSO4  
5 µ buffer with 
15 mM MgSO4  
5 µl KOD 
buffer 
5 µl buffer with 
15 mM MgSO4  
MgSO4 (25 mM) 5 µl 5 µl 5 µl 5 µl 
dNTPs 10 mM ea 1 µl 1 µl 1 µl 1 µl 
forward primer 10 µM 0.5 µl 0.5 µl 0.5 µl 0.5 µl 
reverse primer 10 µM 0.5 µl 0,5 µl 0,5 µl 0.5 µl 
polymerase 
0.5 µl Pfu-Pol 
(2,5 U/µl) 
0,5 µl Pfu-Pol 
(2.5 U/µl) 
KOD-Pol 
(1 U/µl) 
0.5 µl Pfu-Pol 
(2.5 U/µl) 
template DNA, 
60 ng/µl 1 µl 1 µl 1 µl 1 µl 
aqua dest. ad 50 µl 36.5 µl 36.5 µl 40 µl 36.5 µl 
          
Initiation 94 °C, 3 mins 94 °C, 3 mins 94 °C, 2 mins 94 °C, 3 mins 
Denaturation 94 °C, 1 min 94 °C, 1 min 94 °C, 15 sec 94 °C, 1 min 
Annealing 60 °C, 1,5 mins 62 °C, 1,5 mins 55 °C, 30 sec 65 °C, 1,5 mins 
Elongation 72 °C, 2,5 mins 72 °C 2,5 mins 68 °C, 1 min 72 °C 2,5 mins 
terminal elongation 72 °C, 7 mins 72 °C 7 mins 68 °C, 3 mins 72 °C 7 mins 
     
 
 
 
 
Subsequently, the PCR reactions were analysed by agarose gel electrophoresis. 
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2.2.1.3 AGAROSE GEL ELECTROPHORESIS 
 
Gel electrophoresis includes a group of techniques to separate and characterise 
molecules in terms of their physical properties, such as size, shape or charge. 
The simplest method to detect and analyse nucleic acid is agarose gel electrophoresis. A 
PCR-product, digestion fragment or genomic DNA can be separated and visualised in 
the agarose via ethidiumbromide staining. Depending on the fragment size, the densitiy 
of agarose was chosen from 1.5 % for smaller PCR-products, 1 % for larger PCR-
products and restriction reactions as well as 0.8 % for genomic DNA samples. 
 
 
2.2.1.4 GEL CLEAN-UP 
 
To extract and dissolve single DNA fragments from the gel matix, the NucleoSpin® 
Extract II-kit by Macherey & Nagel was used according to the manufacturer’s 
instructions. In brief, the DNA containing gel piece was redissolved in buffer and 
loaded onto a silica membrane that catches the DNA. The purified DNA fragment was 
then eluted in distilled, sterile water. All subcloned Irf1 DNA fragments designated for 
cloning into the target vector were excised from the agarose gel and purified as 
described above. 
 
 
2.2.1.5 PCR CLEAN UP 
 
DNA fragments that did not need to be separated from a mixture of DNA fragments of 
different sizes such as PCR products, were also purified by using the NucleoSpin® 
Extract II-kit by Macherey & Nagel. Here, the main point was buffer exchange and 
removal of unbound nucleotides and unused primers. DNA fragments were eluted in 
distilled sterile water. All Irf1 PCR fragments appointed for subcloning into the 
pBluescript vector and the 5 prime probe for Southern blot detection were purified as 
just described.  
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2.2.1.6 CLONING OF THE TARGET VECTOR 
 
The targeting strategy was based on the Cre-lox system (see 1.3.1.2). For this purpose 
the plasmid pEasyFlox, which contains 3 loxP sites was used. The fragment for the 
inner arm (IA) was cloned into this target vector between two loxP sites. The vector 
also carries a neomycin gene cassette for selection of positively targeted ES cell clones 
(see 2.2.1.16), which is also flanked by loxP sites.These loxP sites served to remove the 
neomycin gene cassette later on. The process of site-directed recombination from the 
vector into the ES cell requires flanking genomic regions, the so called short arms 
(herein termed SA3’ and SA5’), which were cloned on both sides of the floxed region. 
In the following, this cloning is described in detail.  
 
 
 
 
 
Figure 2.1: Homologous recombination and targeting strategy for the conditional gene targeting of 
the Irf1 locus with indicated exons 1-10. The exons 4-8 (inner arm=IA) will be deleted. The short arms 
(SA5’ and SA3’) are designated for homologous recombination. The 5’probe (5’fp) is located in the 
untouched adjacent region to detect all manipulations. 
 
 
According to the targeted disruption of the Irf1 gene in the conventional knockout 
mouse that has been generated by Tak Wah Mak and colleagues (MATSUYAMA ET AL. 1993), 
the same genomic location for the conditional knockout was chosen, with one 
exception: Whereas Mak and colleagues eliminated exons 3-7, we decided to disrupt 
exons 4-8, because this way we did also not stay in the reading frame, and because the 
initially intended strategy implied the use of a genomic Sfi-restriction site, which was 
also available in the target vector. This Sfi restriction site is located at the 3’ end of the 
intron sequence (SA3’) adjacent to exon 8 and therefore the area downstream of exon 8 
rather than exon 7 was used for homologous recombination. After the first attempts of 
the construction of the target vector the advantage of this Sfi restriction site was revised 
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and a closely located ClaI restriction site was finally used. However, by exchanging the 
restriction site, the overall strategy was still applicable and not changed.  
Staying out of the reading frame was of great importance for our strategy. The starting 
point of translation is at the beginning of the second exon. Together with the third exon, 
this region encompasses less than 200 nucelotides. By destroying the reading frame as a 
result of the Cre-mediated recombination, any transcript of the exons behind the 
targeted exons will (together with the short product of exons 2 and 3) encode for a 
product that has no IRF1-related function, because it most likely forms no functional-
related 3-dimensional structure. Alternatively, the knock-out may be able to influence 
splicing of the hypothetical transcript of exons 9 and 10 so that splicing is no longer 
possible. In this situation, only exons 2 and 3 will result in a very small product which 
most likely will be degraded by nonsense mediated decay processes (personal 
comunication with Dr. Sandra Beer-Hammer, AG Prof. Dr. Pfeffer). The conventional 
knockout mouse only transcribes a short mRNA, which is not yet translated (MATSUYAMA 
ET AL. 1993). This small RNA is detectable by Nouthern blot. In analogy, if our 
conditional knockout mouse (after crossing with a Cre-deleter mouse) would transcribe 
a similar small RNA, it should also be detectable by Northern blot. 
Sequences for flanking probes that are needed for genomic Southern blotting were 
chosen in adjacent regions which are not to be manipulated to ensure exact genomic 
positioning of the recombined Irf1 exons. 
In a first step, specific Irf1 PCR products were subcloned into pBluescript (Fermentas) 
and were sequenced by the Sequence Laboratory Seqlab. By using Blast alignment, the 
sequences were verified. The plasmids were transformed into E.coli strain DH10B by 
heat shock transformation. To do this, chemically competent (refer to section 2.2.1.9) 
bacteria were mixed with ligated vector and incubated at 42 C for 2 mins, followed by 
30 mins rest on ice and finally plated on LB agar dishes, supplemented with ampicillin 
(refer to section 2.2.1.10).  
From the pBluescript vector, the Irf1 gene fragments were then cloned into the target 
vector pEasyFlox. This vector was constructed by Klaus Rajewskys Lab and was kindly 
provided by Prof. Dr. Klaus Pfeffers Lab in Düsseldorf. 
After completion, the target vector was re-sequenced (see appendix) and several control 
digestions were performed to verify correctness of the insertions. 
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2.2.1.7 Digestion of DNA 
 
Plasmid (usually 500 ng or up to 1 µg) or genomic DNA (for Southern blotting up to 10 
µg) was digested according to the manufacturer’s instruction for the individual enzyme. 
In general, 5 units of a given enzyme were used for plasmid digestion and 20-30 units 
were used for genomic DNA (see also section 2.2.1.19). 
 
 
2.2.1.8 Ligation of DNA 
 
Ligation of vector with insert DNA was performed according to the manufacturer’s 
recommendation for T4-ligase (Fermentas). 
 
 
2.2.1.9 PREPARATION OF CHEMICALLY COMPETENT CELLS 
 
Competent cells are bacteria in a physiological state which allows DNA uptake from the 
surrounding medium. By manipulation with rubidium chloride, this state can be 
experimentally induced. 
 
A fresh LB-medium culture was inoculated with 500 µl of a 3 ml overnight bacterial 
culture and was incubated on a shaker at 37 ºC until an optical density OD600 of 0.6-0.7 
was reached. This is equivalent to 3.3 Macfarlane (McF). The bacteria were pelleted at 
3000 rpm for 8 mins at 4 ºC. The supernatant was discarded, the pellet was resuspended 
in 33 ml RF1 buffer and incubated on ice for 15 mins. 
Again, the suspension was centrifuged at 3000 rpm for 8 mins at 4 ºC, followed by 
resuspension of the pellet in 5 ml RF2 buffer and 15 mins incubation on ice. After 
repeated resuspension, the solution was shock frozen at 100 µl aliquots and stored at 
-80 °C. 
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2.2.1.10 HEAT SHOCK TRANSFORMATION  
 
Each single aliquot of chemically competent bacteria was supplemented with 1-5 µl of 
ligation mix from an overnight ligation reaction and incubated on ice for 30 mins. 
Subsequently, the mixture was heat shocked at 42 ºC for 2 mins, immediately cooled on 
ice for 5 mins before being transferred into 1 ml of pre-warmed LB-Medium and shaken 
for 45-60 mins at 37 ºC. Subsequently, the bacteria were pelleted in a centrifuge at 1500 
rpm. The pellet was resuspended in 100 µl LB-Medium, 10 µl and 90 µl were plated 
seperately on selection agar plates supplemented with antibiotics and incubated 
overnight at 37 ºC. 
 
 
2.2.1.11 PLASMID CRACKING 
 
E.coli cells can be disrupted in alkaline solution containing detergent. 
This method is a quick test for the presence of the desired insert in plasmids, as long as 
the insert is at least approximately 1000 bp in size. The lysate of one large colony 
contains a sufficient amount of DNA to be detected in a single lane of an agarose gel. 
Cell material from a single colony was transferred into a reaction tube containing 25 µl 
cracking mix and 25 µl 10 mM EDTA. The mixture was incubated for 5 mins at 70 ºC, 
followed by cooling on ice. Vigorous vortexing may help to break genomic DNA into 
fragments of 20-30 kb in size, although this step is not mandatory. The samples were 
completed by adding 3 µl of loading dye, consisting of 50 % (v/v) 4 M KCl and normal 
6x gel loading dye. This mixture was incubated on ice for 5 mins followed by a 
centrifugation step for 5 mins at 15000 rpm at room temperature. The supernatant was 
loaded onto a 1 % agarose gel. The empty vector served as control standard instead of a 
DNA ladder. 
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2.2.1.12 PLASMID PURIFICATION 
 
Plasmids needed to be extracted from bacterial cultures and were purified by using the 
NucleoSpin® Plasmid-kit according to the manufacturer’s instructions. Plasmid DNA 
was eluted in destilled sterile water.  
Since a BAC clone is an extremely large plasmid, it needs specialised buffer conditions 
and a size-adapted silica membrane. Hence, the NucleoBond® BAC 100 Kit was used to 
purify the Irf1 BAC clone since it provided optimal purification conditions for BAC 
clones. 
 
 
2.2.1.13 PREPARATION OF EMBRYONIC FIBROBLASTS 
 
All embryonic stem (ES) cell culture work was conducted in the lab of Prof. Dr. Klaus 
Pfeffer (Düsseldorf) with the support of Karin Buchholz.  
 
CD1 mice were killed on day 14 after a positive plug test. Uteri were extracted and 
placed in feeder medium. Embryos were dissected and yolk bags, liver and heads were 
removed. Embryos were sieved, washed and plated on 10 cm culture dishes. When the 
cells had grown to confluence, they were split on 15 cm culture dishes until the cells 
had again grown to confluence, approximately after 4-5 days. These murine embryonic 
fibroblasts (MEFs) were subsequently used as feeder cells in murine stem cell cultures. 
A confluent 15 cm dish was treated with 5 ml Trypsin/EDTA for 10 mins. The reaction 
was stopped with 5 ml feeder medium. 50 µl/well of this suspension were used for 96 
well plates, 100 µl/well for 48 well plates. Larger culture plates were used when 
containing a confluent MEF layer to feed the stem cells. 
 
 
2.2.1.14 FREEZING OF EMBRYONIC FIBROBLASTS 
 
When the embryonic fibroblasts had grown to confluence on 15 cm culture dishes, the 
plates were washed with PBS and trypsinised with 5 ml trypsin/EDTA for 10 mins. 
Resuspended cells were washed once in feeder medium and frozen in freezing medium 
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constisting of 80 % feeder medium, 10 % FCS and 10 % DMSO. One 15 cm dish was 
sufficient for 4 freezing tubes. 
 
 
2.2.1.15 ELECTROPORATION OF EMBRYONIC STEM CELLS WITH THE TARGET VECTOR 
 
To prepare the E14.1 embryonic stem cells for targeting, feeder cells (MEFs) had to be 
thawed 3 days before starting the actual stem cell culture. MEFs were always treated 
with mitomycin C (10 µg/ml), to prevent proliferation. Each feeder cell culture needed 
to be renewed after 3-4 days in order to have sufficient numbers of MEFs, since they 
survive only approximately 4 days.  
Embryonic stem cells were cultured for 10 days in ES- cell medium together with the 
MEFs before electroporation. The ES cells were treated every day by either exchange of 
media or splitting onto larger MEF containing plates, starting with dishes 5 cm in 
diameter via 10 cm dishes up to 15 cm in diameter; 5x107 stem cells (usually pooled 
from 3 15 cm-dishes, resuspended in 7 ml PBS without Mg2Cl) are sufficient for 10 
vials for parallel electroporation with the linearised target vector.  
The ES cells were electroporated in 800 µl PBS without salts at 125 µF and 500 V. 
After a rest of 10 mins on ice, the contents of each cuvette was distributed onto two 
MEF containing 10 cm dishes for 2 days before selection with Geneticin (G418, 
200 µg/ml) was begun. G418 is an antibiotic that can be neutralised by a neomycin 
resistance gene which was included in the target vector. Cells that survived in G418 
supplemented media were successfully transfected. To select against non-homologous 
recombination events, the nucleosid analogue Gancyclovir (2 mg/mg) was added to 
the culture. In the case of random insertion of the thymidine kinase from the target 
vector into the ES cell DNA as an indication of non-homologous recombination, the 
cells die. The use of the guanine analogue Gancyclovir leads to early termination of 
DNA replication, which results in nonsense gene products.  
Positive (=“targeted”) clones were picked on day 10 and verified by Southern blotting. 
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2.2.1.16 SCREENING OF ES CELL CLONES AFTER GENE TARGETING 
 
The medium in the 10 cm culture dishes was exchanged by PBS. 
Single clones were picked from culture dishes with a microtitre pipette in a maximum 
volume of 20 µl and placed in individual wells of a 96 well plate. Only colonies round 
in shape without any obvious signs of differentiation were chosen. Cells of a single 
colony were separated by treatment with trypsin/EDTA at 37 °C for 3 mins only, since 
ES cells react extremely sensitive and may die due to prolonged incubation times. The 
reaction was stopped by adding stem cell medium and fresh feeder cells which were 
provided for each well.  
After 24 hrs the culture medium was replaced by fresh stem cell medium, on day two 
the clones of one 96 well plate were split onto two 48 well plates for freezing on day 4 
(see 2.2.1.15), whereas the 96 well plate was kept cultured until day 7 for screening by 
Southern blotting. On day 4, the 96 well plate was split again onto another 96 well plate 
to generate a duplicate as backup for a second Southern blot screening. Every day the 
culture medium was exchanged, and on day 3 fresh MEFs were provided. For DNA 
preparation directly from the 96 well plates, refer to the Southern blotting section 
2.2.1.19.  
 
 
2.2.1.17 FREEZING OF ES CELLS 
 
First, the culture plates were washed with PBS. To generate a single cell suspension, 
stem cell colonies were separated by trypsin/EDTA for 3 mins at 37C, very 
thouroughly resuspended with stem cell medium to stop the reaction and completed 
with the same amount of freezing medium. The whole plate was sealed, wrapped with 
Saran wrap and cooled down at -20 C for 30 mins and finally stored at -80 C. 
 
 
 
 
 
 
 
MATERIAL AND METHODS 53
2.2.1.18 CRE-MEDIATED DELETION OF THE NEOMYCIN GENE CASSETTE IN EMBRYONIC 
STEM CELLS 
 
It is necessary to delete the neomycin gene cassette (neo) from the genome to generate a 
targeted site which is only modified by loxP sites. Therefore, the ES cell clones, in 
which integration of the targeting vector had been verified by Southern blotting, were 
transiently transfected by electroporation with 30 µg of the pICre plasmid which 
encodes for the Cre-recombinase. It expresses low amounts of Cre-recombinase and 
does not replicate. Finally, it vanishes from the culture by dilution due to cell 
expansion. The efficiency of neo deletion is approximately 1-10 %. 
Positively targeted clones (as depicted in Fig. 2.2) were thawed and expanded in stem 
cell medium with MEFs until they formed a confluent layer on a 10 cm culture dish. 
Approximately 5x106 cells were electroporated as described in paragraph 2.2.1.15. Two 
days after electroporation, the cells were plated at low densities (5x103, 1x104, 5x104 
cells) on 10 cm dishes with feeder cells. The stem cells were fed daily with fresh 
medium. On day 8 after electroporation, clones were picked and cultured as before for 
the targeting and subsequently for screening as described in paragraph 2.2.1.16. 
 
 
 
 
 
Figure 2.2: Scheme of the successfully targeted Irf1 gene with indicated exons 1-10. Arrows indicate 
the inserted loxP sites. IA=inner arm, SA5’=short arm 5’ of IA, SA3’=short arm 3’  of IA, neo=neomycin 
resistance gene cassette. 
 
 
2.2.1.19 SOUTHERN BLOTTING 
 
Southern blotting is a combined method for the detection of specific DNA sequences 
within a DNA sample first separated by agarose gel electrophoresis and transfered to a 
positively charged nylon membrane, subsequently followed by probe hybridisation. The 
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gene-specific probe can be labelled either radioactively or with a fluorescent dye. Here, 
radioactive labelling was used, as it provides higher sensitivity. This method was first 
introduced by the British biologist Erwin Southern (SOUTHERN 1975).  
 
 
PREPARATION OF GENOMIC DNA FROM ES CELL CULTURES 
 
96 well culture dishes with grown ES cells were washed with PBS and cell lysis buffer 
was applied, freshly supplemented with 0.4 mg/ml proteinase K. After overnight 
incubation in a wet chamber at 56 C, the DNA was precipitated by 100 % ethanol, 
followed by two washing steps with 70 % ethanol.  
For verification of single positive clones, cells were thawed from 48 well plates, 
recultured and subsequently split on 6 well plates via 24 well and 12 well plates. The 
confluent cell culture on the final 5 cm dish was harvested and distributed equally into a 
precooled cryotube (see section 2.2.1.17 for freezing details) and into a 15 ml tube for 
lysis. After precipitating with 100 % ethanol, the DNA could be wound up with a 
pipette tip or glass stick and rinsed by dipping into 70 % ethanol. The DNA was then 
resolved in distilled water or 10/1-Tris/EDTA buffer. 
 
 
DIGESTION OF GENOMIC DNA  
 
For largescale screening of ES cell clones, digestion of DNA was performed within the 
96 well dishes, and for single clones in Eppendorf reaction tubes. Overnight digestions 
were performed by mixing end-concentrations of 1 x enzyme-specific reaction buffer 
with 1 mM DTT, 100 µg/ml BSA, 50 µg RNaseA and 20-30 units of enzyme in distilled 
water. 20-30 units of enzymes were used per digestion in a 96 well dish or per 15 µg 
DNA. 
For targeting confirmation, digestion with AvrII/XmaJI was used to detect insertion of 
the neomycin gene cassette into the target site of the Irf1 gene, since AvrII restriction 
sites flank this region. 
As the neomycin gene introduces a new SpeI restriction site into this genomic region, a 
digestion with SpeI was performed for additional confirmation. 
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For neomycin deletion, an additional digestion was performed with BamHI. This 
restriction site was used to insert SA3’ into the target vector and is not located in the 
wildtype genome. This way it was possible to distinguish between a wildtype allele and 
a floxed allele after neo deletion.  
 
 
 
 
 
 
 
Figure 2.3: Overview of all possible events on the Irf1 gene by intracellular Cre expression and how 
to distinguish between these fragments. Restriction analysis with BamHI will result in a fragment of 5263 
bp for the wildtype allele, 1215 bp, if both IA and Neo were removed, 2877 bp in case of neo deletion in 
the floxed allele and 4823 bp in case of inactive Cre in the targeted Irf1 sequence. Additional information 
will be given by restriction analysis with SpeI to prove neo existence with a fragment of 5247 bp. 
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SOUTHERN BLOTTING  
 
Digested DNA was separated by agarose gel electrophoresis with 0.6-0.8 % agarose at 
25-30 V overnight. Afterwards, the gel was incubated on a shaker in 0.25 N HCl, 
followed by denaturating buffer and neutralising buffer, each step for 20-30 mins. 
Capillary blotting was performed with 10x SSC overnight (Fig. 2.4). For fixation of the 
DNA on the membrane, the membrane was baked for a minimum of 30 mins at 80 C. 
 
LABELLING AND HYBRIDISATION 
 
The probe was labelled with 32P by random priming with 32P--dCTP nucleotides 
according to the manufacturer`s instructions. In brief, 20 ng of 5’ probe DNA were 
mixed with reaction buffer, random primers, 50 µCi 32P and Klenow-fragment and 
incubated for 30 mins at 37 C, followed by 120 mins incubation at room temperature. 
Unbound nucleotides were removed by using sephadex columns according to the 
manufacturer’s instructions. For better efficiency, samples were loaded twice. The 
labelling efficiency was measured in a scintillation counter by Cherenkov radiation 
measurement. This is electromagnetic radiation emitted when a charged particle such as 
an electron passes through an insulator at a constant speed which is greater than the 
speed of light in that medium. The charged particle polarises the surrounding molecules, 
which then rapidly return to their ground state by emitting light. This is the 
characteristic blue glow of nuclear reactors in atomic power plants is due to Cherenkov 
radiation, named after the Russian scientist Pavel Alekseyevich Cherenkov, who 
received the Nobel Prize in 1958 and was the first to characterise this phenomenon 
(CHERENKOV 1934). 
 
For hybridisation, the large blot membranes were rolled into hybridisation meshes to 
ensure open access of the labeled probe to the whole membrane. Hybridisation was 
performed overnight in hybridisation flasks at 42 C, followed by several washing 
steps:  
2x washing buffer 1 at RT 
1x 30 mins at hybridisation temperature 42 C with washing buffer 1 
1x 30 mins at 50 C with washing buffer 1 
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followed by several washing steps each for 30 mins with washing buffer 2 and 
increasing temperature up to a maximum of 65 C, until the radiation intensity was 
below 80 Bequerel (Bq). 
 
For autoradiography, each membrane was wrapped with Saran foil before being placed 
on a film. The film was exposed in an exposure cassette with two intensifying screens 
overnight or for 3 days at -80 C to enhance the signal. 
 
 
 
 
 
Figure 2.4: Scheme of a Southern blot set up. The DNA is transferrd from the gel onto the membrane 
by capillary forces that run through the pile. 
 
 
2.2.1.20 BLASTOCYST INJECTION 
 
This work was conducted by Nicole Küpper, technician in Prof. Dr. Klaus Pfeffer’s lab, 
our cooperation partner in Düsseldorf. 
 
12 C57BL/6 females were treated with 5 U pregnant mare’s serum (PMS) and two days 
later with 5 U human chorionic gonadotropin (hCG) to induce super-ovulation before 
being mated to C57BL/6 males. 
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Uteri of pregnant C57BL/6 females (day 3.5 post “conception”) were extracted and 
placed into a 35 mm culture dish containing M2 medium. Horns of uteri were flushed 
with M2 medium using a 0.25 gauge needle to blow out the blastocysts.  
 
Vasectomised males are needed to produce pseudopregnant females which will receive 
the blastocytes by uterine transfer. After mating with a sterile male, the female 
reproductive tract becomes receptive for transferred embryos, while the own unfertilised 
eggs degenerate.  
 
Blastocyst transfer was performed according to standard procedures (HOGAN ET AL. 1994). 
In brief, for blastoycst transfer, the lower back of the anesthesised recipient mouse was 
shaved and desinfected. The transfer pipette was loaded with blastocysts. The uterus 
was layed open during surgery and blastocysts were gently transferred. In general the 
transfer results in 75 % of embryos coming to term. 
 
 
 
2.2.2 PROTEIN-BIOCHEMICAL METHODS 
 
2.2.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
ELISA is a biochemical method of detecting and quantifying antibodies or antigens in a 
liquid sample which bind to a surface-bound capture antibody. In a second step an 
antigen-specific detection antibody is bound onto the antigen that receives either 
another amplifying antibody which carries an enzyme such as horseradish peroxidase 
(HRP) or alkaline phosphatase (AKP) or is linked to the enzyme itself. The substrate for 
the enzyme causes a colour change which is detectable by photometric analysis.  
Cell culture supernatants and brochoalveolar lavage (BAL) fluid were tested for 
secreted cytokines such as IL-22, IL-17 and IFN-γ. For IL-17 the DuoSet ELISA®-kit 
was used whereas for IL-22 Ready-SET-Go! ®-kit was applied. 
For quantification of secreted OVA-specific immunoglobulins of the IgG1 and IgG2a 
(BALB/c mice) IgG2c (C57BL/6 mice) subclasses ELISAs from serum samples were 
performed. The consecutive procedure, when a non-commercial protocol was applied, 
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was the following. 96-well flat-bottom plates were coated overnight in a wet chamber at 
4 ˚C with a suitable capture antibody or with 20 µg/ml OVA (Grade VI) in 0.1 M 
NaHCO3 pH 8.3. The next day, the plates were washed and blocked with PBS/1% BSA 
for 2 hrs at room temperature. After several washings, 40 µl of the samples were loaded 
and incubated overnight at 4 ˚C in a wet chamber. Cell culture supernatants and BAL 
were used pure or diluted up to 1:20. For the detection of OVA-specific antibodies 
sample dilutions of 1:1000 for IgG1 and 1:10 for IgE were used. Secondary antibodies 
were applied after further washing. Depending on the enzyme coupled to the detection 
antibody, either p-nitrophenyl phosphate (PNPP) or blue horseradish peroxidase (POD) 
substrate solution was added. Finally, the absorption at 405 nm or 450 nm was 
measured in a photospectrometer. 
 
 
2.2.2.2 SURFACE STAINING 
 
Expression of surface molecules was verified by specific fluorescence-labelled antibody 
staining. Cultured cells were washed in PBS/1% FCS and incubated for 15 mins in the 
fridge with the desired antibody. Thereafter, unbound antibodies were removed by a 
following washing step with PBS/1% FCS. 
 
 
2.2.2.3 INTRACELLULAR CYTOKINE STAINING (ICS) 
 
After surface staining the cells were fixed in 2 % paraformaldehyde for 15 mins at room 
temperature. A washing step with PBS/1% FCS and one with saponin-buffer was 
followed by adding of 100 µl of staining solution containing cytokine-specific 
antibodies in saponin-buffer. The resuspended cells were incubated for 15 mins at 4° C 
in the dark. Surplus antibodies were washed off with saponin-buffer and subsequently 
PBS/1% FCS. 
Afterwards  the cell samples were analysed by flow cytometry using a FACS Calibur 
machine. 
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2.2.3 ASTHMA EXPERIMENTS 
 
2.2.3.1 MOUSE MODEL FOR ADJUVANT-FREE ACUTE ALLERGIC ASTHMA 
 
The induction of allergic asthma is based on an inflammatory reaction against an 
otherwise harmless allergen. For this model 3 subcutaneous injections (s.c.) of 10 mg 
ovalbumin Grade VI (OVA) in PBS without any adjuvant, such as alum, were applied 
for sensitisation (day 0, 7 and 14), followed by 20 mins 1 % OVA Grade V aerosol 
treatment on days 26, 27, 28 (Fig 2.5). The inhalation of the allergen causes the 
infiltration of eosinophils and lymphocytes into the lung tissue. If lung function was 
measured on day 29, then the mice were killed on day 30 by a final dose of narcosis 
solution, otherwise the mice were killed on day 29. 
In the herein described experiments Irf1-/- and control mice (n=8 mice per group) were 
sensitised as indicated.  
These experiments were performed in collaboration with the SFB/TR22 and the group 
of Prof. Renz in Marburg. 
 
 
 
 
 
 
Figure 2.5: Sensitisation protocol for acute murine experimental asthma induction. Numbers indicate 
days of treatment. 
 
 
2.2.3.2 PREPARATION OF SERUM  
 
Mice were killed with a final dose of 5x narcosis-solution. Blood was drawn from 
axillary blood vessels for serum antibody analysis. After clotting (45 mins at RT) serum 
was separated by centrifugation at 4000 rpm for adjacent quantification of 
immunoglobulins by ELISA as described above. Meanwhile, serum samples were 
stored at -20 C. 
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2.2.3.3 BRONCHOALVEOLAR LAVAGE (BAL) 
 
The thorax was opened and lungs of OVA-sensitised or PBS control mice were first 
rinsed with 1 ml PBS through the trachea with a 20 G needle, followed by additional 4 
ml PBS. The BAL contains cells from proximal and distal airways. The cell content of 
the first millilitre was pelleted and the supernatant was stored at 20 C for later analysis. 
The cells were again resuspended in 1 ml of PBS, counted in a Casy® cell counter and 
further analysed for morphological quantification of invaded cell populations per 
millilitre using a cytospin. Afterwards, both the residual of the first millilitre and the 
4 ml were jointed and the remaining cells were restimulated with PMA and ionomycin 
(refer to section 2.2.4.7) in the presence of BrefeldinA for cytokine expression analysis 
by intracellular cytokine staining. Since the amount of cells in the BAL fluid differ 
between the individual animals, equal numbers of cells, usually 1x105-2x105 cells/ well 
on 96 well plates, were restimulated. 
 
 
2.2.3.4 CYTOSPIN ANALYSIS 
 
The BAL cells were pelleted, supernatants were stored for other analyses, and the cells 
were again resuspended in PBS/1% BSA. 50 µl of this suspension was diluted in 150 µl 
PBS/1 % BSA. By using a cytospin at 700 rpm for 5 mins the cells were directly 
adhered onto an object slide. For differential cell type counts the cells needed to be 
stained. To do this, the DiffQuick® method was used. After air drying of the object 
slides, the cells were fixed and dipped into eosin staining solution for 1 min, followed 
by staining with heamatoxyllin solution. Surplus staining solutions were rinsed away 
with water. At 400 x magnification the cells were microscopally distinguished and 
populations were counted. 
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2.2.3.5 LUNG EMBEDDING 
 
After the BAL, the left lung was disconnected from the rest of the organ close to the 
bifurcation of the lungs by using a thin thread. This part of the lung was frozen in liquid 
nitrogen and stored for the possibility of later RNA analysis. 
The right lung was then filled and thereby fixed with 6 % paraformaldehyde (PFA). 
Fixation was completed by storing the lung in 6 % PFA for 24 hrs. Subsequently, the 
lungs were embedded in 2 % agarose and according to „Systematic Randomised 
Uniform Sampling“ (SURS) cut into 6 mm thick pieces and embedded in paraffin wax. 
The embedding of the lungs was conducted in Marburg in the Institute of Pathology of 
the University Hospital Gießen and Marburg. 
 
 
2.2.3.6 PREPARATION OF LUNG SLIDES 
 
The paraffin-embedded lungs were cut into thin slices of 3 µm thickness by using a 
microtome and placed onto object slides. This work was done in the group of Prof 
Renz, our cooperation partners within the SFB/TR22. 
 
 
2.2.3.7 HAEMATOXYLIN-EOSIN-STAINING ( HE)-STAINING 
 
For examination of actual pathophysiological changes and lung damage induced by 
allergic asthma, the lung slices were stained with haematoxylin and eosin. First the 
samples were de-paraffinated in xylol (2x 10 mins) before rehydration in descending 
alcoholic concentrations (each step 2x 5 mins in 100 %-, 5 mins 96 %,- and 5 mins 
70 %- ethanol). After rinsing with water, the slides were stained in haematoxylin for 3 
mins. A resting step in water for 5 mins secured persistence of the blue staining in the 
tissue. Next, the samples were stained in eosin for 2 mins and again rinsed with water. 
Afterwards the tissue was dehydrated in ascending alcoholic solutions (1 min in 96 %-, 
2x 3 mins in 100 % ethanol followed by 2x 10 mins xylol). Histomount® was used to 
cover the samples with cover slides. 
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2.2.3.8 PERIODIC-ACID SCHIFF STAINING, PAS STAINING 
 
Mucus production by goblet cells can be taken as a characteristic of the asthmatic lung. 
Because goblet cells are only rarely found in healthy tissue. The periodic-acid Schiff 
staining (PAS) makes these cells visible. Deparaffinated and rehydrated tissue slices 
(see section for HE staining) were incubated in 0.5 % periodic acid for 10 mins and 
washed in water for another 3 mins. The samples were transferred into Schiff’s reagent 
for 15 mins, followed by 1 min in haematoxylin. After a final rinsing step the samples 
were dehydrated in alcoholic solutions (1 min each 70 %, 96 % and 100 % ethanol). 
After final 15 mins incubation in xylol, the object slides were covered. 
 
 
2.2.3.9 OVA-SPECIFIC RESTIMULATION OF LYMPHOCYTES 
 
Trigger-dependent cytokine production gives an additional impression on the severity of 
asthma in line with all other measured parameters. For this purpose spleen and lung 
lymphnodes from all animals of an experiment were meshed for single cell suspension. 
The lymphocytes were antigen-specifically restimulated at 1x106/ml with 10 µg/ml 
OVA in complete medium for 72 hrs on 24 well culture plates. Since the spleen reflects 
only the systemic immune condition of the organism which does not necessarily comply 
with the local immune response in the lung, the option of investigating splenocytes was 
abandoned in later studies. 
 
 
 
2.2.4 -T CELL EXPERIMENTS 
 
IRF4 deficient precursor CD4+ T cells were found to be unable to differentiate into 
Th17 cells (BRÜSTLE ET AL. 2007). The missing transcription factor was responsible for the 
induction of IL-17 cytokine production. However, γδ T cells are partially considered as 
cells of the innate immune system and the regulation of their IL-17 production may 
function differently.  
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2.2.4.1 EXTRACTION OF LYMPHOCYTES FROM LIVER 
 
Mouse livers were prepared, meshed through a sieve with pores of 70 µm in size, and 
again filtered through a second sieve. The pelleted homogenate was resuspended in 5 ml 
40 % Percoll solution (diluted in RPMI media) and layered on 3 ml 70 % Percoll 
solution. The gradient centrifugation was performed at 1600 rpm for 20 mins without 
break and at room temperature. The thin interface contained the lymphocyte population, 
which was harvested by careful pipetting and washed twice in PBS/1%FCS. 
Erythrocytes were lysed by incubation with erythrocyte lysis buffer for 3 mins. The 
procedure was stopped by adding PBS/1 %FCS and cell preparation was finalised by an 
adjacent washing step. 
 
 
2.2.4.2 PREPARATION OF LYPHOCYTES FROM LYMPHOID ORGANS  
 
Thymi, spleens, peripheral and mesenterial lymphnodes were dissected from sacrificed 
mice and sieved through a nylon filter of 70 µm pore size. Erythrocyte lysis followed as 
described before. 
 
 
2.2.4.3 PREPARATION OF WHOLE LUNG HOMOGENATE 
 
Streptococcus pneumoniae-infected mice were killed by injection of a final dose of 5x 
narcosis-solution. Lungs were perfused with PBS through the heart-lung-circulation 
system, before lungs were removed. The organs were cut into small pieces and digested 
with 1 mg/ml collagenase D in PBS for 30 mins at 37 °C. Tissue pieces were sieved 
through nylon filters and centrifuged at 1500 rpm for 5 mins. The resulting homogenate 
was used for restimulation experiments. 
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2.2.4.4 PREPARATION OF INTRAEPITHELIAL LYMPHOCYTES FROM GUT 
 
The faeces was removed from the gut of wildtype and Irf4 knockout mice after 
lengthwise opening and the gut was cut into several pieces. After a quick rinse in PBS, 
the gut pieces were transferred into a 50 ml reaction tube containing 25 ml of complete 
medium and shaken by gentle agitation at 37 °C for 30 mins. Afterwards, the reaction 
tube was shaken vigorously by hand to dissolve the cells out of the epithelium. The 
supernatant was filtered through a sieve, while the gut pieces were shaken again in 10 
ml of fresh media. Again, the supernatant was filtered through a sieve with 70 µm pore 
size. The liquid phase containing the desired cells was centrifuged for 5 mins at 1500 
rpm. If only lymphocytes were desired, a Percoll gradient was subsequently conducted 
as described in 2.2.4.1. 
 
 
2.2.4.5 MAGNETIC CELL SORTING - MACS® OF   T CELLS 
 
To purify  TCR+ T cells out of a mixed cell sample such as lymphoid organ 
homogenate, the MACS® separation technique for positive purification of  T cells 
was used following the manufacturer’s instructions. In brief, magnetically labelled  T 
cells in a given suspension were retained in a magnetic field and eluted after removal of 
the MACS column from the magnetic separator. This method allows a high purity at 
reasonable or even high recovery of the desired cell population. 
 
 
2.2.4.6 STIMULATION OF  T CELLS 
 
Gamma delta T cells were purified as described from peripheral lymphnodes and spleen 
and cultured in 96 well round bottom plates at 1x105 cells/well in 200 µl volume of 
clone media in the presence of 25 ng/ml IL-23, 10 ng/ml IL-1β or both. Polyclonal T 
cell stimulation was induced by adding α-CD3 and α-CD28 dynabeads to the culture at 
a 2/3 ratio, meaning 2 beads/3 cells. These beads mimic activation by antigen presenting 
cells by utilising the same surface molecules bound to a three-dimensional bead similar 
in size to an antigen presenting cell. For the inhibition experiments the NFκB inhibitor 
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PS1145 was used at 5 µM. The cells were cultured for 3 days at 37 °C. If supernatants 
were taken after 48 hrs of culture and FACS measurement was intended, the golgi 
blocker monensin was added to the culture for 4 hrs at a final concentration of 2 µM 
(usually 1 µl/ml) to enrich the amount of intracellular cytokine and prevent its secretion. 
 
 
2.2.4.7 RESTIMULATION WITH PMA AND IONOMYCIN 
 
For ex vivo analysis cells or restimulation after 72 hrs of in vitro culture, 1x105/well γδ 
T cells on 96 well plates were restimulated for 4 hrs with 50 ng/ml PMA and 750 ng/ml 
ionomycin in a total volume of 200 µl. If intracellular cytokine staining was desired, a 
golgi blocker was added to the cell culture, either 10 µg/ml of brefeldinA or a final 
concentration of  2 µM (usually 1 µl/ml) monensin, to enrich the amount of intracellular 
cytokine and prevent secretion. 
 
 
2.2.4.8 CULTURE OF STREPROCOCCUS PNEUMONIAE 
 
For mouse infection experiments, 10 µl of a Streptococcus (Strep.) pneumoniae frozen 
aliquot were plated on Columbia agar plates and incubated at 37 C overnight. The next 
day, 20 ml of a 1:1 mixture of LB-medium and FCS were inoculated with 1-3 colonies 
and placed on a shaker at 37 C with intermediate rotation until an optical density of 1 
McF was reached, taking approximately 8 hours, since Strep. pneumoniae is a relatively 
slow growing bacterium. This density equals 250-500 million cfu/ml.  
For infection of mice, the bacteria were pelleted by centrifugation at 4000 rpm for 5 
mins and washed 3 times with PBS. After resuspension in 1 ml PBS, the bacterial cells 
were ready for infection. 
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2.2.4.9 INFECTION OF MICE WITH STREPTOCOCCUS PNEUMONIAE 
 
C57BL/6 mice and Irf4-/- mice were anesthesised with 1x narcosis solution. Their neck 
slightly overstretched and 20 µl of bacteria-in-PBS-solution was applied intranasally. 
Mice were killed on day 3 after infection, lungs were removed prepared and analysed as 
described. 
 
 
2.2.4.10 CYTOKINE MEASUREMENT BY QUANTITATIVE REALTIME PCR (QRT-PCR) 
 
This PCR technique is used to amplify and simultanously quantify a specific target 
DNA by including a fluorescent probe or dye in the reaction. 
For analysis of the transcriptional regulation of the IL-23 production by γδ-T cells, a 
TaqMan®-PCR for Tbx21, rorc and rora was performed on an ABI Prism 7500 
Sequence Detection System. For RNA sample preparation, cell pellets were washed 
twice in PBS and resuspendend in 200 µl of PBS, followed by RNA isolation via the 
„RNeasy Micro Kit®” according to the manufacturer’s instructions. The resulting RNA 
content was measured by photometric analysis; cDNA synthesis was performed using 
the “cDNA Maxima First Strand Systhesis Kit for RT-qPCR®“ with oligo-dT-primers. 
The following PCR conditions were used for the detection of tbet and rorc/a 
expression: 1x reaction buffer, 2.5 mM MgCl2, 200 µM dNTPs, 250 nM (Tbx21) or 
500 nM (rorc/a) each primer, SybrGreen 1:2000 dilution, 0.025 U of HotGoldstar 
polymerase. The temperature profile was the following: 50 °C 2 mins, 95 °C 10 mins, 
40 repeats 95 °C 15 seconds 60 °C 1 min. Results were normalised to hprt as 
housekeeping gene by the ct method as specified by Applied Biosystems. 
 
 
2.2.4.11 LUCIFERASE ASSAY 
 
293-mTLR9-luc cell are previously described HEK293 cells, which are stably 
transfected with a NκFB luciferase reporter plasmid and mTLR9 104 cells/well were 
seeded in 96 well microtiter plates in 100 µl (DMEM high glucose, 7,5% FCS). After 
8 hrs, the cells were stimulated with CPGs (1 µM CpG-ODN 1668, 
TCCATGACGTTCCTGATGCT; kindly provided by Prof. Dr. S. Bauer; BAUER S. ET AL. 
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2001) and the NFκB inhibitor PS 1145 (Sigma; 5 nM) or medium alone in a total volume 
of 200 µl overnight. The next day, the supernatants were discarded, the cells were lysed 
in 50 µl lysis buffer (Dual-Luciferase Reporter Assay System, Promega) and an equal 
volume of substrate solution (D-luciferin 470 µM, CoenzymeA 279 µM, DTT 33.3 
mM, ATP 530 µM, (MgCO3)4Mg(OH)2x5H2O 1.07 mM, MgSO4 2.67 mM, Tricin 20 
mM, EDTA 0.1 mM, pH7.8, kindly provided by Prof. Dr. Stefan Bauer) was added for 
luciferase detection measurement. This assay was used as a positive control for the 
NFκB inhibitor PS 1145. 
 
3. RESULTS 
 
3.1 GENERATION OF A CONDITIONAL KNOCKOUT MOUSE LINE FOR IRF1 
 
 
Irf1 is expressed in a variety of different cell types. Its functions as tumor suppressor 
and also as key transcription factor for T helper cell differentiation towards a Th1 
immune response are well known in the literature. In order to reveal a cell–specific 
function of IRF1 and a potential role of a certain IRF1 producing cell type in the course 
of a given disease or malfunction, the availability of a conditional IRF1 knockout 
system would be of great benefit. The main task of this thesis project was to generate a 
conditional knockout mouse for Irf1. 
 
Amplification of Irf1 PCR fragments for conditional gene targeting. 
 
With the indicated primers (see 2.1.10) and the availability of the Irf1-BAC clone as 
template DNA, all PCR protocols for the necessary Irf1 gene fragments were able to be 
established (Fig. 3.1.1, the sizes refer to the genomic lengths). The primers comprised 
also the necessary sythetic restriction sites for the respective subsequent cloning step as 
indicated in the following paragraph. 
 
 
 
 
Figure 3.1.1: Successful generation of the PCR products for targeting. a) PCR fragment of the 3’ 
short arm (SA3’), 573 bp in size. b) temperature gradient 60-70 oC for the 5’ short arm (SA5’). 62 oC was 
later used for amplification of the 541 bp long fragment. c) the fragment of the inner arm (IA) was 1662 
bp in size and perfectly amplified. 
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After PCR amplifications and purifications from the gels, all fragments were 
consecutively cloned into the target vector pEasyFlox. First, SA3’ was inserted into the 
vector by digestion of vector and PCR product with ClaI and BamHI, followed by 
ligation. SA5’ was added to the resulting intermediate vector, using XhoI and HindIII 
digestion, thereby also inserting a NotI restriction site into the vector next to the XhoI 
restriction site for later linearisation. Finally, the inner arm (IA) was cloned to complete 
the target vector using only SalI. It was of great importance to keep a determined order 
of insertion for the PCR fragments, since the inner arm sequence came with an internal 
restriction site for XhoI which would have disturbed cloning of SA5’. Hence, IA had to 
be cloned last. 
 
To screen for clones which had incorporated the SA3`and subsequently SA5`, plasmid 
preparations of approximately 50 colonies each of SA3’ and SA5’ (for each insertion 
attempt) were prepared and the plasmids were tested by digestion with the enzymes 
used in the correlative cloning step. Positive clones showed a band of the size of the 
PCR product in addition to the linearised vector. 
 
The insertion of an insert of at least 1000 bp in size could be detected by plasmid 
cracking; Usually, all three bands (supercoiled, linearised and nicked) run more slowly 
in the gel than the bands of an empty vector. This way it was possible to screen litterally 
hundreds of potential clones for successful insertion of the inner arm. The respective 
vector without the desired insert was then used as standard instead of a DNA ladder. 
Fig. 3.1.2 shows an example of an agarose gel of cracked bacterial DNA with a 
promising candidate for IA cloning (and therefore of the completed target vector) that 
was subsequently further analysed. 
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Figure 3.1.2: Agarose gel with DNA-containing supernatant of cracked bacterial clones: check for 
insertion of the inner arm (IA). The left lane contains the empty vector control as standard. 
 
 
In a subsequent step, a clean plasmid preparation of the clone of interest was generated. 
To verify this plasmid as the completed target vector (=“pEasyIRF1”), the sequences of 
all cloned fragments were confirmed and several control restrictions were performed 
(Fig. 3.1.3). 
 
 
 
 
Insertions of all Irf1 gene fragments were reconfirmed by cutting them out the way they 
had been inserted, using the restriction sites that had been added to the inserts during 
PCR-generation in the first place. SA5’ was able to be cut out with HindIII and XhoI or 
NotI (resulting in fragments sized 8031 bp, 1024 bp and 555 bp or 9063 bp and 547 bp, 
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respectively), thereby also verifying the correct direction of IA, which comprises a XhoI 
restriction site asymetrically. SA3’ was able to be cut out with BamHI and ClaI 
(resulting fragments were 9023 bp abd 587 bp) and finally IA insertion was proven by 
digestion with SalI (resulting fragments 1668 bp and 7942 bp). As an additional control 
of the target vector the neomycin cassette was removed by digestion with SalI and 
BamHI (lane 5), thereby again checking for the presence of IA. In addition, general 
vector single enzyme digestions with EcoRI or EcoRV were performed to rule out any 
additional insertions. The in silico predicted fragments of 5185 bp and 4425 bp for 
EcoRI digestion and 4034 bp, 3141 bp and 2331 bp forr EcoRV could be verified after 
digestion with these enzymes. Finally, the linearisation of pEasyIRF1 was tested by 
single restriction with NotI. A linearised plasmid increases the frequency of 
homologous recombination within the target cell after introduction of the target vector 
into embryonic stem cells (ES cells) by electroporation (ORR-WEAVER ET AL. 1981). 
 
 
 
 
Figure 3.1.4: Plasmid map of the finalised targeting vector pEasyIRF1 for the generation of the 
conditional Irf1 knockout (9610 bp). The short arm 3’(SA3’) was cloned via ClaI and BamHI, adjacent 
to the first loxP site. Between the second and third loxP site, the inner arm (IA) was inserted via SalI. 
Bordering the third loxP site, the short arm 5’ (SA5’) was joined in by using HindIII and XhoI. 
 
After proven correctness by restriction analyses and sequencing, 50 µg of the vector 
pEasyIRF1 (Figure 3.1.4) were linearised with NotI and send to Düsseldorf for 
electroporation into E14.1 stem cells, derived from the SV129 mouse strain. 
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SV129 ES cells were electroporated with the linearised pEasyIRF1 and cultured as 
described (see 2.2.1.15). On day 10, 400 ES cell clones were picked from the Petri 
dishes and again cultured in 96 well plates (see 2.2.1.16). Genomic DNA was extracted 
after another 7 days of culturing and digested with XmaJI. The size of the included 
neomycin gene cassette of roughly 2000 bp enabled the easy identification of positively 
targeted ES cell clones by Southern blotting. If any, only one allele would have been 
altered by homologous recombination. Hence, 2 fragments, one for each allele would be 
detected in the successfully targeted ES cell clones. An 8 kb fragment of the targeted 
area was generated by restriction of the wildtype Irf1 allele with AvrII (isoschizomere 
XmaJI); this fragment increased in size in the floxed allele due to the insertion of the 
neomycin gene cassette by approximately 2 kb (Fig 3.1.5). 
 
 
 
 
 
 
Figure 3.1.5: Southern blot autoradiography of large scale ES clone screening. E14.1 ES  cells 
were electroporated with pEasyIRF. 7 days after picking, the genomic DNA was digested with XmaJI and 
Southern blotting was performed. The clones #70 and # 214 show the 8 kb wildtype band and the 10 kb 
band of the targeted allele. For hybridisation, the 5’probe was used. Double combs were used in order to 
load as many samples as possible onto the gel, thereby producing a zigzag pattern of bands. 
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The clones 70 and 214 showed a wildtype band of 8 kb as well as a fragment of 10 kb 
for the targeted allele, which includes the neomycin cassette. 
Hence, both clones were positively targeted (Fig. 3.1.5) and verified separately 
(Fig.3.1.6). For this purpose, the clones were thawed and cultured again as described to 
extract larger amounts of genomic DNA for reliable detection. Both clones could be 
validated as positively targeted ES cell clones. Untargeted ES cell DNA (E14.1) was 
used as control. Both clones #70 and #214 were most likely mixed clones, consisting of 
targeted and untargeted cells, because the wildtype band appeared to be stronger.  
 
 
 
 
Figure 3.1.6: Southern blot autoradiography. Confirmation of the ES cell clones #70 and #214. The 
clones were recultured for expansion and genomic DNA was digested with XmaJI. Untargeted E14.1 ES 
cell DNA was used as a wildtype control. The genomic DNA was digested with XmaJI and Southern 
blotting was performed. For detection, the blots were hybridised with the 5’ probe. 
 
 
Although neomycin is very useful for identification of targeted ES cell clones, it can 
interfere with the expression of neighbouring genes, since it is placed into an intron and 
gene introns also include regulatory elements. Moreover, the target vetcor carries an 
independent promotor for expression of the neomycin gene cassette. This could lead to 
misdirected DNA sequence expression within the targeted cell. To generate a 
conditional knockout as close to wildtype as possible and to exclude any side effects of 
neomycin, the elimination of this resistance gene cassette was desired. Hence, the two 
targeted ES cell clones were transiently transfected by electroporation with the plasmid 
pICre that carries the gene for the Cre recombinase. During clonal expansion the low 
copy plasmid was “diluted out“ of the cell culture. To do this, the clones #70 and #214 
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were thawed, cultured as for the electroporation with target vector, and finally 
electroporated with pICre. This second electroporation also offered the posibility of 
subcloning at the same time, resulting in a pure clone containing only targeted cells. 
Subsequently, ES cell clones were picked and analysed by Southern blotting.  
For verification of neomycin excision and simultaneous detection of the floxed allele 
with distinction from the wildtype allele, BamHI restriction was applied. Since the 
target vector pEasyFlox carried 3 loxP sites, 3 different events could occur (Figure 
3.1.7) and needed to be distinguished. 
 
 
 
 
Figure 3.1.7: Scheme of events that could possibly occur after electroporation of targeted ES cell 
clones with pICre. The Cre recombinase will operate all loxP sites (red) in equal measure. a) Targeted 
DNA with the indicated flanking short arms, inner arm and neomycin resistance cassette, and the 
location of the 5’ probe. b) genomic situation after excision of the inner arm, c) the desired event: 
excision of neomycin, d) deletion of both the inner arm and the neomycin resistance gene. All events can 
be detected with the 5’probe, which was chosen at the border (light blue bar) of the manipuleted 
sequence 
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In order to determine each possible event and to screen for the desired event of only 
neomycin gene cassette deletion, a reliable detection strategy had to be developed, 
which is depicted in the next graph (Fig. 3.1.8). By using naturally occuring genomic 
restriction sites and inserted restriction sites in this specific location of the Irf1 gene, it 
was possible to discriminate each event and to distinguish it. 
 
 
 
 
Figure 3.1.8: Restriction strategy to reveal each event and distinguish from the desired neomycin 
exision. In the panel (a) the wildtype situation is depicted, in which two genomic BamHI restriction site 
are used to generate a fragment of 5263 bp. (b) indicates the location of the used restriction sites and 
loxP sites (black bars). The lower panels show the genomic situations of the targeted Irf1 locus 
depending on the activated loxP sites, flanking the inner arm and the neomycin gene cassette. SpeI 
restriction is only possible in case of presence of the  neomycin gene cassette, unmodified targeted DNA 
can be detected by BamHI restriction (resulting fragment 4823 bp (c) and by SpeI digestion resulting in a 
fragment of 5247 bp. In case of neo excision BamHI restriction results in a 2877 bp fragment size (d). If 
IA is deleted the fragment size is 3161 bp in a BamHI restriction and 3585 bp  after SpeI digestion (e) if 
IA and neo are deleted 1215 bp should be visible (f). 
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The targeted region is located close to two BamHI restriction sites. With the cloning of 
the SA3’ an additional BamHI restriction site was inserted. Therefore, by BamHI 
digestion it was possible to distinguish between the real, untouched wildtype allele and 
the manipulated targeted allele. 
As the neomycin gene imported a SpeI restriction site into this genomic region of the 
Irf1 gene that otherwise did not appear in this genomic region of Irf1, digestion with 
SpeI offered a second control for the elimination of the neomycin gene cassette.  
The bands expected in a correct ES cell clone were the following: After restriction with 
BamHI a band of 5263 bp in size should appear for the untargeted wildtype allele, 2877 
bp should derive from the targeted allele after removal of the neomycin gene cassette, 
and after restriction with SpeI no band should be visible. The lengths of the fragments 
were calculated from the targeted genomic sequence, regardless of single nucleotides 
which might disappear during restriction with the indicated enzyme. But this is only a 
question of a few nucleotides that do not interfere with the analysis in general at all. 
This remark is only mentioned for complete and understandable traceability. 
 
 
 
 
 
Figure 3.1.9: Southern blot autoradiography of large scale screening for identification of  neomycin 
deletion. Genomic DNA was digested with BamHI and Southern blotting was performed using the 5’ 
probe. Clones 290 and 293 (arrows) showed bands approximately 2877 bp in size and larger than 5 kb.  
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The screening procedure after the electroporation with pICre was the same as for the 
first electroporation with pEasyIRF1. Again, large scale screening of several hundreds 
of single clones was performed. As potential candidates the clone numbers 160, 351, 
357 and the two clones depicted in Fig. 3.1.9, namely 290 and 293 were identified by 
Southern blotting. These five ES cell clones were thawed and recultured (2.2.1.19) to 
gain a larger amount of DNA to repeat this digestion and finally verify the targeting. 
DNA of surplus ES cell clones that were not picked for a closer look was pooled and 
used as control DNA on the blot as well as untargeted E14.1 ES cell DNA. 
The DNA was digested with BamHI to confirm the deletion of the neomycin gene 
cassette and with XmaJI was used as an additional control, just as in the first screening 
for a positively targeted clone for confirmation. After deletion of the neo gene cassette, 
only a single fragment of 8 kb in size should be visible after digestion with XmaJI and 
two bands (5263 bp and 2877 bp) after BamH1 digestion (Fig. 3.1.10). 
 
By BamHI digestion clone numbers 160, 290 and 293 out of these five clones could be 
verified for neo deletion, but only for the clones 290 and 293 restriction with XmaJI 
resulted in the expected single band of 8 kb. The band of the wildtype allele and the 
floxed targeted allele overlayed to one thick band. This band could not be detected for 
clone #160. The other clones (351 and 357, as well as the DNA pool) clearly showed a 
fragment lower than 5 kb (4823 bp) and one larger than 5 kb (5263 bp) in size, meaning 
neomycin was not deleted (4823 bp = untouched targeted allele). The other one 
displayed the wildtype allele, just as 160, 290 and 293 did.  
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 79
  
 
 
 
 
Figure 3.1.10: Southern blot autoradiography for confirmation of neomycin elimination in selected 
clones distinguished from the real Irf1 wildtype allele. DNA was digested with BamHI and XmaJI 
restriction as control to perform Southern blotting with hybridisation of 5’probe. Clones 160, 290 and 
293 show band sizes larger than 5 kb and smaller than 3 kb, indicating the desired fragment sizes of 2877 
bp and 5263 bp. The XmaJI digestion revealed only one merged band for these clones at 8 kb. Clones 351 
and 357  showed bands for 5263 bp (real wildtype) and 4823 bp targeted allele without Cre-
recombination) after BamHI digestion. 
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Figure 3.1.11: Southern blot autoradiography for confirmation of neomycin gene cassette 
elimination in selected clones. The indicated clones were recultured and digested with SpeI to perform 
Southern blotting. The 5’ probe was used for hybridisation. The clones 160, 290 and 293 show no band, 
just like the control DNA E14.1.  
 
 
As an additional control, restriction of genomic DNA with SpeI (Fig 3.1.11) should 
reveal the presence of neomycin gene cassette, since no other SpeI restriction site is 
available in this specific genomic region of Irf1 than the one that comes with the 
neomycin resistance gene. As expected, in the clones 160, 290 and 293 no neomycin 
gene cassette was detectable, just as in the E14.1 ES cell DNA. In contrast, the other 
clones 351 and 357 also contained neomycin according to this analysis, just like the 
DNA pool that was used as a control. Not surprisingly, the band for the DNA pool is a 
bit fainter than the ones of the purified clones, since the DNA pool is most likely a 
mixture of all possible events induced during Cre activity. 
RESULTS 81
Based on these results, clones #290 and #293 were used for blastocyst injection. 
Blastocysts were prepared from C57BL/6 animals. If transferred ES cells contributed to 
the blastocysts, the offspring should present a chimeric fur pattern. The colour of the fur 
of these brindled mice can appear in different shadings, from small dots of agouti within 
the black to pure bright cream. Clone #290 generated no offspring whereas clone #293 
did do so (scheme in Fig 3.1.12).  
 
These chimeric animals were mated to C57BL/6 partners to check for germline 
transmission of the targeted allele. The offspring revealed the germline transmission by 
their agouti-brownish fur colour. 
 
 
 
 
 
 
Figure 3.1.12: Scheme of blastocyst injection with targeted SV129 ES cells. The blastocysts were 
taken from C57BL/6 mice. By injection of E14.1 ES cells derived from the SV129 mouse strain a chimeric 
mouse is generated. (modified from: http://www.unituebingen.de/Klinische_Genetik). 
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Figure 3.1.13: Southern blot autoradiography to check germline transmission in chimera offspring. 
(A) DNA was digested with BamHI and Southern blotting was performed using the 5’probe. Arrows 
indicate germline transmitting animals showing the wildtype (5263 bp) and the floxed (2877 bp) allele. 
(B) DNA was digested with BamHI and Southern blotting was performed using the neo-probe. Only the 
positive control (pEasyKA3’) bound the probe, none of the animals. 
 
 
In the germline transmitting animals, the presence of the floxed Irf1 gene allele was 
proven by genetic analysis via Southern blotting (Fig 3.1.13), using the same strategy as 
for the ES cell screening after the deletion of the neomycin gene cassette. After BamHI 
digestion, the floxed allele produced a fragment size of 2877 bp whereas the wildtype 
allele resulted in a 5263 bp fragment. Additionaly, the presence of any neomycin gene 
cassette was excluded by hybridisation with the neo-probe, which was generated by 
digestion of the target vector pEasyFlox with BamHI and EcoRI, thereby cutting out a 
fragment of the neomycin resistance gene cassette. The purified DNA fragment was 
radioactively labelled like the 5’probe. The intermediate targeting vector pEasyKA3’ 
served as positive control for neo. 
The targeting for the conditional Irf1 knockout was confirmed by this. The mice 32-454, 
-457, -458, -460, -461, -463 and -466 are heterozygous animals for the floxed allele of 
Irf. Due to the genetic background of the SV129-derived ES cell clone and the C57BL/6 
blastocyst, the chimeric animals have a mixed background that needs to be backcrossed 
to a pure genetic background. Only then the mice should be mated with a given tissue-
specific Cre-expressing mouse to generate a conditional knockout. A recommended 
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control is the generation of a complete knockout by using a Cre-deleter mouse. The 
offspring should express the same phenotype like the conventional Irf1 knockout. 
In order to verify the inhibition of any Irf1 transcript, Northern blotting should be 
performed. 
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3.2 OVA MEDIATED ASTHMA INDUCTION IN IRF1-/- MICE 
 
In parallel to the above described generation of the floxed Irf1 mouse, the conventional 
knockout mouse for Irf1 (MATSUYAMA ET AL. 1993) was to be investigated in the settings of 
asthma as a model of a Th2-mediated disease. IRF1 deficient mice show an enhanced 
production of IL-4 due to their genetical predisposition to develop a Th2-driven 
immune response. This phenomenon comes along with a stronger susceptibility for 
intracellular pathogens and higher IgG1 as well as IgE levels in serum (LOHOFF ET AL. 
1997). These parameters are also seen during allergy. Hence, the hypothesis was to 
induce an acute phase asthma in these animals to study the presumably potentiated 
immune response in Irf1 knockout mice. Asthma is widely seen as a Th2-driven 
condition. The OVA-model offered the possibility to deduce a specific implication of an 
enhanced Th2 response that could be responsible for a potentially stronger allergic 
phenotype in these mice. 
Several readout systems served as puzzle pieces to complete a comprehensive picture of 
the allergic reaction in the Irf1 knockout mouse. 
 
BAL fluid was taken from the mice and investigated for a variety of parameters. 
Cytokines were detected by ELISA and the cell content was morphologically identified 
by cytospin analysis. Surplus cells were directly restimulated for 4 hours with PMA and 
ionomycin in the presence of brefeldin A and stained immediately for CD4 and IL-4 to 
determine the percentage of IL-4-secreting T helper cells. These cells could be the main 
mediators of a worse asthma phenotype in IRF1 knockout mice, in case of verification 
of the hypothesis.  
Figure 3.2.1a shows cell infiltrates in BAL fluid from wildtype and Irf1 knockout mice, 
listed seperately for individual populations as determined by cytospin analysis. An 
OVA-dependent influx of leukocytes and eosinophils was significant in wildtype, yet 
surprisingly not in Irf1 knockout mice. Migration of lymphocytes to the lung was hardly 
induced and did not reach statistical significance. Macrophages did not migrate 
treatment-dependently into the lung and neutrophils were not found at all. Thus, 
regarding cell migration there was no noteworthy difference found between the two 
mouse strains. The restimulated BAL cells were FACS analysed and showed an OVA-
dependent increase for IL-4+CD4+ cells, which turned out to be slightly, but 
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significantly increased in IRF1 deficient animals. Cytokine levels in BAL fluid (Fig 
3.2.1b) were measured by ELISA and showed that IFN-γ production was reduced in 
OVA-treated groups, but yet to very low amounts. This effect was highly significant in 
wildtype mice, yet not in the knockout mice. This decline in IFN-γ levels upon OVA-
stimulation was expected, because an allergic response is Th2-driven and IFN-γ is a 
cytokine mainly produced during a Th1 response. However, the absolute amounts of 
this cytokine were detected at the detection limit of the ELISA method. The same holds 
true for the IL-10 and the IL-6 measurement. No relevant amounts of these cytokines 
were produced. The secretion of IL-5 was not altered by OVA, nor were differences 
found in between the groups. In summary, an OVA-induced reaction is supported by the 
findings of an OVA-dependent influx of leucocytes and eosinophils in wildtype mice, 
the decrease of IFN-γ levels and the detection of IL-4+CD4+ cells. However, against our 
hypothesis no striking difference in the reaction to OVA was noted in Irf1 knockout 
versus wildtype mice. 
An allergic pathology is measured by determination of many factors. For a complete 
picture, several parameters in addition to BAL analyses were collected (Fig. 3.2.2). To 
assure that any effect that might be seen was not due to the size of an individual mouse, 
the weight of all mice in this experiment was measured at the end before they were 
killed. 
The next parameter to be tested were OVA specific antibodies in the sera. In mice, IgG1 
is Th2-dependently produced and can account for the severity of a Th2-driven disease. 
In the experiment depicted in Fig. 3.2.2, IgG1 was OVA-dependently produced with 
high significances in wildtype and even more in the Irf1 knockout mice. In contrast, IgE 
levels did not shift in response to OVA, because comparable amounts were found in all 
groups. IgG2a indicates the part of counterregulation and is normally secreted in a Th1 
response. Here, IgG2c was measured, because the C57BL/6 mouse strain carries a 
defective gene for IgG2a. Instead, they produce IgG2c (JOUVIN-MARCHE ET AL. 1989 AND 
MARTIN ET AL. 1997). No IgG2c was detectable in any of the serum samples, as expected 
from an allergic phenotype.  
Based on these results, a Th1 immune response was not detectable in this experiment. 
Some parameters that indicate a Th2 response such as IgG1 or the IL-4 production by 
CD4+ cells again confirm that the immunisation with OVA was in principle successful, 
but the expected stronger reaction expected in Irf1 knockout mice was absent. 
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Figure 3.2.1: Acute asthma model. Animals were treated with OVA or PBS s.c. on days 0, 7 and 14 
and were challenged on days 26, 27 and 28. Analyses refer to day 29, when the mice where killed and 
samples were taken. Bronchoalveolar lavage fluid (BAL) analyses in wildtype (WT) and Irf1-/- animals for 
cell infiltrates (a) and cytokine levels as measured by ELISA (b) as well as FACS analysis of restimulated 
BAL CD4+ cells. Statistical analysis was done by one way ANOVA and Tukey’s multiple comparison test. 
Standard deviation (SD) and significances (*p=<0.005; ** p=<0.001; *** p<0.0001; ns= not 
significant), if applicable are shown. Outliers were determined using Grubb’s test and excluded from the 
analysis. 
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Figure 3.2.2: Acute asthma model. Histological quantification of goblet cell counts, comparison of 
animal weight at the end of the experimental phase and ELISA results of OVA-specific serum 
immunoglobulin levels. Statistical analysis was done by one way ANOVA and Tukey’s multiple 
comparison test. SD and significances (* p<0.005; ** p<0.001; *** p <0.0001; ns= not significant), if 
applicable are shown. Outliers were determined  using Grubb’s test and excluded from the analysis.  . 
 
The predominant sign of allergic asthma is the lung inflammation accompanied with 
excessive mucus production. Therefore, histological analysis of the whole lung 
(proximal and distal region were statistically equally assessed) was the final and in fact 
the most important readout. 
Lung slices were stained for mucus production by PAS staining and goblet cells were 
microscopally quantified in relation to the airway surface using the CellF software. The 
amount of goblet cells is a direct hint of the disease severity in the lung. The graph (Fig. 
3.2.2) displays an increase in the goblet cell number per mm of airway in an OVA-
dependent manner in both mouse strains, with slightly more significance in the Irf1 
knockout mouse. However, there was again no obvious difference seen between the two 
mouse strains.  
The optical impression of the lung pathology in wildtype and Irf1 knockout animals 
confirms the counted goblet cell analysis. As visualised by PAS staining, PBS control 
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mice had healthy lungs (Figure 3.2.3 a and c) whereas the asthmatic mice showed 
mucus-producing goblet cells within the lung epithelium (Figure 3.2.3 b and d). 
 
 
 
 
Figure 3.2.3:  Histological slices of the lung. Periodic acid Schiff (PAS)-stained for mucus producing 
goblet cells in PBS-(a and c, pictures taken at 40 x magnification) or OVA-treated (b and d, pictures 
taken at 20 x magnification) wildtype (WT) and Irf1-/- mice. Mucus-producing goblet cells are silhouetted 
in pink against the purple background of lung epithelium and tissue. 
 
Altogether, all analyses demonstrate clearly the same asthma phenotype in both mouse 
strains, wildtype C57BL/6 and IRF1 deficient mice. 
No significant alterations compared to wildtype mice were notable in the Irf1-/- mouse, 
despite the known overall “Th2 character” of this mouse strain in other models, such as 
infection with intracellular pathogens. 
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3.3 IL-17 PRODUCTION BY IRF4-/-  T CELLS 
 
In a final and independent part of this thesis, my task was to analyse the capacity of T 
cells other than conventional  T cell receptor (TCR) expressing CD4+ and CD8+, to 
secrete IL-17. Here, the molecule that we were interested in was IRF4 rather than IRF1, 
because (as specified in the introduction) Irf4-/-  T cells are able to produce IL-17 to 
the same extent as wildtype  T cells ex vivo and also after in vitro culture in response 
to IL-23. This fact was very surprising, because Irf4-/- CD4+ T cells have a severe defect 
in the production of IL-17. The third part of this thesis work was dedicated to closer 
characterise this phenomenon. 
First, IL-17 production in IRF4 deficient  T cells was confirmed in different organs 
from wildtype and knockout mice. Peripheral and mesenterial lymphnodes, thymi, 
spleens and livers were excised, single cell suspensions were prepared and ex vivo 
restimulated for 4 hrs with PMA/ionomycin in the presence of the golgi blocker 
monensin. IRF4 deficient  T cells were capable to produce IL-17 in comparable 
amounts as wildtype cells in all tested organs. In contrast, CD4+ IRF4 deficient T cells 
produced hardly any detectable amounts of IL-17 in this direct ex vivo analysis (Fig 
3.3.1). 
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Figure 3.3.1: FACS staining for IL-17 and IFN-γ production in ex vivo PMA/ionomycin-stimulated 
cells from different organ homogenates of  wildtype and Irf4 knockout mice. Cells were stained for 
expression of the γδ TCR, CD4 or intracellular IL-17. Plots show cells gated on either CD4+ T cells or γδ 
T cells. γδ T cells from IRF4 deficient animals produced IL-17. Irf4-/-= deficient in interferon regulatory 
factor 4. 
 
Obviously, the defective IL-17 production in CD4+T cells of the IRF4 deficient mouse 
is not applicable for γδ T cells. This phenomenon is also not a question of organ-
specific distribution of this cell type.  
 
The fact that  T cells can produce IL-17 upon stimulation with IL-23 is well accepted 
in the recent literature (GRAY ET AL. 2011, PETERMANN ET AL. 2010, NESS-SCHWICKERATH AND 
MORITA 2010). Since IRF4 deficient  T cells showed IL-17 secretion in many different 
organs per se, the question raised, whether they would also make IL-17 upon IL-23 and 
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IL-1β stimulation. These two cytokines have been shown to induce IL-17 production in 
 T cells upon in vitro culture for several days. So,  T cells were purified from 
spleens and peripheral lymphnodes by using the MACS® technology and were activated 
with αCD3/αCD28 activation beads and stimulated with IL-23 and IL-1β or each of 
these cytokines alone for 48 or 96 hrs. For intracellular cytokine staining, monensin was 
added after 44 hrs for 4 hrs. For testing of soluble IL-17, IL-22 and IFN- levels in 
culture, supernatants were quantified by ELISA at both time points. The results clearly 
show that IRF4 deficient  T cells were able to produce IL-17 upon individual 
stimulation with IL-23 or IL-1β as nicely as the wildtype cells did. This effect was even 
potentiated by stimulation with both cytokines together. The ELISA data supported 
these findings, though the Irf4 knockout mice produced overall even higher amounts of 
cytokines. 
The analyses revealed also IL-22 expression in a similar profile as for IL-17 production. 
Again the IRF4 deficient  T cells produced higher amounts of cytokine compared to 
wildtype. 
However, IFN-γ secretion seemed to be affected rather by IL-1β than by IL-23. The 
simultaneous stimulation with both cytokines, IL-1β and IL-23 resulted in a further 
increased IFN- secretion in the IRF4 knockout cells.  
The extended culture period of 96 hrs did not reveal any other results. The induction 
profile of cytokines upon stimulation with IL-23 and/or IL-1β was comparable.  
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Figure 3.3.2. Cytokine production by  T cells upon stimulation with IL-23 and/or IL-1β. MACS®-
purified  T cells from C57BL/6 or IRF4 deficient mice were stimulated with αCD3/αCD28 beads (2 
beads/3 cells) and the indicated cytokines (IL-23 25 ng/ml; IL-1β 10 ng/ml) and were cultured for 48 h or 
96 hrs. (A) FACS analysis for intracellular IFN-γ and IL-17 was performed on day 2 after adding 
monensin to the culture during the final 4 hrs of culturing. Graphs show gated cells positively stained for 
 TCR. Numbers indicate percentages of positive cells located in the respective quadrant (B) culture 
supernatants were taken after 48 hrs and analysed by ELISA for IL-17, IL-22 and IFN-γ production. (C) 
culture supernatans were taken after 96 hrs and analysed by ELISA for IL-17, IL-22 and IFN-γ 
production. Three experiments were performed with similar outcome. WT = wildtype, Irf4-/-= deficient in 
interferon regulatory factor 4. 
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In addition to a normal environment, the presence and in vivo expansion of  T cells 
were to be assessed in the settings of an inflammation, thereby identifying possible 
misfunctional properties of IRF4 deficient  T cells compared to wildtype. To do this, 
Irf4-/- mice and heterozygous littermates were infected with Streptococcus pneumoniae 
intranasally. Three days post infection, the lungs were harvested and cell homogenates 
were prepared. After 4 hours of restimulation with PMA/ionomycin in the presence of 
monensin, the cells were FACS stained for TCR, CD4 and intracellular IFN- as well 
as IL-17 (Fig. 3.3.3). 
 
 
 
 
Figure 3.3.3: FACS analysis of lung homogenates after infection with Strep. pneumoniae: IRF4 
deficient and heterozygous mice were infected with 20000 cfu Strep. pneumoniae. Lungs were harvested 
on day 3 post infection, homogenised and the cells were stained for  TCR, IFNγ and IL-17. The FACS 
plots depict gated  T cells. Numbers indicate percentages of positive cells located in the respective 
quadrant. Two experiments were performed with similar outcome. 
 
 
The investigation of the infected lungs demonstrated the presence of  T cells in both 
genetic backgrounds and these cells produced similar amounts of IFN-γ. The IRF4 
deficient mice showed an even higher production of IL-17 compared to control mice. 
Also CD4+ T cell were present, but IL-17 was not produced at all by them, while only 
the IRF4 deficient CD4+ cells were highly positive for IFN-γ. Interestingly, there were 
not any double positive cells detectable at all. 
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Since Irf4-/- CD4+ T cells cannot differentiate into IL-17 producing Th17 cells, the 
question raised, how the signaling pathway was altered in  T cells. To investigate, if 
the IL-17 production by  Tcells in the Irf4-/- mouse correlates with the expression of a 
transcription factor that is known to be in general involved in the expression of IL-17 
and/or IL-23 signaling, realtime PCR analysis for rora, rorc and Tbx21 was perfromed. 
For this purpose, TCR+ cells were enriched by staining of the  TCR, followed by 
labelling with anti-fluorchrome beads and a purification step via MACS® colums. The 
resulting suspension was then sorted with an Aria III FACS sorting machine for high 
purity. From this fraction, RNA and cDNA was prepared and used for TaqMan PCR. 
 
 
Figure 3.3.4: TaqMan® analysis of transcription factors in  T cells. RNA was prepared from ex 
vivo sorted  T cells and tested for expression of rora, rorc and Tbx21. The result show respresentative 
data out of 3 independent experiments. 
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By quantitative realtime PCR all 3 transcription factors could be detetcted in ex vivo 
analysed  T cells. Rora and rorc were expressed to similar extent in wildtype and 
IRF4 deficient  Tcells. In contrast, T-bet-expression was slightly up-regulated in the 
Irf4 knockout cells. These findings are not surprising, since RORγt and RORα are 
involved in the development of Th17 cells while inhibition of T-bet by IL-23 is a pre-
condition for IL-22 (MUS ET AL. 2010). Hence, transcription factors known to be of 
relevance in IL-23 singaling and/or important for Th17 differentiation are also 
expressed in IRF4 deficient  Tcells. 
 
Another attractive candidate for mediating IL-17 production in  T cells is NFB 
whose signaling molecules RelA and RelB have recently been demonstrated to 
determine IL-17 expression by  T cells ex vivo (POWOLNY-BUDNICKA ET AL. 2011). Hence, 
the strong suspicion was obvious that the NFB pathway was also activated in IL-17 
expression by IRF4 deficient  T cells during stimulation with IL-23 and/or IL-1. In 
order to assess this question, the NFB inhibitor PS1145 was used in the further 
experiments to test the respective pathway. This inhibitor blocks both, the RelA 
(classical) and the canonical activation of NFB via BAFF which involves RelB 
(YEMELYANOV ET AL. 2006 AND TAI ET AL. 2006).  
 
The proper function of the inhibitor was tested in a luciferase assay, in which the 
NFB–reporter cell line 293-mTLR9-luc was used. The luciferase production upon 
CpG stimulation was almost totally blocked by administration of PS1145 (Fig 3.3.5 A). 
However, the cytokine expression by  T cells, either in wildtype or in IRF4 deficient 
cells was not affected. (Fig. 3.3.5 B). Therefore, in cytokine stimulated  T cells, 
NFB is neglectable for IL-17 production. 
 
STAT molecules have been reported to be important mediators in IL-23 signaling 
(PARHAM ET AL. 2002). However, the induction of IL-17 by IL-23 in STAT4 deficient  T 
cells was also comparable between wildtype (Fig. 3.3.5 C) and STAT4 deficient  T 
cells (as shown in Fig.3.3.2), thereby also precluding STAT4 as critical actor in this 
pathway. 
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Figure 3.3.5: Analysis of the potential signaling pathway. (A) Luciferase assay in 293-mTLR-luc 
cells, stably transfected with luciferase under the control of the NFB-promoter and inducible by CpG 
administration. The NFB inhibitor PS1145 was used at 5 nM. Luciferase measurement after 15 hrs. (B) 
  T cells from wildtype (WT) and Irf4 knockout mice (Irf4-/-) were stimulated with or without PS1145 in 
the presence of IL-23 (25 ng/ml) and/or IL-1 (10 ng/ml) or in medium alone. IL-17 and IL-22 production 
was determined by ELISA from supernatants harvested after 15 hrs. (C)  T cells from  wildtype (WT) 
and STAT4 knockout mice (STAT4-/-) were stimulated with IL-23 (25 ng/ml) and/or IL-1 (10 ng/ml) or in 
medium alone. IL-17 production was determined by intracellular staining after 48 hrs. Two experiments 
with similar outcome. 
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Together, this final part of my thesis establishes that IRF4 is required for IL-17 
production only in some, but not in all types of T cells. Apparently, a so far unknown 
pathway for production of this cytokine exists in non-conventional T cells expressing 
the  TCR. When IL-17 production in these cells is induced in response to the 
cytokines IL-1β and IL-23 in vitro, this pathway acts independently not only of IRF4, 
but also of NFB and STAT4. 
4. DISCUSSION 
 
 
4.1 GENERATION OF A CONDITIONAL KNOCKOUT MOUSE LINE FOR IRF1 
 
The transcription factor Irf1 is expressed in a variety of cell types and was first 
described for its properties as a tumor suppressor gene. Later on its essential function in 
Th1 cell differentation came more into focus. These two capabilities differ completely 
and are not related to each other. It is also known that the IRF1 knockout mouse has a 
strong defect in thymic CD8+ T cell development. Only about 3 % of circulating T cells 
are CD8+ T cells and it remains uncertain whether the cells have no other intrinsic 
defect. To question the effects of IRF1 in a given experimental setting in vivo, a 
conditional knockout system would be of great benefit, because due to the tissue 
specificity of this system one can exclude any other than the desired developmental 
defect in the organism. 
In this thesis work, a targeted chimeric mouse for Irf1 was successfully generated by 
using the Cre-lox system. The flox sites-containing target vector was cloned for gene-
specific targeting and introduced into embryonic stem cells. After blastocyst injection, 
chimeric mice were generated. 
 
The Cre-lox sytem has been widely used to generate knockout mice, and Cre-expressing 
mice under cell-specific promoters are similarly accessible. The herein used target 
vector pEasyFlox offered indeed a simple system, but also bears possibilities for 
improvement. The deletion of the neomycin resistance cassette is eligible to avoid 
unpredictable regulatory effects due to destruction or modification of potential 
regulatory sites in the intron of the target gene by the additional neomycin sequence. 
Several reports suggest that the presence of an intron contributes to regulation of 
general gene expression, even if derived from a different gene (BUCHMANN AND BERG 1988, 
CHUNG AND PERRY 1989, REID ET AL. 1990). As an example, a targeted reporter knock-in 
mouse for Irf1 exists that includes the insertion of a lacZ gene and still carries the 
neomycin resistance cassette. This mouse has been established by the European 
Conditional Mouse Mutagenesis Programm (http://www.eucomm.org/). An overview of 
all available mouse strains and ES cell lines regarding Irf1 targeting are examinable on 
Discussion 99
the webpages of the International knockout mouse Consortium 
(http://www.findmice.org//index.jsp). All of these constructs still contain the antibiotic 
resistance gene as well as additional non-Irf1-related sequences, which were designed 
for better homologous recombination (personal communication).  
To avoid these disadvantages in the current conditional knockout Irf1 preparation, the 
selection marker neomycin was to be deleted by a second transfection with a Cre-
expression vector. Unfortunately, all three loxP sites were addressed this way and the 
excision of neo had to be distinguished from the other events. In any future project, this 
problem can be circumvented by turning towards the flippase-flippase recognition target 
(FLP-FRT) system. It has similarities with the Cre-lox system and is derived from 
baker’s yeast Sacharomyces cerevisiae (REVIEWED BY SCHWEITZER 2003). The combination 
of loxP sites flanking the target gene and FRT sites flanking the antibiotic resistance 
cassette in a target vector of this system will decrease the number of stem cells clones to 
be screened drastically and no extra screening strategy for this step would be necessary, 
which makes the whole procedure easier and more efficient. 
 
Irf1 is expressed in a variety of different cell types, but its function in a specific cell 
type in the context of a given disorder is only poorly understood. Therefore, it would be 
of great interest to study the effects of IRF1 in different disease settings using a 
conditional knockout.  
 
In the following, examples for putative future projects will be given.  
 
In allergic asthma, the contribution of IRF1 in airway epithelial cells could shed a light 
on a possible function during inflammation, manifestation of the disease or airway 
remodelling. A mouse expressing Cre in Clara cells is available (BERTIN 2005). The 
expression of IRF1 in epithelial cells in general has been demonstrated by several 
studies. In HK2 cells, derived from proximal tubule epithelium of human kidney, Irf1 
was induced upon glucose stimulation, underlining also the implication of IRF1 in the 
development of diabetes (ALI ET AL. 2010, SUK 2001). A complete suppression of insulitis 
and diabetes was observed in NOD mice lacking IRF1 (NAKAZAWA ET AL. 2001). The 
implication of CD8+ T cells in this disease has been well established. Since the 
complete Irf1 knockout mouse shows a defect in CD8+ T cell development, one could 
argue that the resistance of IRF1 deficient NOD mice is secondary to a defect in 
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surviving CD8+ T cells in the periphery. To answer this question and study the exact 
function of IRF1 in diabetes at the same time, a conditional knockout for IRF1 in CD8+ 
T cells would be helpful. 
In 2000, Clavell and colleagues demonstrated Irf1 expression in lamina propria 
mononuclear cells (CLAVELL ET AL. 2000), and it may also play a role for the integrity of the 
epithelium. For the investigation of ciliated epithelia such as in the lung and in the gut, a 
transgenic Cre-system designed for ciliated cells is available (ZHANG ET AL. 2007). The 
Jackson Laboratory database lists a wide range of Cre-expressing mice, which includes 
an even finer possibility to investigate the gut epithelium apart from the lung: Cre-
mediated deletion can be achieved in only small and large intestine 
(jaxmice.jax.org/models/cre_flp_loxp). Beside organ-specific knockout, cell type-
specific elimination of Irf1 might be desired, to determine an effect mediated by one 
type of cell. Since IRF1 is a key transcription factor in T helper cell differentiation, it 
could also be interesting to disrupt the gene in all CD4+ T cells. Could asthma then be 
prevented? This could also help to reveal IRF1-related functions in other T helper cell 
subsets than Th1. 
Taken together, the massive impact of IRF1 on many different kinds of diseases can 
hardly be foreseen, but the usefulness of a conditional knockout is incontestable. So, 
there will be many applications for the mouse which was generated in the current thesis! 
 
 
 
4.2 OVA-MEDIATED ASTHMA INDUCTION IN IRF1-/- MICE 
 
Undifferentiated CD4+ T cells from Irf1-/- mice fail to properly respond to an adequate 
immune stimulus and do not differentiate into Th1 cells. This effect is mainly mediated 
by the incapacity of antigen presenting cells (APCs) to produce IL-12, due to the lack of 
IRF1 that activates the transcription of the IL-12p40 subunit of this cytokine (TAKI ET AL. 
1997, LOHOFF ET AL. 1997). Its absence leads to induction of Th2 cells instead. Consistent 
with these findings is the observation that Irf1 knockout mice are susceptible for 
intracellular pathogens such as Leishmania major and Listeria monocytogenes, but 
resistent to extracellular parasites such as Nippostrongulus brasiliensis (TAKI ET AL. 1997; 
LOHOFF ET AL 1997). 
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The paradigm of asthma being a Th2-mediated disease is well established (LARCHÉ ET AL. 
2003). Hence, the assumption that IRF1-deficient mice could develop a significant more 
severe asthma phenotype seemed to be likely. To test this hypothesis, asthma was 
induced in conventional Irf1 knockout mice in comparison with wildtype mice using the 
acute OVA model. Surprisingly, the simple idea of a worse pathology was a bad shot. In 
almost every parameter measured, the IRF1 deficient mice reacted to the same extent as 
the wildtype mice. Even if one might determine a faint tendency of Irf1-/- mice towards 
a stronger reaction, these values were not significant. Although the restimulated BAL 
cell content of the Irf1 knockout mice showed significantly more CD4+IL-4+ cells, this 
most likely only reflects the overall tendency of these animals to react in a Th2 response 
per se, since this effect was not very strong. Besides, the expression of the cytokines in 
the BAL was measured at the detection limit of the system, so any statements, 
especially regarding IFN-γ, IL-10 and IL-6 production and relevance should be made 
and considered only with caution. Overall, the pathology arising during the induction of 
asthma was not stronger in the Irf1-/- compared to wildtype mice. Hence, this mouse 
does not react any stronger in response to OVA as the wildtype. Altogether, the 
analyses on the asthma phenotype in Irf1 knockout mice were very disappointing. It 
should be stressed, however, that all analyses were made in the genetic C57BL/6 
background which is far less susceptible to allergy than the BALB/c background. 
Therefore, I have backcrossed Irf1 knockout mice to the BALB/c background, to 
provide the opportunity for the lab to repeat the experiments in a better suited setting in 
the future. 
 
 
Many different cell types are involved in the pathogenesis of asthma (AFSHAR ET AL. 2008), 
suggesting many cellular cooperations, where contributions of single cell types may be 
negligible and taken over by other cells. Beside Th cells, CD8+ T cells were shown to 
play a crucial role in the early development of asthma (KOYA ET AL. 2007). Here, a finely 
tuned interplay of CD4+ and CD8+ T cells was demonstrated in OT-I mice, in which 
CD8+ T cells express the transgenic TCR for OVA257-264 peptide (SINFEKL). Without 
presence of CD4+ as well as CD8+ T cells already at the time of the first sensitisation, 
these mice failed to develop asthma syptoms and measurable paramaters such as airway 
hyperresponsiveness, airway eosinophilia and Th2 cytokine elevation. The Irf1 
knockout mouse is unable to release a normal level of CD8+ T cells into the periphery 
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mainly due to thymic misregulation of MHC I molecules. Transferred donor wildtype 
CD8 cells develop normally in the Irf1 knockout environment (PENNINGER ET AL. 1997). 
Hence, the lack of a bias towards asthma in the Irf1-/- mice may arise due to the fact that 
there are either not enough CD8+ T cells in the periphery for sufficient intercellular 
crosstalk or that these CD8+ T cells are defective for certain functions. Koya and 
colleagues showed that an initial priming step for both CD4+ and CD8+ T cells is 
necessary to mount an allergic immune response (2008). 
Adoptive transfer experiments where wildtype CD8+ T cells are introduced into Irf1 
knockout mice could shed a light on the interaction of CD4+ and CD8+ T cells in this 
knockout setting. However, CD8 is not solely expressed on T cells. Dendritic cells 
(DCs) do express CD8 as well and encounter T cells in the spleen. An interesting study 
suggests evidence for CD8+DCs to enable a specific γδ T cell population expressing 
Vγ1, but not Vγ4 T cell receptor chains thereby mediating airway hyperresponsiveness 
(COOK ET AL. 2008), suggesting another CD8-dependent function that might be insufficient 
in IRF1 knockout mice. The fact that γδ T cells are involved in the asthmatic disease is 
also supported by the observation in human patients having increased Th2 cytokines all 
produced by gammadelta T cells in line with a decreased level of Th1 cytokines (KRUG 
ET AL. 2001; SPINOZZI ET AL. 1995). In addition, IL-4 and IL-5-producing γδ T cells are 
resident in nasal passages of asthmatic patients (PAWANKAR ET AL. 1996). These data all 
support a contribution of these cells in asthma. These finding can also be found in 
experimental mouse studies, where contradicting functions for γδ T cells have been 
demonstrated. There are reports of enhanced airway inflammation mediated by γδ T 
cells (ZUANY-AMORIM ET AL. 1998) and that mice deficient in γδ T cells are protected from 
developing airway hyperresponsiveness (AHR) (LAHN ET AL. 1999), while Hamelmann et 
al. demonstrate that γδ T cells contribute to AHR, but have no significant role in 
regulating airway inflammation (1996). This can be explained by the above mentioned 
distinct subsets of γδ T cells.  
As for DCs, they can be found throughout the airways and lung interstitium, lung 
vasculature and bronchial lymphnodes (REVIEWED BY GEURTSVANKESSEL AND LAMBRECHT 
2008) and have sentinel function since they express an amazing variety of receptors for 
inflammatory mediators as well as pattern recognition receptors, such as Toll-like 
recpetors or C-type lectin receptors (BARRETT ET AL. 2009). Some of the receptors are 
released upon tissue damage. CD8+ DCs receive antigen and activating signals from 
phagocytes which commute between the periphery such as lung or skin and the 
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lymphnodes (BELZ ET AL. 2004; ALLAN ET AL. 2006). Hereupon, the DCs present the antigen 
and can prime T cells to differentiate into cytotoxic T cells or T helper cells (DEN HAAN ET 
AL. 2000; BELZ ET AL. 2005; BELZ ET AL. 2004A). These features give the DCs a dominant 
position in connecting the innate and the adaptive immune sytem (VERMAELEN ET AL. 2001) 
and make the activation of specific cell types such as γδ T cells even more plausible. 
 
Very recently, a new cell type has been introduced and characterised: nuocytes expand 
in vivo in response to IL-7, IL-25 and IL33 and represent an early source of IL-13 (NEILL 
ET AL. 2010). Nuocytes were examined in the context of helminth infection, but keeping 
the hygiene hypothesis in mind and that allergic diseases may be a misled “substitute 
reaction” of the immune system, these cells may also contribute for a “Th2” response in 
asthma. This hypothesis is supported by an independent study that reports of a CD4+ T 
cell subset producing IL-5 and IL-13 independently of IL-4 upon IL-33-polarisation and 
that these cells exacerbate OVA-specific airway inflammation (KUROWSKA-STOLARSKA ET 
AL. 2008).  
Altogether, there are plenty of possibilities, why it is not solely the Th1/Th2 paradigm 
that determines the severity of asthma. This may explain, why IRF1 deficient mice are 
not affected by stronger asthma phenotype despite of having a bias towards Th2 
responses. It would be interesting to address the question, if IRF1 also orchestrates the 
intercellular crosstalk of the other above mentioned cells during asthma, e.g. by 
regulating cytokine expression other than for Th1 cell differentiation. It is also 
concievable that IRF1 deficient DCs have reduced amounts of surface CD8 and are 
impaired to properly prime T cells and to comply with their surveillance duties. 
Despite these considerations, there is no doubt that the recuitment of T cells towards the 
lung is crucial in the development of asthma. Here, chemokines and lipid mediators 
critically lead the way. Thus, it is also possible that IRF1 alters the expression of 
homing receptors, lipid mediators or the receptors for them. IRF1 takes action in CC 
chemokine ligand 5/RANTES production (MATSUZAKI ET AL. 2010), so it would be 
worthwhile to investigate homing and cell trafficking capabilities in the Irf1 knockout 
mouse. Besides, increased levels of leukotriene B4 (LTB4) have been found in the blood 
(SHINDO ET AL. 1995, SAMPSON ET AL. 1995), BAL (WENZEL ET AL. 1995, ZAITSU ET AL. 1998) and 
exhaled condensates (CSOMA ET AL. 2002, MONTUSCHI AND MARNES 2002) of asthmatic patients. 
Pathogenic functions of LTB4 include survival signals for leukocytes, neutrophils and 
eosinophils (HÉBERT ET AL. 1996), as well as a role in T cell trafficking (TAGER ET AL. 2003).  
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 Apart from distinct T cell subsets or/and other cell types that may be involved in the 
development of allergic pulmonary inflammation, one should not forget the role played 
by the environment. IRF1 is an important mediator of IFN- signaling and Schmitz et 
al. reported of a connection of IFN- and signaling via the Toll like receptor (TLR) 9 
that recognizes bacterial and viral nucleotides (2007). IFN--production in myeloid DCs 
requires IRF1, which is recruited and activated by MyD88, which, in turn is involved in 
many TLR signalling pathways. Although IFN- can induce high amounts of IRF1, it 
does not care for its activation and transport into the nucleus, which results in an 
insufficient IFN--response (NEGISHI ET AL. 2006). However, if TLR9 is activated at the 
same time, IRF1 is also activated and migrates into the nucleus. This synergy of TLR9 
and IFN- demonstrates a tight interaction of the innate and the adaptive immune 
system and proves a function of IRF1 also in innate immunity, although its importance 
in T helper cell differentiation is unquestioned. Hence, one could argue that the main 
function of IRF1 in allergic asthma lies not within the T cells, but instead in the innate 
immune system, and a modified experimental setup for acute asthma by also giving 
TLR9 ligands to a conditional Irf1 knockout mouse could be applied, keeping in mind 
that among others, viral infections may trigger the development of asthma. TLR9 binds 
unmethylated CpG containing DNA fragments derived from bacteria and viruses, which 
results in a strong immunomodulatory reaction, but implies anti-allergic mechanisms 
(BAUER ET AL. 2001, HORNER AND RAZ 2003). However, certain SNPs in the promotor of TLR9 
were associated with a moderately increased risk for the development of asthma and 
insufficient TLR9 expression could account for a higher risk to develop asthma 
(KORMANN 2007) and chronic lung inflammation (ITO ET AL. 2009). It could be worthwhile to 
test the contribution of IRF1 in this context, because TLRs could be used as possible 
therapeutic target molecules in asthma treatment. SNPs in the IRF1 gene have also been 
associated with a higher risk to develop asthma (SCHEDEL ET AL. 2008, WANG ET AL. 2006). If a 
given set of SNPs in both genes (for TLR9 and IRF1) occurred at the same time, a 
possible effect of a drug was circumvented. Indeed, targeting TLRs as preventive 
strategy is already used in hyposensitisation. First studies suggested that indoor 
endotoxin levels (derived from house dust, most likely house dust mite or certain 
bacteria) in early childhood may lower allergen sensitisation later on (GEREDA ET AL. 
2000A, GEREDA ET AL. 2000B). Animal studies reported contradictory results (PURKERSON 
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&ISAKSON 1994, GERHOLD ET AL. 2002 AND 2003). However, asthma protection in offspring can 
be mediated by TLR signaling in the respiratory tract of the mother as induced by 
Acinetobacter lwoffii application during pregnancy (CONRAD ET AL. 2009). Still, the exact 
beneficial, microbial components have yet to be identified as well as their recognition 
pathways in order to develop a proper treatment on this basis; also, one should be aware 
of possible limitations when addressing these targets (AGRAWAL ET AL. 2003, EISENBARTH ET 
AL. 2004, REDECKE ET AL. 2004). It is conceivable that TLR9 expression in patients is 
insufficient, thus resulting in a much higher risk of asthma. In this situation, the 
therapeutic potential of the TLR targets CpG to raise a protective immune response 
dominated by IFN-γ may be limited (IKEDA ET AL. 2003), along with a limited potential to 
inhibit Th2-induced factors, produced by lung mast cells (CHRISHOLM ET AL. 2004). 
Moreover, severe side effects of therapeutic TLR ligands are possible. Malignant B cells 
do express TLR9 (DECKER ET AL.2000, JAHRSDÖRFER ET AL. 2002 AND 2005) and CpG ODN can 
induce their proliferation as most extensively studied in the context of chronic 
lymphocytic leukemia (CLL) (DICKER ET AL. 2006). Of interest, CpG ODN can up-regulate 
the IL-21 receptor and the combination of CpG ODN and IL-21 resulted syergistically 
in apoptosis (JAHRSDÖRFER ET AL. 2005A), but also in the production of functional granzyme 
B in CLL cells (JAHRSDÖRFER ET AL. 2006). These results demonstrate that unexpected 
mechanisms might cause significant damage that does not counterbalance the initially 
intended benefits. 
 
In summary, the fact of a great variety of different cell types which are involved in the 
pathogenesis of allergic asthma explains well, why the Irf1 kockout mouse does not 
mount a significantly stronger pathology in the OVA model of acute asthma. The single 
contribution of Th2 cells does apparently not play the overwhelming role in this disease 
and the newly dicovered cell types and subsets produce cytokines formerly ascribed to 
Th2 cells! 
The identification of new T helper subsets and investigation of the underlying 
mechanisms of intercellular crosstalk and their involvement in the pathogenesis of 
asthma took a step forward in understanding the disease. However, more questions 
raised, but these new cell populations may also represent targets for medical treatment 
of allergic diseases such as asthma. 
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4.3 IL-17 PRODUCTION BY IRF4-/- γδ T CELLS 
 
In contrast to conventional  T cells, which leave the thymus as naïve cells and 
develop effector functions after antigen contact in the periphery,  T cells raise effector 
capabilities within the fetal thymus as early as of day 14 to day 18 (TONEGAWA ET AL. 1989; 
RAULET 1989). At least parts of these cells are released from the thymus into the periphery 
as IL-17-producing cells (JENSEN ET AL. 2008; RIBOT ET AL. 2009; SHIBATA ET AL. 2008). One of 
their most striking features is their ability to rapidly produce IL-17 and IFN- (ROARK ET 
AL. 2007 AND 2008). For this reason, they are considered to belong to the innate immune 
system. Th17 cells need IL-6 and TGF- for differentiation and subsequent IL-17 
production. However, in peripheral  T cells, IL-23 and IL-1 were shown to enhance 
IL-17 production, and by that support Th17 effector function and co-operate with Th17 
cells in mediating autoimmune pathology (SUTTON ET AL. 2009). The differentiation of 
Th17 cells is dependent of IRF4. In its absence, even EAE development is completely 
blocked (BRÜSTLE ET AL. 2007). 
 
Surprisingly, my thesis shows that Irf4 knockout  T cells are indeed perfectly capable 
to produce IL-17. Direct restimulation of organ homogenates of Irf4 knockout mice 
resulted in IL-17 detection in  T cells to the same extent as in wildtype controls, 
proving the general capability of these cells to express IL-17 independently of the 
organ, they were found in. On order to test the in vivo expansion of these cells in a 
natural setting, mice were infected with Streptococcus pneumoniae. The results revealed 
the presence of IL-17+  T cells in the lung of Irf4 knockout mice, which produced 
even more IL-17 than heterozygous littermates (Fig. 3.3.3). This finding underlines that 
 T cells from Irf4 knockout mice are fully immune competent. In humans,  T cells 
are able to respond and display cytolytic activity to a variety of bacterial superantigens 
(REVIEWED IN RUST AND KONING 1993). They have also functions in host-micobial 
homeostasis at mucosal surfaces and protect the host from invasion of commensal 
bacteria in the small intestine (ISMAIL ET AL. 2011). Mucosal epithelia produce 
antimicrobial proteins to defend these surfaces against microbial attacks. This is in line 
with a report for  T cells being the major source of IL-17 during infection with 
Mycobacterium tuberculosis (LOCKHART ET AL. 2006) and with Listeria or Nocardia (KING ET 
AL. 1999, RIOL-BLANCO ET AL. 2010, SKEEN AND ZIEGLE 1993). These data also suggest that  T 
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cells might orchestrate the production of this defense mechanism and could be an 
attractive therapeutic target for example in intestinal or pulmonary inflammatory 
diseases. 
 
Of course, we attempted to get more insight into why  but not Th cells of Irf4 
knockout mice can produce IL-17. Meanwhile, RORt is well established as lineage-
specific transcription factor for Th17 differentiation, with support by ROR (IVANOV ET 
AL. 2006). Herein, realtime analysis of freshly isolated and sorted Irf4 knockout and 
wildtype  T cells showed no difference in the expression of these transcription factors 
as well as of the Th1 master regulator Tbet (Fig. 3.3.4). Recently, it has been shown that 
mRNAs of these transcription factors are expressed in T cells in response to 
PMA/ionomycin, in support of the production of IL-17 and IFN by these cells 
(POWOLNY-BUDNICKA ET AL. 2011).  
In addition the same authors also present evidence for a NFB function during 
differentiation of  T cell precursors into IL-17 producing cells which involved the 
lymphotoxin receptor β (LTβR). They claim that the activation of the NFB member 
RelB as a result of LTβR signal transduction is inevitable, because LTβR-deficient mice 
failed to develop IL-17 producing  T cells in vivo. 
Our experiments primarily tested for IL-17 production in vitro rather than in vivo. In 
this experimental setting, our results clearly refute any NFB involvement for the IL-17 
production of this T cell subset in the Irf4 knockout mice, as demonstrated in a 
suppression assay with the NFB inhibitor PS 1145 (Fig. 3.3.5). The cytokine 
production was not impaired at all. During these experiments, we made use of previous 
finding that IRF4 deficient  T cells are not only capable to express IL-17 per se, but 
also produce IL-17 in response to IL-23. This effect was even potentiated by stimulation 
with IL-1 at the same time. Both cytokines help to promote and sustain the Th17 
phenotype in normal mice, but also IL-17 production in  T cells, thereby supporting 
Th17 responses (SUTTON ET AL. 2009).  
For further investigation of the underlying pathway of this IL-17 production, I repeated 
the  experiments in STAT4 deficient mice, because STAT4 has previously been shown 
to be involved in the signaling of IL-23 (PARHAM ET AL. 2002). Interestingly, in this case, 
STAT4 was not addressed and dispensable for IL-17 production by  T cells in 
response to IL-23. This was equally true for cells from Irf4 knockout and wildtype 
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mice. Besides STAT4, STAT3 is activated during IL-23 signaling (PARHAM ET AL 2002). In 
order to generate a complete picture, it will therefore be necessary to also address this 
molecule in the IL-17 production of the IRF4 deficient γδ T cells. Yet, Shibata et al. 
also declared STAT3 to be dispensable for IL-17 cytokine production in γδ T cells 
(SHIBATA ET AL. 2011). However, just as for the importance of NFκB, this statement stems 
from a different experimental design, and certainly was not tested in the case of the 
IRF4 deficient mouse. Hence, the involvement of STAT3 should still be formally 
excluded in this mouse. 
 
All findings together could unfortunately not reveal the mechanism, by which IL-17 
production is initiated in IRF4 deficient  T cells. So, what may be the underlying 
signaling pathway? On the one hand the chances that several evolutionally 
independently developed signaling pathways lead to the same gene product might be 
rare due to an apparent inefficacy. On the other hand, our data suggest a pathway 
different from NFB but also independent of IRF4.  
 
Obviously, this pathway involves signaling via IL-1 and IL-23, which are major factors 
in chronic inflammation (CUA ET AL. 2003; YEN ET AL. 2006). The function of IL-23 is not yet 
completely understood, but it may act as growth factor for Th17 cells (KORN ET AL. 2009) 
and prevents conventional  T cells to convert into Foxp3+ regulatory T cells 
(PETERMANN ET AL. 2010). In turn, IL-1 is a proinflammatory cytokine that mediates fever, 
recruitment of neutrophilic granulocytes and triggers the secretion of IL-6. Its signalling 
also involves NFB (LIEB ET AL. 1996). Together, stimulation of  T cells by IL-23 and 
IL-1 leads to a further increase of the IL-17 production by these cells, more than by 
each of them alone. It is very likely that the mechanism that has been activated in the 
thymus is simply reinforced in the periphery by stimulation with these two cytokines. In 
chondrocytes, IL-1 is able to induce the Notch-hairy enhancer of split (Hes)1 pathway 
and thereby provides a signal for the expression of certain activation marker genes in 
chondrocytes, such as matrix metalloproteinase 13 and agrecanase disintgrin and 
metallopreotease (ADAM) with thrombospondin type 1 motif, 5 (ADAMTS5) 
independently of Notch (OTTAVIANI ET AL. 2010). Interestingly, this pathway has recently 
been shown to be responsible for the development of IL-17-producing  T cells in the 
thymus and periphery (SHIBATA ET AL. 2011). This could mean that likewise in peripheral  
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T cells, the induction of IL-17 by IL-23 and IL-1 could be mediated by the Hes1 
pathway. This signaling may or may not be related to RelA and RelB (POWOLNY-
BUDNICKA ET AL. 2011), but may circumvent all STAT molecules that have been connected 
to the IL-23 receptor signaling. However, the fact that in my hands a functional NFB 
inhibitor does not have even the slightest effect on IL-17 production, suggests that if the 
Notch-Hes1-pathway is involved in the herein reported IL-17 production of IRF4 
deficient  T cells, it acts independent of RelA and RelB. These assumptions, of 
course, have to be fully proven in the Irf4 knockout mouse in the future.  
 
A final remark refers to the implications of our findings for the role of  T cells in the 
pathogenesis of autoimmune diseases (ODYNIEC ET AL. 2004). These cells have been found 
in lesions of multiple sclerosis (MS) patients (RAJAN ET AL. 1998). Apparently, they 
clonally expand by the restricted usage of TCR variable chain segment (V)9 
(WUCHERPFENNIG ET AL. 1992) and by this even represent a cell fraction in blood, which can 
be considered as predictor for disease activity (POGGY ET AL 2007, RINALDI ET AL 2006). This 
fact is especially interesting with regard to the Irf4 knockout mouse, because this mouse 
is completely resistant to the murine model of MS, namely EAE and strongly requires 
Th17 cells. Therefore  T cells my not play a role in the initiation of the disease, but 
their functions lies rather in supporting Th17 cells. 
 
All together, despite of many attempts to reveal the underlying mechanism of IL-17 
production by IRF4 deficient T cells, it was not yet possible to find the final clue. 
However, several hints might be given here for further investigation. 
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Figure A1:  Targeted locus of the Irf1 gene. Upper panel includes the sequence in  
  front (further 5’) of the targeted site; the lower panel includes a section  
  behind (further 3’) of the targeted site. 
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Figure A2:  Sequence verification of SA3. The sequence between the two restriction  
  sites ClaI and BamHI matches 100 %. The genomic Sfi restriction site is  
  also correct. 
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Figure 2Aa:  Sequence verification of SA3’, reverse strand reaction. The sequence  
  between the two restriction sites ClaI and BamHI matches 100 %. The  
  genomic Sfi restriction site is also correct. 
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Figure A3:  Sequence verification of IA. The first part of the sequence matches  
  100 %. The restiction sites are also correct. 
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Figure A3a:  Sequence verification of IA. The middle part matches 100 %. 
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Figure A3b:  Sequence verification of IA, reverse strand reaction. The rearmost part  
  of the sequence matches 100 %. Restriction sites and loxP sites are also  
  correct. 
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Figure A4: Sequence verification of SA5’. The sequence matches 100 %. 
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Figure A4a:  Sequence verification of SA5’, reverse reaction. The sequence matches  
  98 %. The missing nucleotides at position 46 and 49 were verified in the  
  forward reaction, and were additionally verified in an additional   
  sequencing reaction. 
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